Development of improved methodologies for the discovery of novel bioactive compounds and their application to problems of biomedical relevance. by Den Haan, Helena
ESCUELA INTERNACIONAL DE DOCTORADO
Programa de Doctorado en Ciencias de la Salud
TESIS DOCTORAL
Development of improved methodologies for the discovery
of novel bioactive compounds and their application to
problems of biomedical relevance
Autora:
Dña. Helena den Haan Alonso
Directores:
Dr. D. Horacio Emilio Pérez Sánchez
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Dr. D. José Manuel Villalgordo Soto
Dr. D. Alfonso Pérez Garrido
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Abstract
Chemoinformatics is a discipline that has positioned itself both in the world of aca-
demic research and in the industrial field as a fundamental tool given its high effi-
ciency/cost ratio. However, it also has certain limitations that have been addressed
in the development of this industrial thesis.
The principal objective on which this work is based is fundamentally to apply
methodological improvements in chemoinformatic techniques for the discovery of
new bioactive compounds against different therapeutic targets, both in an academic
and industrial context.
The computational techniques used are based on both ligand structure (phar-
macophore modeling, QSAR, three-dimensional similarity) and protein structure
(docking and molecular dynamics). Some of the therapeutic targets studied have
been Zika virus protease NS2B-NS3, acetyl and butyrylcholinesterase enzymes, the
α-galactosidase enzyme and various proteins involved in diabetes.
The first contribution of this thesis (which is presented as a compendium of
publications) investigated the discovery of a pharmacological chaperone for the
enzyme α-galactosidase with the ability to bind to the enzyme in a region other
than the active site of the enzyme so that it would stabilize its three-dimensional
structure and recover its functionality without inhibiting it at high concentrations
as Migalastat (the only drug approved by the Food and Drug Administration for
the treatment of Fabry disease) does. Using a combined strategy of virtual screening
based on the three-dimensional shape of the chemical compounds and the modeling
of the molecular coupling we discovered a compound, 2,6-ditiopurine, which after
laboratory tests was found to be able to stabilize and promote the maturation of the
enzyme.
In the following three contributions, docking techniques were used to describe
the potential mechanism of action as acetyl and butyrylcholinesterase inhibitors of
N-acetyl-tryptophan compounds, different classes of tanshinones, rosmarinic acid,
hyperforin and hyguanin C. In all these cases, our simulation results predict that
more stable binding of these compounds with enzymes takes place in the active site
of the same, so that the compounds would block the entry of the substrate, which
would explain their activity as inhibitors.
In the penultimate contribution we screened Drugbankñ(Law et al., 2013), a
public database containing FDA-approved drugs and compounds used in clinical
research) for searching compounds suitable for the treatment of Zika virus infection.
In this case, protease NS2B-NS3 was selected as a therapeutic target for which
8 enzyme-inhibiting compounds were found by means of structure based virtual
screening. Of these, the Novobiocin compound proved to inhibit both the protein
in vitro and in vivo, obtaining 100 % survival of the animal models used for the
experiment.
An on-line platform was finally developed for the identification of new anti-
diabetic compounds. This thesis presents a work derived from the use of this
platform to carry out an inverse screening and identify the potential therapeutic
target of different natural compounds. We have found bibliographic evidences of
experimental validation for eight of the compounds for which the computational
method predicted a possible therapeutic target confirming the the have certain
activity.
Keywords: Docking, pharmacophore modeling, cheminformatics, Fabry disease, cho-
linesterase, Zika, diabetes.
Resumen
La quimioinformática es una disciplina que se ha posicionado tanto en el mundo
de la investigación académica como en el ámbito industrial como una herramienta
fundamental dado su alto ratio de eficacia/coste. Aunque también tiene ciertas
limitaciones que se han abordado en el desarrollo de esta tesis industrial.
El objetivo fundamental en el que se basa este trabajo son fundamentalmente
aplicar mejoras metodológicas de las técnicas quimioinformáticas para el descu-
brimiento de nuevos compuestos bioactivos frente a distintas dianas terapéuticas,
tanto en un contexto académico como industrial.
Las técnicas computacionales empleadas se basan tanto en la estructura del
ligando (modelado farmacofórico, QSAR, similitud tridimensional) como en la de
la proteı́na (modelado del acoplamiento molecular (docking) y dinámica molecular).
Algunas de las dianas terapéuticas objeto de estudio han sido la proteasa NS2B-NS3
del virus Zika, las enzimas acetil y butirilcolinesterasa, la enzima α-galactosidasa y
diversas proteı́nas involucradas en la diabetes.
En la primera contribución de esta tesis (que se presenta como un compendio
de publicaciones) se investigó el descubrimiento de una chaperona farmacológi-
ca para la enzima α-galactosidasa con capacidad de unirse a la enzima en una re-
gión distinta al sitio activo de la enzima de manera que estabilizase su estructura
tridimensional y recuperase la funcionalidad de la misma sin inhibirla a elevadas
concentraciones como lo hace Migalastat (único fármaco aprobado por la Food and
Drug Administration para el tratamiendo de la enfermedad de Fabry). Usando una
estrategia combinada de cribado virtual basado en la forma tridimensional de los
compuestos quı́micos y el modelado del acoplamiento molecular descubrimos un
compuesto, 2,6-ditiopurina, que una vez realizadas las pruebas de laboratorio se
obervó que era capaz de estabilizar y promover la maduración de la enzima.
En las siguientes tres contribución se emplearon técnicas de docking para des-
cribir el potencial mecanismo de acción como inhibidores de acetil y butirilcolines-
terasa de los compuestos N-Acetil-triptófano, distintas clases de tanshinones, ácido
rosmarı́nico, hiperforina e hyguanin C. En todos estos casos los resultados de nuestra
simulación predicen que la unión más estable de estos compuestos con las enzimas
tiene lugar en el sito activo de la misma, de manera que bloquearı́an la entrada del
sustrato de las mismas, lo que explicarı́a su actividad como inhibidores.
En la penúltima contribución se filtró la base de datos Drugbank (Law et al.,
2013) (base de datos pública que contiene tanto fármacos aprobados para su uso
clı́nico como compuestos actualmente en fases de investigación) en busca de un
compuesto adecuado para el tratamiento de la infección por virus Zika. En este ca-
so se seleccionó la proteasa NS2B-NS3 como diana terapéutica para la que, mediante
técnicas de cribado virtual basado en estructura, se encontraron 8 compuestos inhi-
bidores de la enzima. De todos ellos el compuesto Novobiocina demostró inhibir la
proteı́na tanto in vitro como in vivo, obteniendo un 100 % de superviviencia de los
modelos animales empleados para el experimento.
Finalemnte se participó en el desarrollo de una plataforma web, DIA-DB para
la identificación de nuevos compuestos antidiabéticos. En esta tesis se presenta un
trabajo derivado del uso de esta plataforma para llevar a cabo un cribado inverso
e identificar la potencial diana terapéutica de distintos compuestos naturales. Para
ocho de los compuestos para los que el método computacional predijo una posible
diana terapéutica se han encontrado evidencias experimentales en la bibliografı́a.
Palabras clave: Simulación del acoplamiento molecular, modelado farmacofórico,
quimioinformática, enfermedad de Fabry, colinesterasa, Zika, diabetes.
Index
1 Introduction 1
1.1 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.2 Structure of the Dissertation . . . . . . . . . . . . . . . . . . . . . . . . 4
2 Articles that are part of the doctoral thesis 7
2.1 Fundamentals of the doctoral thesis . . . . . . . . . . . . . . . . . . . 7
2.2 Identification of an Allosteric Binding Site on Human Lysosomal
Alpha-Galactosidase Opens the Way to New Pharmacological Chap-
erones for Fabry Disease . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.3 Selective in vitro and in silico butyrylcholinesterase inhibitory activ-
ity of diterpenes and rosmarinic acid isolated from Perovskia atriplici-
folia Benth.and Salvia glutinosa L. . . . . . . . . . . . . . . . . . . . . . . 25
2.4 Acetylcholinesterase inhibitory assessment of isolated constituents
from Salsola grandis Freitag, Vural & Adıgüzel and molecular mod-
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At present, one of the most important challenges in the field of health and social
security is the discovery of novel bioactive compounds to deal with problems of
pharmacological relevance or where previously known compounds are not suffi-
ciently effective (Drews, 2000). Traditionally the Pharma industry has dealt with
the study of such challenges, due to the great expense this implies and the technical
difficulties involved (Khanna, 2012).
However, for the last two decades new methodologies based on computational
chemistry and cheminformatics have been developed to speed up these discoveries,
which can be carried out efficiently in an academic environment at a much lower
cost (Kola and Landis, 2004). Cheminformatics is a discipline that consists in the
use of computers and computer programs (Jorgensen, 2004) to look for solutions
to problems related to the field of chemistry. The relationship between computer
science and chemistry has been going on for more than 50 years, being the decades
of the 70’s and 80’s when the field was born (Brown et al., 1998). However, it was
not until the 90’s when the first references to this discipline appeared by its name.
Since then this field has been gaining importance both in industry and in academic
research as inferred from the impact it has on publications in recent years. There is
no single definition that can be used to describe this area. David Wild defined it as
“the field that studies all aspects related to the representation and use of chemical
1
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and biological information related to it by means of the computers” (Wild and
Wiggins, 2006). Perhaps one of the broadest definitions was stated by Frank Brown
Brown et al. (1998) who defined it as “the combination of those technological and
management resources used to transform data into information and information
into knowledge for the purpose of making better decisions more rapidly in the field
of discovery and optimization of new drugs”.
This thesis is based on the following core objectives; a) the use of cheminformatic
techniques for the discovery of novel bioactive compounds, and b) the use of
these same techniques to identify the parts of the compounds that are potentially
responsible for this activity as well as the type of interactions that are established
between the compound and the therapeutic target at the binding site (Schenone
et al., 2013). However, this methodology and others used by a large number
of scientists continue to have certain limitations in terms of predictive capacity
and data processing speed (Schneider, 2010), two extremely important factors for
successfully carrying out this type of project. In this thesis, some relevant limitations
in these methods have been identified and we proposed some solutions. The
improvements in both processing speed and predictive quality studied in this
thesis have been applied at the same time to different contexts of pharmacological
relevance. For this purpose, different computational techniques have been used
that can be grouped into techniques based on the chemical structure of the ligands
(Ripphausen et al., 2011) and techniques based on the structure of the therapeutic
targets (Lyne, 2002).
In this thesis, therefore, the practicability of cheminformatics techniques has
been demonstrated by applying a multidisciplinary research process (chemistry,
biology, physics) with the exploitation of high-performance parallel computational
architectures such as supercomputers, grids, clusters, etc. (Banegas-Luna et al.,
2019).
Finally, it should be noted that this work has been carried out both in academic
contexts, where all the results obtained have been published and which form the
skeleton of this compilation, and in industrial contexts, where, due to reasons of
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confidentiality, none of the results obtained could be published.
1.1 Objectives
The objectives on which the dissertation is based are listed and summarized below.
These objectives have been oriented towards three main lines of work: a) the
methodological improvement of chemoinformatic techniques, b) the application
of these improvements to contexts of pharmacological relevance in the academic
world, and c) the exploitation of the aforementioned improvements in industrial
drug discovery projects.
• Objective 1. To improve chemoinformatic techniques methodologies. This
objective aims to propose methodological improvements to deal with some
limitations in cheminformatics techniques. Specifically, the aim is to work on
methods for proposing allosteric pharmacological chaperones (Leidenheimer
and Ryder, 2014), on improving the strategies and analytical capacity of vir-
tual screening techniques based on both the protein structure (Ghosh et al.,
2006) and the ligands (Banegas-Luna et al., 2018), and on the exploitation of
chemical information in polypharmacological contexts.
• Objective 2. Apply the resulting improvements in the context of Fabry
disease. Different techniques from Objective 1 will be applied to discover
allosteric molecular chaperones in the context of Fabry disease (Germain,
2010).
• Objective 3. To use the improved methods for describing the mode of ac-
tion of bioactive compounds that inhibit acetylcholinesterase. Advances
and improvements in the objective 1 will be implemented to analyze exper-
imental results obtained in the context of cholinesterase-inhibiting bioactive
compounds (Birks, 2006) to better describe their modes of action.
• Objective 4. To apply the obtained improvements in the discovery of
inhibitors against the Zika virus. We will apply the methodological novelties
4 Introduction
of the objective 1 to the discovery of novel inhibitors in the context of the Zika
virus (Mlakar et al., 2016).
• Objective 5. Exploiting the improvements mentioned in industrial projects.
The methodological improvements obtained in the objective 1 will be used to
work in a variety of pharmaceutical drug discovery industrial projects bound
by confidentiality agreements (Gray, 2006).
1.2 Structure of the Dissertation
In this section and with the purpose of facilitating the reading of this doctoral thesis,
its composition is briefly indicated according to the chapters that make it up.
• Chapter 1: Introduction.
It is a presentation and contextualization of the main problem from which
this thesis derives, the attack approaches that are addressed and the main
objectives that are intended to be achieved are enumerated.
• Chapter 2: Articles that are part of the doctoral thesis. The rationale of this
thesis is explained in relation to the main published scientific papers and how
these articles form the compendium, connecting them to the initial proposed
objectives.
• Chapter 3: Projects with company intellectual property results.
The industrial projects worked within Eurofins-Villapharma are briefly dis-
cussed due to confidentiality reasons.
• Chapter 4: Conclusions and outlook.
In this part, the main conclusions obtained as a result of the work on the stated
objectives are mentioned. It also lists directions for potential future work.
• Chapter 5: Publications, collaborations and quality of journals.
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The most important quality indexes of the publications that make up the
compendium of this dissertation are detailed in this last section. Other results
obtained in this Industrial PhD thesis are also indicated.
• Bibliography.
This section includes bibliographical details about the most relevant works
cited in this thesis by compendium.
6 Introduction
Chapter 2
Articles that are part of the doctoral
thesis
2.1 Fundamentals of the doctoral thesis
The following sections of this chapter include scientific publications in high-impact
indexed international journals that justify this doctoral thesis by compendium, and
that fulfill the initially proposed objectives.
In the first publication (section 2.2) we worked on the design of methodological
improvements in the context of Fabry disease (Citro et al., 2016). In this lysosomal
storage disease, patients have mutations in the enzyme alpha-galactosidase which
affects the structure of the enzyme which prevents it from performing its biological
function correctly. Work was conducted to discover new allosteric pharmacological
chaperones that could stabilize the enzyme.
The context of the detailed analysis of the modes of action of cholinesterase-
inhibiting bioactive compounds led to four of the publications in this compendium
(Senol et al., 2017; Orhan et al., 2017, 2019; Ślusarczyk et al., 2019), as it can be seen
in the sections 2.3, 2.4, 2.5 and 2.6. In these cases some methodologic improvements
were developed in order to propose which parts of these molecules interacted with
the active sites of the implicated cholinesterase enzymes.
7
8 Articles that are part of the doctoral thesis
The following publication (section 2.7) details how drugs already approved by
the FDA were repositioned as potent inhibitors of the Zika virus (Yuan et al., 2017)
thanks to the methodological advances that were made. At the same time, an
international patent was filed for one of these compounds.
In the last of the publications, section 2.8, efforts were made to process different
sources of chemical data, both based on protein structure and ligands, in order to
study the anti-diabetic potential of a wide variety of bioactive compounds from
African medicinal plants (Pereira et al., 2019).
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Abstract
Personalized therapies are required for Fabry disease due to its large phenotypic spectrum
and numerous different genotypes. In principle, missense mutations that do not affect the
active site could be rescued with pharmacological chaperones. At present pharmacological
chaperones for Fabry disease bind the active site and couple a stabilizing effect, which is
required, to an inhibitory effect, which is deleterious. By in silico docking we identified an
allosteric hot-spot for ligand binding where a drug-like compound, 2,6-dithiopurine, binds
preferentially. 2,6-dithiopurine stabilizes lysosomal alpha-galactosidase in vitro and res-
cues a mutant that is not responsive to a mono-therapy with previously described pharma-
cological chaperones, 1-deoxygalactonojirimycin and galactose in a cell based assay.
Introduction
Fabry disease (FD) is a rare pathology, but accounts for 8.8% of the patients affected by inher-
ited disorders of metabolism [1]. It is caused by mutations in the gene GLA, which is located
on the X chromosome and encodes lysosomal alpha-galactosidase (AGAL) [2]. Enzyme
replacement (ERT) is the only approved specific therapy for FD; it is well tolerated and safe [3].
The large phenotypic and genotypic spectrumof the disease poses several problems and the
cost-effectiveness of ERT is still debated, in particular for patients who have residual enzyme
activity [4]. In FD, about 40% of all missense mutations are associated with a biochemically
mildly damaged enzyme [5]. A therapy with sub-inhibitory concentrations of 1-deoxygalacto-
nojirimycin (DGJ) was first proposed by Suzuki and co-workers [6] and then tested in cells [7–
13], in mouse models of FD [14] [15] and in clinical trials [16] [17]. Such therapy is suitable
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only for patients carrying specificmutations (40%-60% of missense mutants tested in cell
based assays [11, 12]) and requires fine-tuning of the dosage regimen because DGJ is an inhibi-
tor of AGAL. The approach with small molecules for FD is promising, but DGJ is not yet the
ideal drug.Molecules that either substitute DGJ or act in synergy with it to enable reduced dos-
age of DGJ should be sought, in particular for mutants that do not respond to a monotherapy
with DGJ. Analogues of DGJ have been developed [18] [19]. A new family of arylthioureas
showed a better balance between the stabilizing effect, which is required, and the inhibitory
effect, which is detrimental [20]. However, these molecules bind the active site, as demon-
strated by x-ray crystallography, and enhance enzymatic activity only at micromolar concen-
tration, not dissimilarly from DGJ, when administered to eukaryotic cells expressing AGAL
mutants [20].
Ambroxol, a mucolytic agent used in the treatment of respiratory diseases, proved to be use-
ful in association with DGJ to rescue some AGAL mutants [21]. Its mechanism of action is not
clear since ambroxol is not specific for AGAL, but it is effective also on lysosomal beta-gluco-
cerebrosidase [22] and alpha-glucosidasemutants [21].
Discovery of chaperones directed against the active site is facilitated by focusing on mole-
cules with structural similarity to galactose, a natural product of AGAL. Conversely, the discov-
ery allosteric ligands, i.e. ligands that bind AGAL at sites outside the active site, is complicated
by the fact that they may not chemically resemble any known substrates or products. We per-
formed in silico molecular docking (virtual screening) of over ten thousand low molecular
weight structurally diverse compounds previously filtered from ZINC database [23], by looking
for molecules that bind preferentially at a site different from the active site. Among the top
ranking hits we found one molecule, 2,6-dithiopurine (DTP). This molecule was chosen for
further studies since it has already passed some safety tests, is a known chemiopreventive agent
[24] [25] and it is safe when administered to mice [26]. DTP is able to stabilize AGAL against
thermal and urea-induced denaturation and is able to rescue a mutant that is not sensitive to
DGJ. It acts in vivo in synergy with galactose and with very low concentrations of DGJ.
Methods and Materials
Virtual screening
We selected a random subset of 9 million molecules (including FDA-approved drugs) from the
ZINC database [23] for performing the virtual screening calculations in this study. Molecular
docking calculations were carried out on the structure deposited in the PDB with the code
3S5Z [27] with the Leadfinder [28] docking program using default parameters. Protein struc-
ture 3S5Z contains 2 ligands: alpha-D-galactose (GLA) bound at the active site through D92,
D93, K168, E203, R227, D231 (GLA site) and beta-D-galactose (GAL) bound at a different site
through D255 and K374 (GAL site). Thus, two boxes (x, y, z dimensions 40 Å), centered on the
position occupied by either GLA or GAL, were set for docking. Using the global shape similar-
ity tool WEGA [29] alpha-D-galactose (the natural substrate of AGAL) was processed against
the selected compound library and those molecules with the highest values for similarity score,
ranging from 0.8 to 0.95, were selected for posterior docking studies. In total ten thousand pur-
chasable molecules obtained after filtering with WEGA were selected for docking.
Thermal unfolding
Thermal shift assay [30, 31] was adapted as described [32] using commercially available wt-
AGAL, Fabrazyme1 (Genzyme, Cambridge, MA). Melting profiles were recorded under differ-
ent conditions by thermal shift assay with the StepOne Real-Time PCR System (Applied Bio-
systems). The protein (0.5–1 mg/mL final concentration) was equilibrated in Na-Hepes 20
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mM, NaCl 150 mM, pH 7.4 with Sypro Orange 2.5X (Invitrogen Molecular Probes, lifetechnol-
ogies.com), either without ligands or in the presence of ligands (6 mM DTP, 0.040 mM DGJ
(SIGMA, Milan, Italy). The samples were distributed in 48-well PCR plates (0.025 mL in each
well), sealed and heated from 20 to 90° at 1°C/min with increments of 0.6°C. The excitation
wavelength of 490 nm and the emission wavelength of 575 nm, which are optimal for fluores-
cein, were adapted to detect Sypro Orange. Melting profiles of recombinant human phospho-
mannomutase2 were recorded similarly, the only exception was the presence of 1mM MgCl2
in the buffer. Phosphomannomutase 2 had been expressed and purified as described [33].
In order to verify the reversibility of the effect of DTP on Fabrazyme1, the enzyme equili-
brated in Na-Hepes 20 mM, NaCl 150 mM, pH 7.4 was incubated for 1 hour at 4°C in the pres-
ence of 6 mM DTP dissolved in DMSO, then the sample was dialysed by ultrafiltration (by
using Centrifugal ultrafiltration unit 15-mL MWCO 10 kDa, Merck-Millipore). A control
experiment was also conducted incubating the enzyme with DMSO and dialysing it. Each dia-
lysed sample was analysed by enzymatic assay (at pH 7.5) and by TSA (the experiment was
conducted either in the presence of 6 mM DTP or with only DMSO) as described above.
Urea-induced unfolding
The experiment was carried out with a method firstly describedby Kim et al [34] and adapted
as described [35]. In brief, Fabrazyme1 (0.32 mg/mL) was induced to unfold by urea in Hepes
buffer at pH 7.4, with or without DTP 6 mM, in a final volume of 0.028 mL. The enzyme was
incubated in the presence of urea concentrations ranging from 0 to 5 M. The samples were
incubated at 10°C overnight, then each sample was treated with the appropriate amount of
thermolysin necessary to obtain a 1:5 protease to protein ratio in the presence of CaCl2 (10
mM final concentration). After 1 min incubation at 37°C the reaction was stopped by the addi-
tion of EDTA (40 mM final concentration). The samples were separated by SDS-PAGE and
coloured by Coomassie Blue Staining, then undigested proteins (Fabrazyme1 and thermoly-
sin) were quantified with a ChemiDocXRS (Bio-Rad Laboratories, Hercules, CA-USA). Two
rectangular boxes were used to define specific protein bands, one for Fabrazyme1 and one for
thermolysin as shown in S1 File. The intensity of bands was corrected subtracting the appropri-
ate background (adjusted volumes), the ratio between the corrected values was calculated for
Fabrazyme1 and thermolysin in each lane and was plotted against urea concentration.
Transfection into COS-7 cells
COS-7cells were cultured in DMEM containing 10% FBS at 37°C and 5% CO2. The cells were
transfected with individual plasmids containing mutant AGAL-encoding ORF using the Lipo-
fectAMINE2000 cationic lipid reagent in suspension [36].
67.5 micrograms of plasmid DNA in 13.5 mL Opti-MEM (Invitrogen) were mixed with
0.135 mL LipofectAMINE2000 reagent (Invitrogen) and incubated for 30 min at room temper-
ature. COS-7 cells were harvested by trypsin treatment and resuspended in DMEM containing
10% FBS.
COS-7 in suspension (40.5 mL) were added to the transfection mix solution, distributed
into 27 wells of six-well plates at 60% confluency and allowed to adhere for 5h.
The medium was substituted by fresh DMEM, 10% FBS, 1% DMSO (used to solubilize DTP
and ambroxol) (1 mL), and drugs were added either in monotherapy or in binary combination
as indicated in the specific figure legends. After 48 h incubation, the cells were washed in PBS
(5 times), scraped and harvested by centrifugation.Dry pellets were resuspended in 0.030 mL
of water and lysed by freeze-thawing.Three independent transfections were carried out for
A230T, C56Y, C63Y, two for the other mutants, E341D, A37T, P40S, M42T, M42V, S126C,
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C172G, R118C, Q280K, L300F, L310F and G360C. Water-soluble extracts were used for
enzyme assays or western blot. The Bradford colorimetric assay was used for protein quantifi-
cation [37] using the Bio-Rad Protein Assay with bovine serum albumin as standard.
Alpha-galactosidase assay
Tests on transfected mutants were carried out as described in [36]. Briefly: cell lysates (1–2
microliters) were added to 38 microliters of AGAL assay buffer (sodium citrate 27 mM-sodium
phosphate dibasic 46 mM, 4-methylumbelliferyl-alpha-D-galactopyranoside 5 mM and N-ace-
tyl-D-galactosamine 100 mM, pH 4.5) and incubated for 0.5–1 h at 37°C. All chemicals were
obtained from Sigma. The reaction was stopped by adding 0.360 mL of 1 M sodium carbonate
buffer [10]. Fluorescence was detected using a fluorescence spectrophotometer (Cary Eclypse-
Varian) at 355 nm excitation and 460 nm emission.
A 4-methylumbelliferone standard curve ranging from 5 nM to 0.025 mM was run in paral-
lel for conversion of fluorescence data to AGAL activity expressed as nmol/mg protein per
min.
In order to measure the enzymatic activity in the presence of DTP 6 mM a spectrophoto-
metric assay was run. Fabrazyme (1–2 microliters 0.25 mg/ml) were added to 0.038 mL of
AGAL assay buffer (4-Nitrophenyl α-D-galactopyranoside 17 mM in Hepes 40 mM pH 7.4)
and incubated for 3–15 min at 37°C. The reaction was stopped by adding 0.360 mL of 1 M
sodium carbonate and the absorbance at 405nm was measured. The assay was conducted in
the presence of DTP 6 mM (previously dissolved in DMSO) or DMSO.
Western blot analysis
Western blot analysis for the detection of AGAL was performed using rabbit polyclonal anti-
bodies (Abcam 70520) and HRP-coniugated anti-rabbit IgG antibody produced in goat (Bio-
Rad 1706515). After SDS-PAGE (15% acrylamide), proteins were transferred to a PVDF mem-
brane. The membrane was blocked with 5% (w/v) non-fat dried skimmed milk in blot solution
at 4°C overnight, then treated with the primary antibody diluted in a blot solution 1:500 for 1
hour at room temperature. After washing, the detectionwas performed by using the Precision
Plus Protein™ (Bio-Rad). GAPDH was revealed with mouse monoclonal anti lapine GAPDH
(AbD seroTec (cat:4699–9555) 1:2000. All other chemicals were from Bio-Rad. Uncropped
images of the gels are provided as S1 File.
Deglycosylation
Deglycosylation of A230T expressed in COS7 cells (treated or untreated with DTP 6 mM)
(10 μg f each) was performed according to the producer's instructions. wt-AGAL was processed
at the same way as a control. Briefly, EDTA and SDS were added to the proteins (final concen-
trations were 20 mM and 0.1% respectively). The samples were then boiled for 5 min, immedi-
ately cooled before the addition of NP-40 to a final condition of 0.7% and N-Glycosidase F (0.5
unit) and incubated overnight at 37°C. A parallel experiment was conducted avoiding the
denaturation step (SDS and heating) before adding NP-40. The samples was analysed by west-
ern blotting as described elsewhere.
Bioinformatic and Statistical analysis
Standard deviations and p values (paired two-tailed Student's t-test) were obtained using
Microsoft Excel (Microsoft Office professional 2010).
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The effect of mutation on protein stability was predicted either running SDM on-line [38]
or running MUPRO1.1[39] locally. Secondary structure was assigned with SEGNO [40].
Accessibility to solvent was calculated by SDM. Active site residues were identifiedwith Dro-
steP [41]. Molecular dynamics was run with Yasara program under default conditions for 50
nsec [42] and flexibility assessed as described [43]. Protein damaging scores based on sequence
conservationwere derived using PolyPhen-2 software [44] or Fabry_CEP [45].
Results
Molecular docking calculations were carried out on the AGAL structure deposited in the pdb
with the code 3S5Z [27]. In this model AGAL binds two ligands per chain: alpha-D-galactose
at the active site through D92, D93, K168, E203, R227 and D231 (GLA site) and beta-D-galac-
tose at a different site through D255 and K374 (GAL site). This structure offers a good target to
identify molecules that have little inhibitory activity and/or act in synergy with drugs directed
against the active site. In proximity to the GAL site, we identified a hot-spot for binding that
will be referred to as the allosteric site. It comprises residues A37, R38, T39, P40, T41, M42,
E87, Y88 and does not overlap with the active site that is lined by W47, D92, D93, Y134, C142,
K168, D170, E203, L206, Y207, R227, D231, S297 (Fig 1). The allosteric site is different from
the GAL binding site.
We looked for molecules that bind the allosteric site with a high score, but bind the active
site with a very low score. Drug repositioning, which should always be considered as the first
choice when developing new therapies for rare diseases [46], could not be used because none of
the approved drugs tested (FDA database) bound specifically the allosteric site (results not
shown).
As a second choice we selectedDTP, which is not an approved drug, but is a good candidate
because it is safe when tested on human skin cells [25] and on mice [24] [26]. Even if the dock-
ing simulations started at GAL site DTP contacted the allosteric site. As a control we carried
out a simulation limiting the search to a box centred on the active site as described in the meth-
ods. We show the interactions of DTP with the allosteric site in Fig 1B, and the corresponding
energetic contributions in Fig 2A, the potential interactions of DTP with the active site (GLA
site) in Fig 1C and the corresponding energetic contributions in Fig 2B. Docking simulations
calculated a binding affinity at GLA’s binding site 52% lower (absolute value) than at the allo-
steric site (Fig 2). Scores calculatedwith Leadfinder [28] are reported as kcal/mol in Fig 2, but
are meant only for rank-ordering different docking poses of DTP and cannot provide accurate
binding energy predictions.
DTP does not inhibit AGAL (Fabrazyme1, Genzyme) when tested at 6 mM concentration
using 4-Nitrophenyl α-D-galactopyranoside 17 mM in Hepes 40 mM pH 7.4, whereas DGJ
blocks completely the enzyme (1% residual activity) at concentration as low as 0.001 mM.Ther-
mal shift assay was used to evaluate the ability of DTP (6mM) to stabilize wt-AGAL, (Fabra-
zyme1, Genzyme) in the presence or in the absence of DGJ. DTP is able to stabilize the
enzyme against thermal denaturation alone or in synergy with the iminosugar (Fig 3A). with-
out forming covalent bonds. To prove the reversibility of this stabilising effect, DTP (6 mM)
was incubated with enzyme and subsequently removed by dialysis before thermal shift assay.
Results are indicated in Fig 3B (filled squares DTP/DTP; open squares DMSO/DTP; filled cir-
cles; DTP/DMSO; open circles DMSO/DMSO) where the first word of the label corresponds to
the pretreatment and the second part corresponds to the presence of the compound during the
thermal scan. The specificity of effect of DTP was tested running thermal shift assay on phos-
phomannomutase2, an enzyme structurally and functionally unrelated to AGAL in the pres-
ence of DTP 6 mM or a positive control, glucose 1–6 bisphosphate 0.5 mM (S1 Fig).
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The stability of AGAL in the presence or in the absence of DTP was tested by unfolding
induced by a range of urea concentrations, followed by limited proteolysis. The enzyme unfolds
at 2.7 M urea in the absence of DTP, and at 3 M urea in the presence of DTP (Fig 4). A minor
band, which might represent a differently glycosylated form of AGAL, is observed in Fig 4. Its
intensity correlates with that of the major band (data not shown).
AGAL mutants were expressed transiently in COS-7 cells. We tested the effect of DTP on
the mutant A230T [47], which is non-responsive to DGJ [36], but eligible for PC therapy [48].
After transfection of A230T into COS-7 cells, specific bands were revealed by Western blot
(WB) and the total alpha-galactosidase activity was measured in cell extracts. In order to inter-
pret results it is worth remembering that AGAL is synthesized as a precursor of 50 kDa, but it
is converted into a mature form of 46 kDa. A detailed analysis of Ishii and co-workers [49]
demonstrated that when AGAL mutants are correctly processed into a 46 kDa form, they are
also transferred into lysosomes. In Fig 5A we show the migration of transfected wt-AGAL (90
±9 U/mg activity in the lysates) as a reference. A230T shows a faint band corresponding to the
precursor form of AGAL. This is not induced by the treatment with acknowledged PCs, DGJ,
Fig 1. The active site and the allosteric binding site in human lysosomal alpha-galactosidase. The structure of lysosomal alpha-
galactosidase is shown as a cartoon. In Panel A the active site (GLA site) is pinpointed by a blue sphere while the allosteric binding site is
pinpointed by a violet sphere. Residues involved in the 2,6-dithiopurine allosteric and alpha-galactose binding site respectively are shown
as sticks in Panel B or C respectively along with docked DTP. Predicted hydrogen bonds between DTP and AGAL within the allosteric
binding site are shown as yellow dashed lines in Panel B. Best ranked pose of DTP in the alpha-galactose binding site area is shown in
Panel C.
doi:10.1371/journal.pone.0165463.g001
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Fig 2. Energetic contributions to the binding of 2–6 dithiopurine to the allosteric site and the active site of human lysosomal
alpha-galctosidase. Depicted energetic contributions are: van der Waals interactions (dark blue), volume-based free energy of solvation
(green), hydrogen bonds (red), electrostatic energy (cyan), internal energy (pink), metal interactions (light yellow), energy of entropic
losses associated with ligand’s rotatable bonds (dark yellow), dihedral energy (light blue), internal energy penalty (light green) and total
predicted binding affinity (black). A) Decomposition for the allosteric site, and B), decomposition for the active site.
doi:10.1371/journal.pone.0165463.g002
Fig 3. 2–6 dithiopurine stabilizes human lysosomal alpha-galactosidase in thermal shift assay. Panel A.
Fabrazyme® (in Na-Hepes 20 mM, NaCl 150 mM, pH 7.4) was equilibrated in the presence of ligands dissolved in DMSO
20%: DGJ 1 microM (empty triangle) or 40 microM (empty circle); DTP 6 mM (empty diamond); DTP 6 mM plus DGJ 1
microM (filled circle); DTP 6 mM plus DGJ 40 microM (filled triangle). A control (with only DMSO) was also shown (x).
Panel B. Fabrazyme® (in Na-Hepes 20 mM, NaCl 150 mM, pH 7.4) was incubated in the presence of DTP 6 mM for 1 hour
at 4˚C then DTP was eliminated by dialysis. A control experiment was conducted by incubating the enzyme only with
DMSO. Both the aliquots of Fabrazyme® were analysed by thermal shift assay in the presence of DTP 6 mM or in the
presence of DMSO. Filled squares: DTP/DTP; open squares: DMSO/DTP; filled circles: DTP/DMSO; open circles:
DMSO/DMSO where the first word of the label corresponds to the pretreatment and the second part corresponds to the
presence of the compound during the thermal scan. The protein samples were heated from 20 to 90˚ at 1˚C/min in the
presence of Sypro Orange 2.5x. Data were shown as normalized curves.
doi:10.1371/journal.pone.0165463.g003
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galactose [50] or ambroxol [21], at the dosages commonly used to measure their chaperoning
effect on transfected mutants, 0.020 mM, 100 mM or 0.040 mM respectively. However, DTP 6
mM promotes the maturation of A230T. Moreover, its effect is potentiated by galactose and
DGJ, even at very low concentration (0.001mM), but not by ambroxol (Fig 5A, 5B and 5C).
The lowest concentration at which DTP promotes A230T maturation is 2 mM (Fig 5D and
5E). The different bands visualised on WB represent different glycosylated forms, as demon-
strated by treatment of A230T or wt-AGAL with N-Glycosidase F Fig 5F.
We tested the effect of DTP 6 mM on furthermutants expressed in COS-7 cells: C56Y (Fig
6A), C63Y (Fig 6B) and E341D (Fig 6C). In these cases, enzymatic activity was not recovered
(Fig 6D), possibly because the proteins are not catalytically active, but increased protein pro-
cessing was detectable. C63Y and E341D are not responsive do DGJ [12, 13]. C56Y activity
increases in the presence of DGJ although it does not meet the criteria chosen Lukas et al [13]
to define responsiveness.
We tested four mutations affecting residues in the allosteric site, A37T, P40S, M42T, M42V.
None of these mutants responds to DTP (Fig 7). A37T [12], M42T [13] and M42V [8, 9, 12]
are responsive to 0.020 mM DGJ, whereas P40S is not [10, 11, 13]. This finding supports the
idea that DTP binds the allosteric site found in silico, although it does not prove it, because the
same molecule has no effect on mutations that do not affect the allosteric site. An example is
provided by S126C, C172G, and R118C which are not responsive to DGJ, [10–12, 51] (S2 Fig)
and by Q280K, L300F, L310F and G360C (S3 Fig), which are responsive to DGJ [12] [36].
Discussion
The catalytic domain of AGAL is formed by a TIM-barrel and the active site is located at the
carboxyterminal end of beta-strands, as expected [52].
We identified a different druggable pocket located at the opposite side of the TIM-barrel of
AGAL. Some molecules resulting from our virtual screening bind better to the allosteric site
than to the active site. One of these molecules, a chemopreventive 2,6-dithiopurine DTP,
appeared particularly promising because it is actively transported into mammalian cells where
it accumulates at millimolar concentration [25] and it is safe [24] [26].
Fig 4. 2–6 dithiopurine protects human alpha-galactosidase against urea-induced unfolding. Fabrazyme® was
incubated in the presence of urea (from 0 to 5 M), with (B) or without (A) DTP 6 mM, at 10˚C over night, then each sample
was treated for 1 min at 37˚C with thermolysin (1:5 protease to protein ratio). Folded undigested proteins were visualized
by SDS-PAGE. The intensity of the bands was quantified and the relative intensity of major band of Fabrazyme® and
thermolysin in each lane was plotted against urea concentration (C).
doi:10.1371/journal.pone.0165463.g004
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DTP promotes the processing of some mutants of AGAL that are not responsive to DGJ
and in one case, A230T, enhances its activity in monotherapy as well as in synergy with DGJ or
galactose.
Not all missense mutations associated with FD are responsive to PC and we have not yet
found molecular features that are necessary and sufficient to determine responsiveness. Muta-
tions occurring at non conserved sites are generally less severe and responsive to PC, but there
are exceptions to this rule. The best example we encountered is A230T, a mutation occurring at
a non conserved site. A230 is exposed to solvent and exhibits moderate flexibility (Root mean
square fluctuation, RMSF, of alpha carbon 0.74 ±0.02 Å). A230 is not directly implicated in
catalysis, but it flanks D231, a proton donor that is essential for the hydrolysis of the substrate
and belongs to a short stretch in polyproline II conformation. Its mutation to Threonine is clas-
sified as mildly destabilizing by MUPRO [39] or SDM [38]. The position specific substitution
score, which measures the tolerability of the mutation in orthologous sequences and correlates
with responsiveness to DGJ, is benign [48]. A230T is classified as possibly damaging or benign
by HumDiv- and HumVar-trained PolyPhen-2 models respectively [44]. To summarize,
A230T is eligible for PC therapy and does respond to DTP, although it does not respond to
DGJ. Although DTP might be active only on a minority of AGAL missense mutations, we
Fig 5. 2–6 dithiopurine rescues mutant human alpha-galactosidase in monotherapy or in synergy. COS-7 cells
were cultured in conventional medium and transfected with plasmid containing A230T mutant. Cells were treated with:
DTP 6 mM, DGJ 1 microM, DGJ 20 microM, ambroxol 40 microM, ambroxol 40 microM plus DTP 6 mM, galactose 100
mM, galactose 100 mM plus DTP 6 mM, DGJ 1microM plus DTP 6 mM. All the molecules were dissolved in DMSO and an
appropriate control was realized. After 48 h incubation, the cells were scraped and lysed then water-soluble extracts were
analysed by western blotting (A and B) and enzyme assay (C). The effect of DTP 2 mM is shown in D and E. Cell extracts
were treated with N-Glycosidase F and then analysed by WB (F). Standard deviations is indicated by bars and differences
that are statistically significant are flagged by * when compared to the control with DMSO (p < 0.05:*; p < 0.01: **;
p < 0.001:***), are flagged by § when compared to DTP (p < 0.01:§§; p < 0.001:§§§).
doi:10.1371/journal.pone.0165463.g005
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Fig 6. 2–6 dithiopurine promotes processing of some mutant human alpha-galactosidase. COS-7 cells were
cultured in conventional medium and transfected with plasmid containing C56Y, C63Y and E341D mutants. Cells were
treated with: DTP 6 mM, DGJ 1 microM, DGJ 1 microM plus DTP 6 mM. All the molecules were dissolved in DMSO and
an appropriate control was realized. After 48 h incubation, the cells were scraped and lysed then water-soluble extracts
were analysed by western blotting (A, B and C) and enzyme assay (D). Standard deviations are indicated by bars.
doi:10.1371/journal.pone.0165463.g006
Fig 7. 2–6 dithiopurine has no effect on mutations affecting the allosteric site. COS-7 cells were cultured in conventional medium
and transfected with plasmid containing A37T, P40S, M42T, M42V mutants. Cells were treated with DTP 6 mM dissolved in DMSO and an
appropriate control was realized. After 48 h incubation, the cells were scraped and lysed then water-soluble extracts were analysed by
western blotting (A and B) and enzyme assay (C). Standard deviations are indicated by bars.
doi:10.1371/journal.pone.0165463.g007
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suggest that it should be tested in the cases that receive a positive score with Fabry_CEP [45],
but fail to respond to DGJ. We are aware that the interaction of DTP with AGAL, which occurs
in vitro only at high concentration, cannot exclude non specific off-target effects of the drug on
protein homeostasis. Derivatives of DTP obtained by techniques of lead optimization and
medicinal chemistrymight prove to be effective at lower doses and more specific.
Supporting Information
S1 Fig. 2–6 dithiopurine does not stabilizes human lysosomalphosphomannomutase2 in
thermal shift assay. Human Phosphomannomutase2 (in Na-Hepes 20 mM, NaCl 150 mM,
MgCl2 1mM pH 7.4) was equilibrated in the presence of ligands dissolved in DMSO 20%: DTP
6 mM (empty circle) and glucose 1, 6 bisphosphate (G16) 0.5 mM (filled squares) as a positive
control. A control (with only DMSO) was also shown (filled circles).
(TIF)
S2 Fig. 2–6 dithiopurine has no effect on somemutations that are not responsive to DGJ.
COS-7 cells were cultured in conventional medium and transfected with plasmid containing
R118C, S126C and C172G mutants. Cells were treated with: DTP 6 mM, DGJ 1 microM, DGJ
1 microM plus DTP 6 mM. All the moleculeswere dissolved in DMSO and an appropriate con-
trol was realized. After 48 h incubation, the cells were scraped and lysed then water-soluble
extracts were analysed by western blotting (A, B and C) and enzyme assay (D). Standard devia-
tions are indicated by bars.
(TIF)
S3 Fig. 2–6 dithiopurine has no effect on somemutations that are responsive to DGJ. COS-
7 cells were cultured in conventional medium and transfected with plasmid containing L310F,
L300F, Q280K and G360C mutants. Cells were treated with DTP 6 mM. All the molecules were
dissolved in DMSO and an appropriate control was realized. After 48 h incubation, the cells
were scraped and lysed then water-soluble extracts were analysed by western blotting (A, B)
and enzyme assay (C). Standard deviations are indicated by bars.
(TIF)
S1 File. Uncropped gels. Images are relative to gels shown in Figs 4, 5, 6 and 7.
(PDF)
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a b s t r a c t
Cholinesterase inhibition is one of the most treatment strategies against Alzheimer's disease (AD) where
metal accumulation is also strongly associated with pathology of the disease. In the current study, we
assessed inhibitory effect against acetyl- (AChE) and butyrylcholinesterase (BChE) and metal-chelating
capacity of twelve diterpenes: arucadiol, miltirone, tanshinone IIa, 1-oxomiltirone, cryptotanshinone,
1,2-didehydromiltirone, 1,2-didehydrotanshinone IIa, 1b-hydroxycryptotanshinone, 15,16-
dihydrotanshinone, tanshinone I, isotanshinone II, 1(S)-hydroxytanshinone IIa, and rosmarinic acid,
isolated from Perovskia atriplicifolia and Salvia glutinosa. The compounds were tested at 10 mg/mL using
ELISA microtiter assays against AChE and BChE. QSAR and molecular docking studies have been also
performed on the active compounds.
All of the compounds showed higher [e.g., IC50 ¼ 1.12 ± 0.07 mg/mL for 1,2-didehydromiltirone,
IC50 ¼ 1.15 ± 0.07 mg/mL for cryptotanshinone, IC50 ¼ 1.20 ± 0.03 mg/mL for arucadiol, etc.)] or closer [1,2-
didehydrotanshinone IIa (IC50 ¼ 5.98 ± 0.49 mg/mL) and 1(S)-hydroxytanshinone IIa
(IC50 ¼ 5.71 ± 0.27 mg/mL)] inhibition against BChE as compared to that of galanthamine
(IC50 ¼ 12.56 ± 0.37 mg/mL), whereas only 15,16-dihydrotanshinone moderately inhibited AChE
(65.17 ± 1.39%). 1,2-Didehydrotanshinone IIa (48.94 ± 0.26%) and 1(S)-hydroxytanshinone IIa
(47.18 ± 5.10%) possessed the highest metal-chelation capacity. The present study affords an evidence for
the fact that selective BChE inhibitors should be further investigated as promising candidate molecules
for AD therapy.
© 2016 Elsevier Ltd. All rights reserved.
1. Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative
disorder with complex pathology that affects particularly elderly
population. Pathogenesis of the disease still remains indistinct in
most parts due to its multifactorial etiology (Guzior et al., 2015).
Cholinergic hypothesis is one of the most accepted approaches to
explain AD pathology which asserts the deficit in acetylcholine
(ACh) amount as an apparent evident in the brains of AD patients.
Since ACh is hydrolyzed by acetylcholinesterase (AChE), inhibition
of this enzyme has been a popular approach for AD treatment and,
in this regard, cholinesterase (ChE) inhibitors such as rivastigmine,
tacrin, donepezil, and galanthamine are the most prescribed drug
* Corresponding author.
** Corresponding author.
E-mail addresses: hperez@ucam.edu (H. Perez-Sanchez), iorhan@gazi.edu.tr
(I.E. Orhan).
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class towards AD (Orhan et al., 2011). Other member of ChE family
is butyrylcholinesterase (BChE), which is also considered as
promising target for AD drug discovery since it enzymatic activity
upsurges in the late stages of AD. In fact, it has been reported that
BChE inhibitors can also act in a similar way to those of AChE
inhibitors and slows down cognitive decline (Li et al., 2008).
Tanshinones are red to orange-colored nor-abietanoid qui-
nones obtained mainly from Salviae miltiorrhizae radix (danshen,
roots and rhizomes of S. miltiorrhiza Bunge), an important tradi-
tional Chinese herb (Chen et al., 2014) and have been reported to
exhibit some desired pharmacological activities such as anticancer
(Li et al., 2008), anti-aging (Wu et al., 2014), anticonvulsant
(Buenafe et al., 2013), etc. Actually, one of them, e.g. tanshinone IIa,
is currently under phase-III clinical trial for treatment of cardio-
vascular conditions (Shang et al., 2013). Besides S. miltiorrhiza,
several other species of the genus Salvia. along with a few other
genera from the Lamiaceae contain tanshinones in various pro-
portions. Salvia glutinosa L. is a common plant growing in moun-
tainous deciduous forests throughout Europe and in Caucasus.
Notwithstanding, only little information is available on its phyto-
chemical profile up to date. Perovskia atriplicifolia Benth. belongs
to a small genus of aromatic shrubs growing in arid habitats of
Central Asia, which is considered a sister genus to Salvia L. and
Rosmarinus L. from Lamiaceae. Several varieties of P. atriplicifolia
are cultivated worldwide for ornamental purpose, known as
“Russian sage”. Although presence of a large number of auspicious
ChE inhibitors has been reported from plants, only a few tan-
shinone derivatives have been investigated for their ChE
inhibitory potential (Zhou et al., 2011). Consequently, we
undertook the present study in order to test twelve nor-
abietanoids - arucadiol (1), miltirone (2), tanshinone IIa (3), 1-
oxomiltirone (4), cryptotanshinone (5), 1,2-didehydromiltirone
(6), 1,2-didehydrotanshinone IIa (7), 1b-OH-cryptotanshinone (8),
15,16-dihydrotanshinone (9), tanshinone I (10), isotanshinone II
(11), 1(S)-OH-tanshinone IIa (12) as well as rosmarinic acid (13)
(Fig. 1), isolated by our group from the roots of P. atriplicifolia
(Slusarczyka et al., 2015) or S. glutinosa, against AChE and BChE as
well as their metal-chelating properties in vitro.
2. Results and discussion
2.1. ChE inhibitory activity
Compounds 1e13 isolated from Perovskia atriplicifolia and Salvia
glutinosawere assayed in vitro against AChE and BChE at 10 mg/mL.
Except compound 12, all of them exerted higher activity against
BChE than the reference drug (galanthamine) (Table 1), whereas
only compound 9 inhibited AChE moderately. The most potent
BChE-inhibiting compound was miltirone 2.
2.2. Metal-chelation capacity
All of the compounds tested displayed a lower metal-chelation
capacity than 50% (Fig. 2), where only 1,2-didehydrotanshinone
IIa (7, 48.94 ± 0.26%) and b-OH-tanshinone IIa (12, 47.18 ± 5.10%)
were revealed to have the highest metal-chelation capacity than
the rest, which is still below 50%.
2.3. QSAR modeling
Following the computational strategies outlined in the methods
section, the most stable models obtained are presented in Table 2.
We obtained moderately stable models for AChE and for the re-
ceptor selectivity. For BChE inhibitory activity stable and predictive
models were not obtained due to the low values of Q2LOO and Q2boot.
Noting the sign of the coefficients of each descriptorwe can say that
high values of HGM and R2m have a positive influence in the AChE
inhibitory activity, as well as low values in SpMax7_Bh(s) and
RDF080s have a positive influence in BChE inhibitory activity.
Moreover, low values of HATS2u and R3m have an increment in the
selectivity between BChE and AChE receptors. Since the model
developed for the BChE receiver does not offer conclusive results,
wewill focus on the model obtained for the selectivity between the
two receptors. The descriptors HATS2u and R3m are part of the
family of descriptors called GETAWAY that encode information on
structural fragments and therefore they seem to be particularly
suitable for describing differences in congeneric series of mole-
cules, as in the present case. These two descriptors report high
values with the presence in the molecule of external atoms more
close to each other in the molecular space. In this regard, we
observed that the presence of aliphatic groups such as isopropyl (C2
or C6) (farthest atoms) compared to an aromatic ring such as 3-
methyl furan (C3 or C7) (atoms closer) causes a decrease in the
values of both descriptors and thus an increase in selectivity for
BChE versus AChE receptor. So, we emphasized that the presence of
more aliphatic substituents make the molecules more selective for
BChE versus AChE receptor, whereas the presence of more aromatic
substituents make the molecules more selective for AChE versus
BChE receptor.
2.4. Molecular docking
Docking calculations for control compounds, e.g. acetylcholine
(ACh) and butyrylcholine (BCh) were carried out in order to test
capability of the protocol to predict residues that are widely known
to interact with these molecules (Bajda et al., 2013). The results
obtained for ACh in the cavity of AChE and BCh in the cavity of
BChE, respectively, are illustrated in Figs. 3 and 4. In both cases, ACh
and BCh lie close to residues from the catalytic triad, in total
agreement with the enzymatic mechanisms. Therefore, we can
continue forward and analyze the information that docking
methods can yield for the compounds reported in this work. For
that aim, we have focused on the two most representative com-

















PDB Protein data bank
PTZ Pentylenetetrazol
QSAR Quantitative structure-activity relationship
S.E.M. Standard error of the mean
TLC Thin layer chromatography
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in Table 2, C9 is the one that inhibits AChE the most effectively
which has inhibitory activity close to 100% for BChE. Compounds
from 1 to 12 share the same chemical scaffold, hence, which
directed us to focus first on the docking results obtained for C9
against both enzymes, and later on C13, which is a totally different
chemical entity. In Fig. 5, docking results for C9 against AChE are
shown. Main interactions are pi-pi stacking with TYR334 and hy-
drophobic interactions with PHE330, situated at the gorge of the
active site of the enzyme. This way, C9 blocks ACh access to the
catalytic triad, and thus inhibits the enzyme. In addition, crystal-
lographic pose of drug Aricept® is shown in Fig. 6 (purple skeleton)
and we can observe that both molecules share same interaction
area and, as a result, similar enzyme blockingmechanism. From the
other side, docking results for C9 against BChE are shown in Fig. 6.
In this case, main interactions between the compound and enzyme
are due to hydrogen bonds formed between oxygen atoms from
carbonyl groups of C9 and HIS438 from catalytic triad as well as
hydrophobic interactions of C9 with residues TRP82, LEU286 and
VAL288. Here, C9 blocks entry of BCh and also interferes with
availability of HIS438 for interacting with BCh, which leads to the
suggestion that inhibition should be higher here than in the case of
AChE, where only the entry of substrate was blocked. Nevertheless,
the residues from the active site were still free for interactions. As a
final point, interactions of C13 within BChE active site were also
studied as revealed in Fig. 7. According to the findings, main in-
teractions are due to hydrogen bonds between hydroxyl groups of
the compound and residues TRP82 and TYR128, hence, blocking
access of substrate to the catalytic triad.
Fig. 1. Structures of compounds 1e13. Example of carbon atom numbering is shown for nor-diterpenoids in compound 5 (cryptotanshinone).
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The cholinergic hypothesis proposes that AD is caused by a
decrease in ACh level in the brain as well as BCh, leading to gradual
neurodegeneration. In normal brain signaling, ACh is related to
preserving and accessing memory as well as functioning, so
increasing level of ACh is now one of the current pharmacother-
apies of AD. As mentioned earlier, one of the treatment possibilities
has focused on inhibition of the sister enzymes AChE and BChE by
natural plant substances. In this regard, a variety of medicinal
plants has been reported to show AChE inhibitory activity and, so,
may be relevant to the treatment of neurodegenerative disorders
such as AD. A list of plants with noteworthy AChE inhibitory activity
seems to be long, but also limited by the appearance of central and
peripheral side effects (Mukherjee et al., 2007).
The tanshinones have been already reported to display a wide
range of pharmacological activities such as cardioprotective, anti-
cancer, antioxidant, mitochondria-protective, etc. (Adams et al.,
2006). S. miltiorrhiza and some other plant species, i.e. P. abrota-
noides Kar. (Sairafianpour et al., 2001) and S. columbariae Benth.
(Adams et al., 2005), are the known sources of these compounds;
while the species studied herein (P. atriplicifolia and S. glutinosa)
have also been identified as novel sources for tanshinones. Neu-
roprotective property of tanshinones, which are lipid-soluble and
have ability to pass blood-brain barrier, have been revealed in
several studies, e.g. reduction in injured cortex neurons (He et al.,
Table 1
AChE and BChE inhibitory activity (%inhibition ± S.E.M.) and IC50 values of compounds 1e13.
Compound (% Inhibition ± S.E.M.a) (at 10 mg/mL) IC50 values (mg/mL) for BChE inhibition
AChE BChE
1 Arucadiol eb 91.97 ± 0.08 1.20 ± 0.03
2 Miltirone e 98.36 ± 0.89 0.90 ± 0.05
3 Tanshinone IIa 45.16 ± 5.49**** 97.41 ± 0.23 2.79 ± 0.25
4 1-Oksomiltirone 11.08 ± 0.38**** 77.45 ± 1.97 5.06 ± 0.89
5 Cryptotanshinone 28.95 ± 1.74**** 74.37 ± 3.57 1.15 ± 0.07
6 1,2-Didehydromiltirone 10.08 ± 2.22**** 97.36 ± 2.78 1.12 ± 0.07
7 1,2-Didehydrotanshinone IIa 41.88 ± 2.05**** 67.65 ± 1.88* 5.98 ± 0.49
8 1b-OH-Cryptotanshinone 17.70 ± 3.86**** 93.15 ± 2.31 1.21 ± 0.10
9 15,16-Dihydrotanshinone 65.17 ± 1.39** 94.88 ± 1.88 1.71 ± 0.23
10 Tanshinone I 6.19 ± 3.91**** 85.84 ± 4.15 11.24 ± 0.65
11 Isotanshinone II 5.55 ± 3.03**** 77.81 ± 1.45* 9.16 ± 0.11
12 1(S)-OH-Tanshinone IIa 36.32 ± 1.85**** 64.50 ± 1.50* 5.71 ± 0.27
13 Rosmarinic acid 28.18 ± 5.13**** 80.74 ± 4.03 6.59 ± 0.37
Ref.c Galanthamine 85.64 ± 0.78 67.72 ± 1.70 12.56 ± 0.37
[*p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001].
a Standard error mean (n ¼ 3).
b No inhibition.
c Reference for AChE and BChE inhibition tested at 12.5 mg/mL.
Fig. 2. Metal-chelation capacity (% ±S.E.M.) of the compounds 1e13 and reference (EDTA).
Table 2
Statistical parameters extracted for QSAR models.
Receptor Std. Coeff. Descriptor Std. Coeff. Descriptor R2 Q2LOO Q2boot a(R2) a(Q2) F s
AChE 0.47 HGM 0.70 R2m 0.95 0.93 0.91 0.23 0.23 83.64 0.18
BChE 0.76 SpMax7_Bh(s) 0.64 RDF080s 0.66 0.54 0.48 0.32 0.25 8.91 0.34
Selectivity 1.02 HATS2u 0.46 R3m 0.91 0.86 0.79 0.28 0.27 45.13 0.34
F.S. Senol et al. / Phytochemistry 133 (2017) 33e4436
HELENA DEN HAAN 29
2001), decrease in brain injury in tanshinone IIA and IIB-treated
mice through reducing brain infarct volume and edema as well as
restoration of neurological function in an experimental model of
stroke in vivo (Lam et al., 2003), anticonvulsant activity via inhib-
iting pentylenetetrazol (PTZ)-induced seizure activity in zebrafish
larvae (Buenafe et al., 2013), and protecting pyramidal neurons of
the hippocampal CA1 region (CA1) after transient cerebral ischemia
in gerbils via increasing of neurotrophic factors (Park et al., 2014).
Moreover, tanshinones isolated from S. miltiorrhiza together with
phenolic acids have shown protective effect against b-amyloid-
induced cytotoxicity and acted as inhibitors of AChE, probably with
dual mechanism of action (Zhou et al., 2011). Accordingly, the roots
of P. atriplicifolia and S. glutinosa can play a neuroprotective role due
to containing similar active components. Multiple mechanisms of
action of tanshinones and phenolic components as neuroprotective
agents relevant to AD have been described such as anti-amyloid-b,
antioxidant, anti-apoptosis, ChE inhibition, metal-chelation, and
anti-inflammation (Bonaccini et al., 2015). Tanshinone I, tan-
shinone IIA, cryptotanshinone, and 15,16-dihydrotanshinone were
demonstrated to reverse scopolamine-induced cognitive impair-
ments using passive avoidance task test in mice by Kim et al.
(2007). In the same study, modest inhibitory effect of cryptotan-
shinone and 15,16-dihydrotanshinone I was found in vitrowith IC50
values 82 and 25 mM, respectively, whereas IC50 value of tacrine
(the reference) was 118.66 nM, which is consistent with our data on
these compounds (Table 1). On the other hand, dihydrotanshinone,
cryptotanshinone, tanshinone I, and tanshinone IIA were also
tested by Ren et al. (2004) against AChE and the most potent ones
Fig. 3. Interactions of acetylcholine with residues within binding site of AChE. Crystal structure used was PDB:1EVE. Residues are colored according to their binding area as yellow
(catalytic triad), pink (anionic site), grey (acyl pocket), blue (oxyanion hole) and green (peripheral anionic site). (For interpretation of the references to color in this figure legend, the
reader is referred to the web version of this article.)
Fig. 4. Interactions of butyrylcholine with residues within binding site of BChE. Crystal structure used was PDB:1P0I. Residues are colored according to their binding area as yellow
(catalytic triad), pink (anionic site), grey (acyl pocket), blue (oxyanion hole) and green (peripheral anionic site). (For interpretation of the references to color in this figure legend, the
reader is referred to the web version of this article.)
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were established as dihydrotanshinone (IC50 ¼ 1.0 mM) and cryp-
totanshinone (IC50 ¼ 7.0 mM). However, tanshinone I and IIA dis-
played low inhibition in this assay, which is in complete accordance
with our current findings. Relevantly, tanshinones exhibited
modulating effect on AChE and nitric oxide synthase concentra-
tions in the hippocampus of rats with AD, whichwas suggestive of a
benefit in AD (Yin et al., 2008). We previously reported in vitro
inhibitory effect of rosmarinic acid from Rosmarinus officinalis L.
against AChE and BChE (47.3 ± 1.05% and 85.8 ± 1.31%, respectively)
(Orhan et al., 2008) and found consistent results for rosmarinic acid
in the presentwork isolated from S. glutinosa, which was proceeded
to in silico study herein.
Our current investigation revealed significant inhibitory activity
of the isolated tanshinones and rosmarinic acid towards BChE, and
mostly a weak inhibition to AChE. Among them, the most potent
compound against AChE was found to be 15,16-dihydrotanshinone
(9) with 65.17% of inhibition having affinity toward BChE (94.88%,
IC50 ¼ 1.71 mg/mL) which was even higher than that of galanth-
amine (67.72%, IC50 ¼ 12.56 mg/mL). Consequently, it was chosen as
a representative model for in silico experiments of this study in
addition to rosmarinic acid (13).
Molecular docking analysis was used to simulate the binding
conformations of tanshinones and rosmarinic acid into the active
gorge of AChE and BChE. There is still insufficient information
explaining potential SAR and QSAR of tanshinones towards ChEs. It
should be noted that this is the first study on BChE inhibitory effect
of isolated diterpenes and rosmarinic acid, all of which exerted
much stronger inhibition toward BChE rather than AChE.
Fig. 5. Interactions of 15,16-dihydrotanshinone (9) (white skeleton) with residues within binding site of AChE. Crystal structure used was PDB:1EVE. Residues are colored according
to their binding area as yellow (catalytic triad), pink (anionic site) and green (peripheral anionic site). Drug Aricept® is depicted with purple skeleton. (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of this article.)
Fig. 6. Interactions of 15,16-dihydrotanshinone (9) with residues within binding site of BChE. Crystal structure used was PDB:1P0I. Residues are colored according to their binding
area as yellow (catalytic triad), pink (anionic site), grey (acyl pocket), blue (oxyanion hole) and green (peripheral anionic site). (For interpretation of the references to color in this
figure legend, the reader is referred to the web version of this article.)
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Tanshinones were shown to have inhibition of major micro-
somal cytochrome (CYP) isoforms that metabolize testosterone to
hydroxytestosterone in the male rat liver, suggesting potential
importance of furan group. The structural difference between
15,16-dihydrotanshinone and tanshinone I at carbon 15 position of
furan ring resulted in the different modes of inhibition of CYP3A
activity (Wang and Yeung, 2011). Hence, it might bring a possible
explanation for affecting BChE and AChE by this compound. Mil-
tirone inhibited BChE by more than 98%, which was the strongest
activity among the tested compounds. However, miltirone did not
inhibit AChE, what can be explained by possessing of isopropyl
group instead of furan rings, and spatial conformation difference of
binding in the enzyme active cavity.
Metal-chelation effect of is related to AD pathology as metal
ions, i.e. Cu2þ, Zn2þ, and Fe3þ, accumulates in the brain which
causes oxidative damage. Therefore, it might be considered ad-
vantageous to have a metal-chelating property for an anti-AD drug
candidate besides cholinesterase inhibition or reduction in b-am-
yloid plaque formation (Rowinska-Zyrek et al., 2015). In this regard,
when we tested the compounds 1e13 for their possible metal-
chelating effect, all of them exerted capacity to chelate Fe3þ
below 50% (Fig. 2). Only 1,2-didehydrotanshinone IIa and 1-OH-
tanshinone IIa had a closer effect to 50%.
3. Conclusion
In the current study, a number of tanshinones as well as ros-
marinic acid isolated from Perovskia atriplicifolia and Salvia gluti-
nosa have been revealed to exert a strong BChE inhibitory activity
and relatively weaker inhibition against AChE. According to our
findings, all of the compounds tested could be good precursor
models for BChE-inhibiting molecules and among them, 15,16-
dihydrotanshinone (9) in particular could be more promising
since it can display dual inhibition toward both enzymes effec-
tively. Moreover, our in silico data well-matched with the in vitro
outcomes of this study. The in silico results indicated that QSAR
models developed in this work can yield insights about AChE/BChE
selectivity, while molecular docking results revealed that com-
pounds 1e12 share similar interaction patterns, related to
hydrophobic and pi-pi stacking interactions in the case of AChE,
thus blocking entry of substrate, and in the case of BChE, main
interactions are due to hydrogen bonds with the catalytic triad, or
TRP82 and TYR128. In this study, we disclose the first in silico
study on cholinesterase inhibitory effect of tanshinones and ros-
marinic acid, while the first BChE inhibitory data for the tested
compounds, which have promising neuroprotective potential
particularly for AD treatment.
4. Experimental
4.1. Chemicals
All solvents used for this work were of analytical grade and
purchased from POCh (Gliwice, Poland) and Chempur (Piekary,
Poland). HPLC-quality deionized water was obtained using
Hydrolab system (Neunhuben, Poland). LC-MS grade acetonitrile;
methanol, water, and formic acid were obtained from J.T. Baker,
(Deventer, Netherlands).
4.2. Plant materials
The root samples of cultivated P. atriplicifolia Benth. and
S. glutinosa L. (both Lamiaceae) were harvested from the certified
collection of Botanical Garden of Medicinal Plants in Wrocław,
Poland (Ministry of Environment decision No. DOPogiz-4210-26-
6024-/05/kl) in the fall season of 2012. The voucher specimens
have been preserved in the herbarium of the Botanical Garden
under the accession no. “Lamiaceae-Patriplicifolia 2012/1-4” and
“Lamiaceae-Sglutinosa-2012-1”, respectively.
4.3. Instrumentation and chromatographic conditions
4.3.1. Analytical HPLC-MS/MS
The HPLC system (Shimadzu, Japan) consisted of an LC-30ADXR
Pump, DGU-20A3 degasser, SIL-20AXR auto sampler, aCTO-
10ASVP column heater, and a CBM-20A system controller. For
the isolated compounds 1e13, we used an optimization method
(without chromatographic column separation with direction
Fig. 7. Interactions of rosmarinic acid (13) with residues within binding site of BChE. Crystal structure used was PDB:1P0I. Residues are colored according to their binding area as
yellow (catalytic triad), pink (anionic site), grey (acyl pocket), blue (oxyanion hole) and green (peripheral anionic site). (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
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injection to MS system), which allows selection of collision energy
and prominent MS/MS product ions. All data acquisition and peak
integration were performed using LabSolution (5.53 SP2) from
Shimadzu Ltd.
4.3.2. MS/MS
Mass spectrometric (MS) detection was performed on a Shi-
madzu triple-quadrupole system LC/MS-8030 with electrospray
ionization (ESI). The analytes were determined in positive ioniza-
tion mode and quantified by multiple-reaction monitoring (MRM).
The parameters and conditions were optimized as follows: capil-
lary voltage 4.5 kV, desolvatation line (DL) temperature 250 C, heat
block temperature 400 C, nebulizing gas flow and drying gas flow
were 3 L/min and 15 L/min, respectively. The [MþH]þ ion was
selected for collision-activated dissociation (CID) studies as the
precursor ion.
4.3.3. NMR spectroscopy
NMR data were acquired at room temperature on a Bruker
Avance III™ 500 MHz spectrometer (Bruker, F€allanden,
Switzerland) operating at 500.13 MHz for 1H, and 125.77 MHz for
13C experiments. A 1 mm TXI-microprobe with a z-gradient was
used for 1H-detected experiments; whilst 13C-NMR spectra were
recorded with a 5 mm BBO-probe head with z-gradient. Structure
assignment was achieved by comprehensive analysis of 2D NMR
data (1H-1H COSY, HMBC, and HSQC correlation) and by comparison
with the literature data. Purity of the isolated substances was 95%
as calculated by integration of the 1H-NMR spectra. Topspin 2.0
software was used for data processing.
4.4. Isolation procedure of compounds 1e13
The dried and ground plantmaterials from P. atriplicifolia (250 g)
and S. glutinosa (376 g) were extracted in ultrasonic bath (IS-40,
Intersonic, Poland) with n-hexane (1.4 L) four times in 25 C for 4 h
for each and filtrated. The n-hexane phases were evaporated in
vacuo to dryness which finally yielded 2.87 g of n-hexane extract of
P. atriplicifolia. Isolation of compounds was explained in detail in
our recent study (Slusarczyka et al., 2015) on P. atriplicifolia, briefly,
the n-hexane extract of S. glutinosa (1.4 g) was applied on glass
column (50  5 cm) filled with silica gel 60 (200 g, 60e200 mesh).
The column was eluted with dichloromethane-ethyl acetate
(EtOAc) step gradient with EtOAc increasing from 5% to 100%
(Table 1). The eluted fractions (31 in total) were monitored on thin
layer chromatography (TLC, Merck SG-60 F254) and combined
accordingly to obtain 10 subfractions (Table 3). Then, each sub-
fraction was subsequently purified (Table 2) on flash chromatog-
raphy column with n-hexane-EtOAc stepwise gradient starting
from 0.5% EtOAc, then, 2%, 5%, 10%, and 30% of EtOAc and/or pre-
parative TLC on (Silica 20 20, thicknesses 2 mm, Merck Germany)
with n-hexane: EtOAc (9:1 v/v). Details of the isolated compounds
are presented in Tables 3 and 4.
4.5. Structure assignment of compounds 1e13
All isolated compounds were identified based on their MS/MS
and 1D and 2D NMR spectra (NMR details in the Supplemental file,
Table S1). Spectral characteristics (see SI) were in agreement with
literature data (Nagy et al., 1999; Sairafianpour et al., 2001; Lee
et al., 2005; Slusarczyka et al., 2015). Nine of the isolated diter-
penes; arucadiol (1), miltirone (2), tanshinone IIa (3), 1-
oxomiltirone (4), cryptotanshinone (5), 1,2-didehydromiltirone
(6), 1,2-didehydrotanshinone IIa (7), 1b-OH-cryptotanshinone (8)
as well as rosmarinic acid (13) were identified as described in our
previous paper (Slusarczyka et al., 2015 and the references therein),
whereas 15,16-dihydrotanshinone (9), tanshinone I (10), iso-
tanshinone II (11) and 1(S)-OH-tanshinone IIa (12) from S. glutinosa
have been characterized in this study as given below. From this
species, we isolated seven compounds, four of which (9e12) were
not detected in the P. atriplicifolia extract, whereas three other
compounds (3, 5, and 6) were common in P. atriplicifolia. For
compounds 6 and 12, this is a first record of their occurrence in
S. glutinosa.
15,16-Dihydrotanshinone (9): Molecular ion m/z 279 [MþH]þ for
compound 9 is a close analog of tanshinone I (10) with only small
difference between C15eC16 for lack of double bond andmolecular
formula C18H14O3. The fragmentation gave minor ions at m/z 261
[MþHH2O]þ, m/z 233 [MþHH2OCO]þ and m/z 205
[MþHH2O2CO]þ, which were attributed to successive losses of
H2O and CO. Other two product ions at m/z 218
[MþHH2OCOCH3]þ and 190 [MþHH2O2COCH3]þ were
attributed to losses of CH3 radical residue from the precursor ions
m/z 233 and 218, respectively. For compound 9, H1-NMR experi-
ment was done as well.
Tanshinone I (10):m/z 277 [MþH]þ generated preferential losses
of CO and CH3 radical cause to product ions atm/z 249 [MþHCO]þ,
m/z 234 [MþHCOCH3]þ, m/z 221 [MþH2CO]þ and m/z 193
[MþH3CO]þ, respectively. Additionally, in order to confirm its
structure, 1H-NMR experiment was done and results were
compared in detail with the available literature data (Lee et al.,
2005).
Isotanshinone II (11): 1H-NMR spectrum of compound 11 was
very similar to that of compound 10, however signals of proton H6
and H7 in the spectrum appeared as an quartet d 8.36, d 8.38
(J¼ 8.8 Hz) instead of doublet at d 8.32 H-6, and d 7.83 H-7 in that of
compound 10. MRM fragmentation pathway of 11 was similar as
well and we observed molecular ion m/z 277 [MþH]þand m/z 249
[MþHCO]þ, m/z 234 [MþHCOCH3]þ, m/z 221 [MþH2CO]þ
and m/z 193 [MþH3CO]þ, respectively. This compound was iso-
lated previously from this species by Nagy et al. (1999).
1(S)-OH tanshinone IIa (12): Compound 12 possesses hydroxyl
group in C1 position. The target molecular ion in MRM experiments
was m/z 311 [MþH]þ. In positive ion mode, we observed the loss of
a H2O moiety as dominant ion fragmentation at m/z 293
[MþHH2O]þ, followed by COmoiety loss producing ion atm/z 265
[MþHH2OCO]þ, and small abundant fragment corresponding
with the loss of two H2O molecules m/z 275 [MþH2H2O]þ. The
structure was confirmed by 1H-NMR experiments, where OH group
in A ring was revealed as resulting from oxidation of methin group
in position H-1 d 5.36 (dd, J¼ 3.4, 3.41H) d 5.27 (brq, J¼ 3.51H) that
additionally improved 13C-NMR signal for carbon in this position C-
1 d 64.1 ppm. The other NMR signals were similar to those of tan-
shinone IIa (3). The stereochemistry of C1 hydroxyl group was
confirmed by circular dichroismmeasurement. Hydroxytanshinone
IIa was previously isolated by Sairafianpour et al. (2001) from
Perovskia roots but was optically inactive and was interpreted as a
photooxidation product of non-biosynthetic origin. Therefore, we
have also measured circular dichroism using Jasco 1500 CD-
Table 3
Step gradient column fractionation of the n-hexane extract S. glutinosa.
Eluent Volume [ml] Obtained fractions F
DCM 500 1e7





50% EtOAc in MeOH 200 29e30
100% MeOH 400 31
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spectrophotometer (Jasco, Japan) of 12, dissolved in 80% MeOH at
1 mM and superimposed the experimental spectrum over the
simulated spectrum calculated using TDDFT (see Supplementary
information, Fig. S1).
Considering compound 12 isolated from our material, the CD
spectrum revealed the evident circular dichroism indicating optical
activity that was attributed to hydroxylation of the asymmetric
carbon 1 in configuration unambiguously established as 1-S. This
compound is reported for the first time as a natural product from
S. glutinosa.
4.6. Microtiter assays for AChE and BChE inhibition
AChE and BChE inhibitory activity of the compounds was
determined by modified spectrophotometric method of Ellman
et al. (1961). Electric eel AChE (Type-VI-S, EC 3.1.1.7, Sigma) and
horse serum BChE (EC 3.1.1.8, Sigma) were used as the enzyme
sources, while acetylthiocholine iodide and butyrylthiocholine
chloride (Sigma, St. Louis, MO, USA)were employed as substrates of
the reaction. 5,50-Dithio-bis(2-nitrobenzoic)acid (DTNB, Sigma, St.
Louis, MO, USA) was used for the measurement of the cholines-
terase activity. All the other reagents and conditions were the same
as described in our previous publication (Georgiev et al., 2011). In
brief, 140 mL of 0.1 mM sodium phosphate buffer (pH 8.0), 20 mL of
0.2 M DTNB, 20 mL of sample solutions and 20 mL of 0.2 M acetyl-
cholinesterase/butyrylcholinesterase solution were added by
multichannel automatic pipette (Gilson pipetman, France) in a 96-
well microplate and incubated for 15 min at 25 C. The reactionwas
then initiated with the addition of 10 mL of 0.2 M acetylthiocholine
iodide/butyrylthiocholine chloride. The hydrolysis of acetylth-
iocholine iodide/butyrylthiocholine chloride was monitored by the
formation of the yellow 5-thio-2-nitrobenzoate anion as a result of
the reaction of DTNB with thiocholines, catalyzed by enzymes at a
wavelength of 412 nm utilizing a 96-well microplate reader (Ver-
saMax, Molecular Devices, USA). Galanthamine, the anticholines-
terase alkaloid-type of drug isolated from the bulbs of snowdrop
(Galanthus sp.), was purchased from Sigma (St. Louis, MO, USA) and
was employed as the reference.
4.7. Data processing for enzyme inhibition assays
The measurements and calculations were evaluated by using
Softmax PRO 4.3.2.LS software. Percentage of inhibition of AChE/
BChE was determined by comparison of rates of reaction of test
samples relative to blank sample (ethanol in phosphate buffer
pH ¼ 8). Extent of the enzymatic reaction was calculated based on
the following equation: E ¼ (C  T)/C  100, where E is the activity
of the enzyme. E value expresses the effect of the test sample or the
positive control on AChE and BChE enzyme activity articulated as
the percentage of the remaining activity in the presence of test
sample or positive control. C value is the absorbance of the control
solvent (blank) in the presence of enzyme, where T is the absor-
bance of the tested sample (plant extract or positive control in the
solvent) in the presence of enzyme.
Data are expressed as average inhibition ± standard error mean
(S.E.M.) and the results were taken from at least three independent
experiments performed in triplicate.
4.8. Feþ2-ferrozine test system for metal-chelation capacity
The metal-chelating effect of the extracts by Feþ2-ferrozine test
system was estimated using Chua et al.'s (2008) method. Accord-
ingly, 740 mL of ethanol and 200 mL of the samples dissolved in
ethanol (75%) were incubated with 2 mM FeCl2 solution. The re-
action was initiated by the addition of 40 mL of 5 mM ferrozine
solution into the mixture, shaken vigorously, and left standing at
ambient temperature for 10 min. The absorbance of the reaction
mixture was measured at 562 nm. Ethylenediaminetetraacetic acid
(EDTA) was employed as the reference in this assay and metal-
chelation capacity was calculated as given below and the results
were expressed as percent inhibition (I%):
I% ¼ [(Ablank  Asample)/Ablank]  100, where Ablank is the
absorbance of the control reaction (containing all reagents except
the test sample), and Asample is the absorbance of the extracts.
Analyses were run in triplicate and the results were expressed as
average values with S.E.M. (Standard error of the mean).
4.9. Statistical analysis of data
Data obtained from in vitro enzyme inhibition experiments were
expressed as the SEM. Statistical differences between the reference
and the sample groups were evaluated by ANOVA (one way).
Dunnett's multiple comparison tests were used as post hoc tests.
p < 0.05 was considered to be significant [*p < 0.05; **p < 0.01;
***p < 0.001, ****p < 0.0001].
4.10. QSAR modeling
Assessment of quantitative structure-activity relationship
(QSAR) is a technique widely used in medicinal chemistry
(Nantasenamat et al., 2009; Roy and Das, 2014). With this tech-
nique, we can correlate the observed biological activity with a se-
ries of variables called descriptors that codify several aspects of the
molecules under study, such as structure, topology, charge distri-
bution, etc. Thus, these methods have predictive abilities and they
can also be used in the analysis of structural characteristics that can
give rise to the activities of interest.
For this work, the activity values used to develop a QSARmodels
Table 4
Process and amount of compounds isolated from the n-hexane extract S. glutinosa.
Fraction combination Amount (mg) Process of purification Obtained compounds (mg)
F1eF10 81 Flash chromatography Tanshinone IIa (16.4)
F11 18 NPa
F12 184.2 Flash chromatography Cryptotanshinone (23)
Tanshinone I (7.2)
F13 63.5 Preparative chromatography 1,2-Dihydrotanshinone (9.5)
F14 74.5 Preparative chromatography Isotanshinone II (2.4)
F15 32.8 NP
F16eF17 289.6 Flash chromatography 15,16-Dihydrotanshinone IIa (38.6)
F18eF19 89.4 Flash chromatography 1(S)-OH-Tanshinone IIa (13.1)
F20eF23 172.7 NP
F24eF31 113.2 NP
a Not purified because of lack of target compounds or too small amount.
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were based on the transformation of the inhibition percentage
given in Table 1. The activity was transformed into logarithmic by
the equation:
I ¼ log½%I=ð100 %IÞ (1)
Where %I was the inhibition percentage.
We did also study the selectivity between two receptors for the
compounds of Table 2, being selectivity a widely used aspect in
drug design and QSAR (Salt et al., 2004; Weber et al., 2006;
Helguera et al., 2013). For selectivity models, we used the differ-
ence between both activities and for both receptors through the
following equation:
S ¼ IðBChEÞ  IðAChEÞ (2)
Where I(BChE) and I(AChE) was the activities calculated by Eq. (1)
for BChE and AChE inhibition activity, respectively.
Fig. 8. Optimized structures at the selected DFT level of theory. Each atom is colored by the computed ESP charge (see charge color range). (For interpretation of the references to
color in this figure legend, the reader is referred to the web version of this article.)
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The DRAGON (Todeschini et al., 2004) and MOE (2008) de-
scriptors were used as the variables to correlate with the activities
and applied a full search procedure for selecting the variables, as
implemented in Mobydigs software ver. 1.0.43. Goodness of fit of
the models was assessed by examining the determination coeffi-
cient (R2), the standard deviation (s), and the Fisher ratio (F). The
robustness and predictivity of the models were evaluated bymeans
of cross-validation, basically leave-one-out (LOO) (Cruciani et al.,
1992) and bootstrapping testing techniques (Efron, 1987) were
calculated with the training set, by looking to the outcome statistics
of both techniques (i.e. Q2LOO and Q2boot). Further, the stability
under heavy perturbations in the training set was checked by
examining the outcome statistics of a response randomization
procedure (Y scrambling) for the training and test sets (a(R2) and
a(Q2) values) (Lindgren et al., 1996). Good quality of the models is
indicated by high F and by low s, as well as by values closed to one
for R2, Q2LOO and Q2boot and values of a(R2) and a(Q2) close to
zero.
4.11. Molecular docking experiments
The geometry of each ligand was fully optimized within the
density functional theory (DFT) framework at the B3LYP/6-31G(d)
level (Becke, 1993; Lee et al., 2005). Vibrational calculations were
subsequently performed to ascertain the nature of every localized
structure: a stable structure corresponds to a minimum in the
potential energy surface and consequently all frequencies are real.
Partial atomic charges were next computed by using the Merz-
Singh-Kollman ESP protocol (Singh and Kollman, 1984; Besler
et al., 1990) to be used during docking simulations. All quantum
chemical calculations were performedwith the Gaussian 09 suite of
programs (Gaussian, 2009), and partial charges distribution for all
compounds that can be seen from Table 2 and Fig. 8.
The molecular structures used in this study were built manually
using AutoDock tools (Morris et al., 2009) or derived from experi-
mental data. The structures for AChE and BChEwere extracted from
the crystal structures of protein data bank (PDB) with codes 1EVE
and 1P0I, respectively and converted to PDBQT format using default
parameters. Molecular docking calculations were carried out using
default parameters in AutoDock Vina (Trott and Olson, 2010).
Graphical representations of the docking results were prepared
using PyMOL (Molecular Graphics System, version 1.3, Schr€odinger,
LLC).
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A B S T R A C T
S. grandis Freitag, Vural & N. Adıgüzel is an endemic plant species to Turkey. Since some other Salsola
species have been reported to exert cholinesterase inhibitory effect, we aimed to investigate its inhibitory
potential against AChE. The EtOH extract and thirteen constituents [ten flavonol derivatives; e.g.
isorhamnetin-3-O-rutinoside (1), quercetin-3-O-rutinoside (2), quercetin-3-O-metylether (3), tiliroside
(4), isorhamnetin-3-glucuronide (5), isorhamnetin-3-O-glucoside (6), quercetin-3-O-galactoside (7),
quercetin-3-O-rhamnoside (8), quercetin (9), and manghaslin (10), two oleanane-type saponosides; e.g.
momordin II b (11) and IIc (12) as well as one amino acid derivative, N-acetyltryptophan (13)] isolated
from the aerial parts of Salsola grandis (Chenopodiaceae) were tested for their possible inhibitory activity
against acetylcholinesterase (AChE), related to pathogenesis of Alzheimer’s disease. Although the EtOH
extract was inactive, among the isolated compounds, only compound 13 exerted a notable inhibition of
64.90  1.61% at 50 mg mL1, while compound 12 displayed a low inhibition (21.72  0.99%). Then,
compound 13 was further subjected to molecular modeling experiments in order to give insights about
its interactions at atomic level with AChE. The data indicated that N-acetyltryptophan (13) could be a
promising model molecule for AD treatment.
ã 2016 Phytochemical Society of Europe. Published by Elsevier Ltd. All rights reserved.
1. Introduction
The genus Salsola L. (Chenopodiaceae) is represented by sixteen
species in the flora of Turkey, among which S. grandis Freitag, Vural
& N. Adıgüzel is an endemic species (Freitag, 2000). The
phytochemical studies on Salsola species have pointed out to rich
presence of alkaloids in particular such as salsolin and salsolidin,
besides flavonoids and isoflavonoids (Dauletmuratov and Komar-
ova,1980; Mnatsakanyan et al.,1981; Berhanu and Yordanos,1990),
lignans, saponosides, and coumarins (Narantuyaa et al., 1986;
Syrchina et al., 1992; Han et al., 2003). Salsola species have been
reported to contain various constituents that have shown several
biological activities such as anti-inflammatory, analgesic, anti-
hypertensive, antioxidant, hepatoprotective, and tyrosinase inhib-
itory activity (Nofal et al., 2002; Han et al., 2003). In a previous
study, the alkaloid extracts from S. oppositofolia Desf., S. soda L., and
S. tragus L. growing in Italy were reported to have a varying degree
of inhibition against acetylcholinesterase (AChE, EC 3.1.1.7) (Tundis
et al., 2009).
AChE inhibitors are currently the most prescribed drug class for
the treatment of Alzheimer’s disease (AD), which is a progressive
neurodegenerative disease encountered mainly in elderly popula-
tion. According to the cholinergic hypothesis, deficit of acetylcho-
line (ACh) has been found in the brains of AD patients and,
therefore, inhibition of AChE, the critical enzyme that hydrolyses
ACh, is the most accepted treatment approach toward AD (Orhan
et al., 2011). Several AChE inhibitors such as tacrine, rivastigmine,
donepezil, and galanthamine are clinically available (Hogan, 2014).
Abbreviations: ACh, acetylcholine; AChE, acetylcholinesterase; AD, Alzheimer’s
disease; MPLC, medium pressure liquid chromatography; NMR, , nuclear magnetic
resonance; SCC, silica gel column chromatography; TLC, thin layer chromatography.
* Corresponding author.
E-mail address: iorhan@gazi.edu.tr (I.E. Orhan).
1 To whom all molecular modeling correspondence should be addressed.
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However, due to their side effects and limited bioavailability, new
AChE inhibitors of both natural and synthetic origins are under an
extensive search.
Up to date, we have investigated a large number of medicinal
plants as well as natural compounds using in vitro and in silico
(molecular docking) experiments, which led us to find different
cholinesterase inhibitors such as Salvia L. species, Angelica
officinalis L., Hypericum perforatum L., etc. (Senol et al., 2011a,b;
Altun et al., 2013). As part of our ongoing efforts for this purpose,
we have now aimed to investigate AChE inhibitory potential of the
isolated constituents (1–13) and the main ethanol (EtOH) extract
from Salsola grandis in the current study.
2. Results and discussion
Our phytochemical studies on the main EtOH extract of the
aerial parts of S. grandis resulted in isolation of thirteen known
compounds (Fig. 1). The chemical structures of the isolated
flavonoids and saponosides were identified as isorhamnetin-3-O-
rutinoside (1), quercetin-3-O-rutinoside (2), quercetin-3-O-mety-
lether (3), tiliroside (4), isorhamnetin-3-glucuronide (5), isorham-
netin-3-O-glucoside (6), quercetin-3-O-galactoside (7), quercetin-
3-O-rhamnoside (8), quercetin (9), and manghaslin (10), momor-
din II b (11), and momordin II c (12) by comparing their
spectroscopic data with the relevant literatures previously
published (Mabry et al., 1970; Mnatsakanyan et al., 1981; Tomas
et al., 1985; Vidal-Ollivier et al., 1989; Mizui et al., 1990; De Rosa
et al., 2000; Kazuma et al., 2003; Tsukamoto et al., 2004; Guvenalp
and Demirezer, 2005; Simon et al., 2006). Among them,
compounds 3, 4, 5, 7, 8, 10,11, and 12 have been found to be
isolated from the genus Salsola for the first time (Kucukboyaci
et al., 2016). It should be also noted that presence of compounds 1,
2, 6, 9, and 13 were reported for the first time in S. grandis by our
group. Compound 13 was earlier isolated from S. collina Pall., which
is widely distributed in Northeastern and Southwestern of China
(Jin et al., 2011).
In spite of the large number of isolated compounds in the EtOH








1 Isorhamnetin-3-O-rutinoside OCH3 6-O-α-L-Rhamnopyranosyl-β-D-glucopyrano se
2 Quercetin-3-O-ruti noside OH 6-O-α-L-Rhamnopyranosyl-β-D-glucopyrano se
3 Quercetin-3-O-metylether OH CH3
4 Tili roside H 4-O-E-Coumaroyl-β-D-glucopyrano se
5 Isorhamnetin-3-glucuron ide OCH3 β-D-Glucuron opyrano se
6 Isorhamnetin-3-O-glucoside OCH3 β-D-Glucopyranose
7 Quercetin-3-O-galactoside OH β-D-Galactopyranose
8 Quercetin-3-O-rhamnoside OH α-L-Rhamnopyranose
9 Quercetin OH H
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Fig. 1. Chemical structures of the isolated compounds 1-13.
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AChE inhibition (64.90  1.61%) at 50 mg mL1, whilst a low level of
inhibition was observed with compound 12 (21.72  0.99%) at the
same concentration (Table 1).
Docking calculations for control compound acetylcholine (ACh)
were carried out in order to test capability of the protocol to predict
residues that are widely known to interact with ACh (Bajda et al.,
2013). In Fig. 3, the results obtained for ACh in the cavity of AChE
are illustrated. We can observe that ACh lies close to residues from
the catalytic triad, totally in agreement with the enzymatic
mechanisms. Therefore, we can continue forward and analyze the
information that docking methods can yield for the new compound
reported in this work. In Fig. 4, docking results for compound 13
against AChE are shown. Key interactions are due to hydrogen
bonds with residues GLU199 and TYR121. This way, compound 13
blocks ACh access to the catalytic triad, and thus, inhibits the
enzyme. In addition, crystallographic pose of the drug Aricept1
(purple skeleton) is shown in Fig. 4 and both molecules are
observed to share the same interaction area and, therefore, similar
enzyme blocking mechanism.
The genus Salsola consists of well-known medicinal plants with
folkloric use and various pharmacological activities desired for
human health. At the best of our knowledge, this work is the first
attempt aimed at rationalizing the cholinesterase inhibitory effect
of Salsola grandis. Nevertheless, a few studies earlier demonstrated
cholinesterase inhibitory effect of several other Salsola species up
to date. For instance; in an earlier similar study by Tundis et al.
(2009), the major components were identified by gas chromatog-
raphy-mass spectrometry (GC–MS) as tetrahydroisoquinoline
alkaloids; salsoline, N-methylisosalsolidine, salsolidine, and car-
negine in the alkaloid extracts of the aerial parts of S. oppositofolia,
S. soda, and S. tragus of Italian origin having varying levels of
inhibition against AChE and butyrlcholinesterase (BChE). Besides
alkaloids, hydroxycinnamic acid, and flavonoid derivatives were
also reported to be present in Salsola species (Oueslati et al., 2006;
Rasheed et al., 2013), while the root extract prepared from S.
vermiculata displayed a robust AChE-inhibiting property (Rasheed
et al., 2013). Indeed, triterpene derivatives from S. bryosma were
demonstrated with BChE inhibitory activity (Ahmed et al., 2007).
The compounds 1, 5, and 6, the isorhamnetin-derivative
flavonoids isolated from S. grandis, did not inhibit AChE. According
to our literature survey, no study is available so far on
cholinesterase inhibitory action of isorhamnetin derivatives.
Nevertheless, a marked number of studies have been published
on anti-cholinesterase effect of quercetin (9) and its derivatives.
Actually, we also previously demonstrated some level of inhibition
by quercetin against both AChE and BChE using in vitro and in silico
methods (Khan et al., 2009), where its inhibitory effect was mild
(IC50 = 353.86 mM) in comparison to that of the reference (galanth-
amine, IC50 = 0.75 mM). Consequently, ineffectiveness of quercetin
(9) against AChE in our study could be explained to be resulted
from testing at a very low concentration herein due to scarcity of
amount of the compound. On the other hand, 3-O-methylquercetin
and 3,7-O-dimethylquercetin isolated from Cistus laurifolius L.
were also not able to inhibit AChE (Akkol et al., 2012) as the
quercetin derivatives isolated herein did not have any inhibition.
Another report by Kim et al. (2014) indicated that quercetin-3-O-
glucuronide and isorahmnetin-3-O-glucuronide strongly inhibited
AChE with IC50 vaules of 8.2 and 23.2 mM, respectively.
Momordin and its glycosides were firstly isolated from
Momordica charantia L., and later on, Panax bipinnatifidus Seem.
and Kochia scoparia (L.) Schrad. However, this compound does not
possess cholinesterase inhibitory effect as we have shown herein
for the first time.
Molecular docking analysis was used to simulate the binding
conformation of compound 13 into the active gorge of AChE
enzyme and provide information about which are the most
important interactions between the compound and the enzyme,
namely hydrogen bonds with residues GLU199 and TYR121. These
results reveal structure of the active site allow us to complete the
picture of the interaction pattern involved.
3. Experimental section
3.1. Chemicals
In the extraction procedure, ethanol (EtOH), n-hexane, chloro-
form (CHCl3), ethyl acetate (EtOAc), and n-butanol (n-BuOH) were
of analytical grade and purchased from Merck Co. Analytical thin
layer chromatography (TLC) was performed on precoated Kieselgel
60 F254 plates (Art. 5554, Merck). The plates sprayed with 1%
vanillin-H2SO4 solution [vanillin (Boehringer Mannheim) and
H2SO4 (Merck Co.)].
3.2. Plant material
The aerial parts of S. grandis were collected at flowering stage
from Nallihan bird sanctuary (Ankara, Turkey) in July 2010 and
identified by Prof. Dr. Mecit Vural from the Department of Botany,
Faculty of Science, Gazi University (Ankara, Turkey). A voucher
specimen (GUE 2641) is deposited at the Herbarium of Faculty of
Pharmacy, Gazi University, Turkey.
3.3. Extraction, fractionation and purification procedure
The aerial parts of the plant sample were dried in shade at room
temperature and powdered to a fine grade using a laboratory scale
mill. The powdered plant material (2270 g) was extracted with 96%
EtOH (30 L) at room temperature and evaporated to dryness under
reduced pressure below 40 C to yield “EtOH extract” (185.28 g).
The EtOH extract (127.54 g) was firstly dissolved in 200 mL of EtOH
and extracted with n-hexane (8  300 mL) in a separatory funnel.
Combined n-hexane extracts were evaporated under reduced
pressure to yield “n-Hexane subextract” (21.71 g). After removal of
EtOH from the remaining extract, it was diluted with distilled H2O
to 150 mL and further fractionated by successive solvent extrac-
tions with CHCl3 (5  250 mL), EtOAc (10  300 mL), and n-BuOH
saturated with H2O (13  300 mL). Each extract as well as the
remaining water phase after solvent extractions was evaporated to
dryness under reduced pressure to yield “CHCl3 subextract”
Table 1
AChE inhibitory activity (%  S.E.M.) of the compounds 1-13.
Samples Inhibition against AChE













12 21.72  0.99****
13 64.90  1.61**
Galanthamined 94.07  0.89
a Standard error mean (n = 3).
b Final concentration in microplate well is 5 mg mL1.
c No inhibition.
d Reference for AChE and BChE inhibition tested at 1000 mg mL1.
*p < 0.05.**p < 0.01.***p < 0.001.****p < 0.0001.
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(3.63 g), “EtOAc subextract” (3.74 g), “n-BuOH subextract” (17.76 g)
and “R-H2O subextract” (52.84 g), respectively.
Chromatographic separation of the n-BuOH subextract using
silica gel and Sephadex LH-20 column chromatography techniques
led us to isolate thirteen compounds identified as ten known
flavonol derivatives; i.e. isorhamnetin-3-O-rutinoside (1), querce-
tin-3-O-rutinoside (2), quercetin-3-O-metylether (3), tiliroside (4),
isorhamnetin-3-glucuronide (5), isorhamnetin-3-O-glucoside (6),
quercetin-3-O-galactoside (7), quercetin-3-O-rhamnoside (8),
quercetin (9), and manghaslin (10), two oleanane-type
saponosides; momordin II b (11) and IIc (12) as well as one amino
acid derivative, N-acetyltryptophan (13). Details of the isolation
procedure and chemical characterization were reported in our
recently published paper (Kucukboyaci et al., 2016).
3.4. Microtiter assay for determination of AChE inhibition
AChE inhibitory activity of the main EtOH extract of S.grandis
and compounds 1-13 was measured by slightly modified
spectrophotometric method of Ellman et al. (1961). Electric eel
AChE (Type-VI-S; EC 3.1.1.7, Sigma, St. Louis, MO, USA) was used,
while acetylthiocholine iodide (Sigma, St. Louis, MO, USA) was
employed as the substrate of the reaction. 5,50-Dithio-bis(2-
nitrobenzoic)acid (DTNB; Sigma, St. Louis, MO, USA) was used for
the measurement of the anti-AChE activity. Briefly, in this method,
140 mL of sodium phosphate buffer (pH 8.0), 20 mL of DTNB, 20 mL
of test solution and 20 mL of AChE solution were added by
multichannel automatic pipette (Gilson pipetman, Paris, France) in
a 96-well microplate and incubated for 15 min at 25 C. The
reaction was then initiated with the addition of 10 mL of
acetylthiocholine iodide. Hydrolysis of acetylthiocholine iodide
was monitored by the formation of the yellow 5-thio-2-nitro-
benzoate anion as a result of the reaction of DTNB with
thiocholines, catalyzed by enzymes at 412 nm utilizing a 96-well
microplate reader (VersaMax Molecular Devices, Sunnyvale, CA,
USA). The measurements and calculations were evaluated by using
Softmax PRO 4.3.2.LS software (Sunnyvale, CA, USA). Percentage of
AChE inhibition was determined by comparison of reaction rates of
the samples relative to blank sample (ethanol in phosphate buffer
pH = 8) using the formula (E-S)/E  100, where E is the activity of
enzyme without test sample and S is the activity of enzyme with
test sample. The experiments were done in triplicate.
Fig. 2. Molecular electrostatic potential map computed for compound 13 (Red and
blue colors stand for negative and positive regions, respectively).(For interpretation
of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
Fig. 3. Interactions of acetylcholine with residues within binding site of AChE [Crystal structure used was PDB:1EVE. Residues are colored according to their binding area as
yellow (catalytic triad), pink (anionic site), grey (acyl pocket), blue (oxyanion hole) and green (peripheral anionic site)].(For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this article.)
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Galanthamine (Sigma, St. Louis, MO, USA), the anticholinesterase
alkaloid-type of drug obtained from the bulbs of snowdrop
(Galanthus sp.), was used as the reference.
3.5. Statistical analysis of in vitro data
Data obtained from in vitro enzyme inhibition assays were
expressed as the mean standard error (SEM). Statistical differ-
ences between the reference and the sample groups were
evaluated by ANOVA (one way). Dunnett’s multiple comparison
tests were used as post hoc tests. p < 0.05 was considered to be
significant [*p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001].
3.6. Molecular modeling experiments
Molecular modeling experiments have been performed only on
compound 13 as it was the only one having AChE inhibition over
50%. The geometry compound 13 was fully optimized within the
density functional theory (DFT) framework at the B3LYP/6-31G(d)
level (Lee et al., 1998; Becker, 1993). Frequency calculations were
subsequently performed to ascertain the nature of every localized
structure: a stable structure corresponds to a minimum in the
potential energy surface and consequently all frequencies are real.
Partial atomic charges were next computed by using the Merz-
Singh-Kollman ESP protocol (Singh and Kollman,1984; Besler et al.,
1990) to be used during docking simulations. Quantum chemical
calculations were performed with the Gaussian 09 suite of
programs (Gaussian, 2009), and distribution of partial charges
for compound 13 can be seen in Fig. 2.
The structure for AChE was extracted from the crystal structures
of Protein Data Bank (PDB) with code 1EVE and converted to
PDBQT format using default parameters of AutoDock tools (Morris
et al., 2009). Molecular docking calculations were carried out using
default parameters in AutoDock Vina (Trott and Olson, 2010).
Graphical representations of the docking results were rendered
with PyMOL (Molecular Graphics System, version 1.3, Schrödinger,
LLC).
4. Conclusions
In the present study, only N-acetyltryptophan (13) among
thirteen compounds (1-13) isolated from S. grandis has been
revealed to exert a prominent AChE inhibitory activity In addition
to the in vitro data for compound 13, molecular modeling studies
using the selected computational protocol provided an insight into
interpreting these results at atomic level, which revealed that
compound 13 shares a similar interaction pattern to the one of the
known drug donepezil (Aricept1). In this study, we disclose the
first in vitro and in silico study on cholinesterase inhibitory effect of
N-acetyltryptophan, which might be a promising precursor model
for AChE-inhibiting molecules with neuroprotective potential
particularly for AD treatment.
Fig. 4. Interactions of compound 13 (orange skeleton, representation in sticks) with residues within binding site of AChE [Crystal structure used was PDB:1EVE. Residues are
colored according to their binding area as yellow (catalytic triad), pink (anionic site) and green (peripheral anionic site). Drug Aricept1 is depicted with purple skeleton.
Hydrogen bonds established between compound 13 and residues TYR121 and GLU199 (these two resides are cyan colored) are depicted with yellow dashed lines].(For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Cholinergic therapy based on cholinesterase (ChE) inhibitory drugs is the mainstay for the treatment of
Alzheimer’s disease. Therefore, an extensive research has been continuing for the discovery of drug candidates
as inhibitors of acetyl- and butyrylcholinesterase. In this study, two natural molecules, e.g. hyperforin and
hyuganin C were tested in vitro for their AChE and BChE inhibitory activity. Both of the compounds were
ineffective against AChE, whereas hyperforin (IC50=141.60�3.39 μM) and hyuganin C (IC50=38.86�1.69 μM)
were found to be the highly active inhibitors of BChE as compared to galantamine (IC50=46.58�0.91 μM) which
was used as the reference. Then, these molecules were further proceeded to molecular docking experiments in
order to establish their interactions at the active site of BChE. The molecular docking results indicated that both
of them are able to block the access to key residues in the catalytic triad of the enzyme, while they complement
some of the hydrophobic residues of the cavity, what is consistent with our in vitro data. While both compounds
were predicted as mutagenic, only hyuganin C showed hepatotoxicity in in silico analysis. According to whole
outcomes that we obtained, particularly hyuganin C besides hyperforin are the promising BChE inhibitors, which
can be the promising compounds for AD therapy.
Keywords: butyrylcholinesterase, enzyme inhibition, molecular docking, natural products, coumarin.
Introduction
Alzheimer’s disease (AD), is a progressive neurodege-
nerative disorder with a complex pathogenesis, which
mainly affects the elderly population and currently it is
the most common type of dementia. For instance; the
number of AD patients only in US was assessed as 5.3
million people, which is estimated to increase up to
7.1 million by 2025.[1,2] Although the pathogenesis of
AD is still under debate, yet, two major mechanisms
have been proposed in order to elucidate the patho-
genesis of the disease as ‘amyloid hypothesis’ and
‘cholinergic hypothesis’.[3] In cholinergic hypothesis,
deficiency in cholinergic neurotransmission through
acetylcholine (ACh) and butyrylcholine (BCh) has been
proven in the brains of AD patients. ACh and BCh are
hydrolyzed by two sister enzymes from cholinesterase
(ChE) family available in the brains of mammals; e.g.
acetylcholinesterase (AChE, EC 3.1.1.7) and butyrylcho-
linesterase (BChE, EC 3.1.1.8), respectively. Therefore,
ChE inhibitors are the mostly prescribed drug class for
the treatment of AD at the moment.[4]
Although BChE, also found in neurons and glia,
possesses ability to hydrolyze ACh, it is known to be
less specific to this substrate than AChE.[5] It has been
reported that BChE activity is increased up to 120%
DOI: 10.1002/cbdv.201900017 FULL PAPER
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and excess amount of the enzyme was observed in AD
patients.[6] However, despite inhibition of BChE is an
important strategy, currently, almost all cholinesterase
inhibitors used in clinic target AChE.[7]
Natural molecules have been highlighted as prom-
ising targets in drug discovery and development
research since numerous clinically available drugs
have been firstly derived from a natural compound.
Up to date, many strong enzyme inhibitors of natural
origin related to cholinesterases have been
reported.[8–11] Among all possible candidates, hyper-
forin (a prenylated carbocyclic acylphloroglucinol de-
rivative) and hyuganin C (coumarin derivative) are the
natural molecules from Hypericum perforatum L. (St.
John’s wort, Hypericeae) and Mutellina purpurea (POIR.)
REDURON, CHARPIN & PIMENOV (Apiaceae), respectively
(Figure 1).[12]
The aim of the present contribution is to inves-
tigate ChE inhibitory potential of these two natural
compounds through in vitro and in silico techniques.
This particular choice of hyperforin as target com-
pound was guided by data available on ChE inhibitory
activity of H. perforatum extracts from findings by our
and other research groups.[13–15] However, no data
was available on type of compounds responsible for
the ChE inhibitory effect of this plant. On the other
hand, coumarin derivatives have shown a marked ChE
inhibitory effect in many studies.[16,17] Therefore, we
decided to test hyperforin and hyuganin C for their
possible ChE inhibitory potential using ELISA microtiter
assays. Later, their BChE inhibitory results were
evaluated by molecular docking experiments and
energy calculations. Additionally, in silico toxicological
analysis were performed on these compounds.
Results and Discussion
Natural products have been shown to exert strong
enzyme inhibitory properties in many cases. Hyper-
forin, one of the well-known biomolecules found in H.
perforatum, has been reported to contribute to
antidepressant effect of the plant. As discussed else-
where, the ethyl acetate extract exerted BChE inhib-
ition (50.79�3.07%) at 200 μgmL  1, which was con-
sistent with a similar study on the same plant growing
in Poland.[18] Since hyperforin amount has been
usually found to be higher than that of hypericin in
this plant,[14,15] we have tested BChE inhibitory effect
of hyperforin in particular. Actually, hyperforin as a
lipophilic natural compound has been shown to
possess neuroprotective effect by various mechanisms
via reducing microglia-mediated neuro-
inflammation,[19] blocking degradation of calpain-
mediated transient receptor potential canonical (sub-
type) 6 channels,[20] improving cognitive performance
through decreasing astrogliosis and microglia activa-
tion as well as increasing spatial memory in vivo[21]
and N-methyl-D-aspartate (NMDA)-antagonistic
effect.[22] Depending on its neuroprotective effect,
hyperforin has been suggested as a promising alter-
native for elderly patients with degenerative disorders
most of who also develop depression as shown by the
latest research.[23–25] Consequently, the current results
on the moderate BChE inhibitory effect of hyperforin
(IC50=141.60�3.39 μM) may also donate to its neuro-
protective effect (Table 1).
Many coumarin derivatives of both natural and
synthetic origins have been shown to possess strong
ChE inhibitory properties.[4,16,17] For instance; 7-hy-
droxycoumarin derivatives[26,27] as well as 4-
methylcoumarins[28] were suggested to be promising
synthetic lead molecules with coumarin skeleton.
Besides, we have revealed three coumarins, e.g.
imperatorin, xanthotoxin, and bergapten isolated from
the fruits of Angelica officinalis L., with a potent BChE
inhibition,[29] while mesuagenin B was reported from
Mesua elegans (KING) KOSTERM. as a marked BChE-
inhibiting coumarin derivative.[30] Taking these find-
ings into account, hyuganin C was tested herein for its
probable ChE-inhibiting effect. Actually, hyuganin C
obtained from Mutellina purpurea is a rare coumarin
Figure 1. Chemical structures of hyperforin and hyuganin C.
Table 1. IC50 Values ([μM]) of hyperforin and hyuganin C (n=3;
� SD)
Compounds tested IC50 [μM]
AChE inhibition BChE inhibition
Hyperforin – 141.60�3.39
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derivative, which was previously isolated only from
Peucedanum japonicum THUNB.[31] and Angelica furciju-
ga KITAGAWA from Apiaceae family.[32] In our wide
screening of natural molecules for their enzyme
inhibitory potential, we have discovered potent BChE
inhibitory activity of hyuganin C (IC50=38.86�
1.69 μM), which was superior to that of galantamine
(IC50=46.58�0.91 μM), the reference drug (Table 1).
Since only a few BChE inhibitors are available,
hyuganin C could be a new model compound for anti-
Alzheimer drug leads acting through this mechanism.
Taking the marked in vitro BChE inhibitory data of
these two natural molecules into consideration, they
were subjected to molecular docking experiments in
order to understand, at the molecular level, the
rationale under their inhibitory activity. Having that
information in hand is important, since it can help to
discover new molecules in the same context. After
analysis of docking results, energetic analysis of
docking results for both hyperforin and hyuganin C is
displayed in Figures 2 and 3.
On the other hand, Figures 4 and 5 show a
representation of the active site of the enzyme with
the two compounds docked and hydrogen bonds and
hydrophobic interactions highlighted. Energetically,
we can see that, in these two cases, the main
stabilizing interactions are electrostatic complementar-
ity between the ligands and the active site of the
enzyme (as reflected by the high values of Gauss1 and
Gauss2 terms), hydrophobic complementarity with
active site residues and established hydrogen bonds
(Figures 2 and 3). When the detailed representation of
docking poses (Figures 4 and 5) was investigated, we
could observe the directionality of the network of
hydrogens bond established and the complementarity
of hydrophobic interactions. In the case of hyperforin,
main hydrogen bonds are formed with residues SER79
and HIS438 (from catalytic triad), while the main
hydrophobic interactions are created with residues
TRP82, THR120, TRP231, VAL288, TYR332 (peripheral
anionic site), PHE398, TRP430, and TYR440. For
hyuganin C, a strong network of hydrogen bonds is
formed with residues GLY115, GLY116, GLY117,
SER198 and LEU286 (catalytic triad), while hydrophobic
interactions are set with residues TRP82 (peripheral
anionic site), PHE329 (anionic site) and PHE398. There-
fore, both compounds block the access to key residues
involved in the normal functioning of the enzyme
such as parts of the catalytic triad and anionic and
peripheral anionic sites and at the same time they
complement some of the hydrophobic residues of the
cavity. All these reasons can explain the inhibitory
activity of the mentioned compounds.
Because of the lack of toxicology data in the
literature for hyperforin and hyuganin C, computa-
tional toxicology assessments were performed for
these compounds and possible toxic effects partic-
ularly mutagenicity and hepatotoxicity were esti-
mated. The mutagenicity analysis was performed in
agreement with current international guideline recom-
Figure 2. Energetic contributions (kcal/mol) to binding of
hyperforin to BChE obtained from docking simulations.
Depicted contributions are; van der electrostatic interactions
type Gauss1 (dark blue) and Gauss2 (green), Repulsive term
(red), Hydrophobic term (light blue), hydrogen bonds (pink),
entropic losses associated with ligand’s rotatable bonds (yellow)
and total predicted binding energy (black).
Figure 3. Energetic contributions (kcal/mol) to binding of
hyuganin C to BChE obtained from docking simulations.
Depicted contributions are; van der electrostatic interactions
type Gauss1 (dark blue) and Gauss2 (green), Repulsive term
(red), Hydrophobic term (light blue), hydrogen bonds (pink),
entropic losses associated with ligand’s rotatable bonds (yellow)
and total predicted binding energy (black).
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mending the combined use of two complementary (Q)
SARs[33] and outcomes obtained from two systems
were assessed by combining[34] (Quantitative) struc-
ture-activity relationship ((Q)SAR) analysis have shown
that hyperforin has most likely mutagenic effect due
to carrying α,β-unsaturated carbonyl as a toxicophore
group. Hyuganin C has also shown mutagenicity. In
terms of hepatotoxicity, although the system did not
show potential hepatotoxicity for hyperforin, this
compound could be out of the applicability domain of
the model. However, hyuganin C was predicted as
hepatotoxic compound with high reliability in the
system. Considering the major predicted biological
and toxicological activity profiles for the compounds,
hyuganin C may cause dyspnea (Pa: 0.872) and sleep
disturbance (Pa: 0.783) while hyperforin have become
important for treatments of depression (Pa: 0.981),
mood disorders (Pa: 0.978), Alzheimer’s disease (Pa:
0.909), and neurodegenerative diseases (Pa: 0.906).
Although in silico methods are not yet capable of fully
replacing in vitro, in vivo toxicological testing or
epidemiological methods, these are suitable tools for
the initial safety screening of compounds. Recently,
regulatory authorities have increasingly supported the
application of these techniques. In addition to the
biological activity studies of hyperforin and hyuganin
C, the further analysis of the possible toxicities,
especially the toxic effects predicted in the study, will
contribute to the process of developing new drugs.
Conclusions
Screening of two natural molecules for their ChE
inhibitory potential resulted in finding a potent
inhibition by hyuganin C and moderate inhibition by
hyperforin in comparison to that of galantamine as
the reference drug, whereas none of them could
inhibit AChE. According to obtained results it can be
concluded that hyperforin is responsible for the
marked BChE inhibitory effect of Hypericum perfo-
ratum extracts reported previously. We herein also
provide with the molecular modeling results, which
enlighten the main interactions involved between
Figure 4. Interactions of hyperforin (orange skeleton, representation in sticks) with residues within binding site of BChE (Crystal
structure used was PDB:1P0I). Residues are colored according to their binding area as yellow (catalytic triad), pink (anionic site), and
green (peripheral anionic site). Hydrogen bonds established between hyperforin and residues HIS438 and SER79 are depicted with
deep blue dashed lines. Grey dashed lines represent hydrophobic interactions.
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the compounds and the enzyme. On the other hand,
hyuganin C seems to be a quite promising natural
compound which can serve as a lead for new drugs
for the treatment of AD.
Experimental Section
Compounds
Hyperforin (Sigma-H1792, purity�98% by HPLC) was
delivered by Sigma-Aldrich Co. (St. Louis, Missouri, USA),
while hyuganin C was isolated according to previously
described method.[8] Briefly, 50 g of the seeds of
Mutellina purpurea was powdered and then extracted
under the reflux with petroleum ether. 300 mg of the
obtained crude dry extract was subjected to high-
performance counter current chromatography (HP-CCC)
to further isolation. A mixture of n-heptane, ethyl acetate,
methanol, and water 3 :2 :3 :2 (v/v) was used. Finally,
hyuganin C was obtained in pure form (7.94 mg) within
26 minutes, which identified using LC-DAD-ESI-(Q)TOF-
MS, and 1D- and 2D-NMR techniques.
Microtiter Assays for ChE Inhibition
Slightly modified spectrophotometric Ellman
method[35] was used for determination of AChE and
BChE inhibitory activity. Electric eel AChE (Type-VI-S;
EC 3.1.1.7) and horse serum BChE (EC 3.1.1.8,) were
used. ACh iodide and BCh chloride were used as the
substrates of the reaction. DTNB (=5,5’-dithiobis(2-
nitrobenzoic acid)) was used for the measurement of
Figure 5. Interactions of hyuganin C (white skeleton, representation in sticks) with residues within binding site of BChE (Crystal
structure used was PDB:1P0I). Residues are colored according to their binding area as yellow (catalytic triad), pink (anionic site) and
green (peripheral anionic site). Hydrogen bonds established between hyperforin and residues GLY117, GLY115, GLY116, SER198 and
HIS438 and SER79 are depicted with deep blue dashed lines. Grey dashed lines represent hydrophobic interactions.
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the anticholinesterase activity and galantamine was
used as the reference drug. All substances were
delivered by Sigma (St. Louis, Missouri, USA). Briefly,
140 μL of sodium phosphate buffer (pH 8.0), 20 μL of
DTNB, 20 μL of test solution and 20 μL of AChE/BChE
solution were added in a 96-well microplate and
incubated for 15 min at 25 °C. The addition of 10 μL of
acetylthiocholine iodide/butyrylthiocholine chloride
initiated reaction. Hydrolysis of acetylthiocholine
iodide/butyrylthiocholine chloride was monitored by
the formation of the yellow 5-thio-2-nitrobenzoate
anion as a result of the reaction of DTNB with
thiocholines, catalyzed by enzymes at 412 nm utilizing
a 96-well microplate reader (VersaMax Molecular
Devices, Sunnyvale, CA, USA). SoftMax PRO 4.3.2.LS
software (Sunnyvale, CA, USA) was used for the
measurements and calculations. Comparison of reac-
tion rates of the samples relative to blank sample
(ethanol in phosphate buffer pH=8) using the formula
[(E  S)/E] ×100, where E is the activity of enzyme
without test sample and S is the activity of enzyme
with test sample, let to calculate the percentage of
inhibition of AChE/BChE. The experiments were per-
formed in triplicate.
Molecular Docking Experiments
The geometry of each ligand was fully optimized within
the density functional theory (DFT) framework at the
B3LYP/6-31G(d) level.[36,37] Vibrational calculations were
subsequently performed to ascertain the nature of every
localized structure: a stable structure corresponds to a
minimum in the potential energy surface and conse-
quently all frequencies are real. Partial atomic charges
were next computed by using the Merz–Singh–Kollman
ESP protocol to be used during docking simulations.[38,39]
All quantum chemical calculations were performed with
the Gaussian 09 suite of programs,[40] and partial charges
distribution for all compounds that can be seen from
Figures 2 and 3.
The molecular structures used in this study were
initially designed using AutoDock tools[41] or derived
from experimental data. The structure for BChE was
extracted from the crystal structure of Protein Data
Bank (PDB) with code 1P0I. The receptor was prepared
for docking in AutoDock by removing water mole-
cules, adding hydrogen atoms and Gasteiger charges,
merging non-polar hydrogens and assigning AD4
atom types. Molecular docking calculations were
carried out using default parameters in AutoDock
Vina.[42] Top pose of every compound was retained for
further analysis. Graphical representations of the
docking results were prepared using PyMOL (Molec-
ular Graphics System, version 1.6, Schrödinger, LLC).
In silico Toxicological Analysis
Mutagenic effects of the hyperforin and hyuganin C
were assessed with statistical-based (VEGA QSAR
model (v1.1.4) – mutagenicity (Ames test) consensus
model (v1.0.2)) and knowledge-based (Toxtree SAR
model (v3.1.0) – in vitro mutagenicity (Ames) alerts by
ISS) in silico systems. Toxtree model conducts the
Benigni/Bossa rulebase.[43] Mutagenicity consensus
model performs a consensus assessment using applic-
ability domain analysis based on the predictions of the
CAESAR, SarPy, ISS and KNN mutagenicity models.
QSAR model for hepatotoxicity was performed based
on the VEGA hepatotoxicity model (IRFMN) 1.0.0. For
prediction of the compounds’ potential biological
activities and possible adverse/toxic effects in humans,
PASS (Prediction of Activity Spectra for Substances)
software (v2.0) was used. The program output file
represents a list of biological or toxicological effects
with two probabilities as Pa (probability to be active)
and Pi (probability to be inactive). In this study, Pa>
0.7, which indicates that the compound is very likely
to show activity in experiments, was taken into
consideration.
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A B S T R A C T
Isoflavonoids and stilbenes were suggested as potential lead structures for inhibition of cholinesterases and in
management of dementia. The Traditional Chinese (TCM) herb Belamcandae chinensis rhizoma (the rhizome of
Iris domestica (L.) Goldblatt & Mabb) contains both classes of natural products. Here, we isolated eight iso-
flavonoids: irisflorentin (1), tectorigenin(2), iristectorigenin B(3), irigenin (4), irilin D (5), iridin (6), tectoridin
(7), iristectorin B (8), two stilbenes; piceatannol (9) and resveratrol (10) as well as the xanthone glucoside –
mangiferin (11). The compounds weretested against acetyl- (AChE) and butyrylcholinesterase (BChE) using
ELISA microtiter assay. Molecular docking studies were also performed on the active compounds.
Among the tested polyphenols, piceatannol inhibited both cholinesterases (up to 67% and 91% of AChE and
BChE, respectively) whereas irilin D and resveratrol were only active against BChE. Irisflorentin was selective
but weak inhibitor against AChE (36% inhibition at 100 μg/mL). The remaining isoflavones were moderately
active against BChE (below 40% inhibition).
In conclusion, the TCM and pharmacopoeial drug – Belamcandae chinensis rhizoma is rich in potential cho-
linesterase inhibitors that can provide lead structures for further development of selective drugs. Moreover, the
in vitro results would suggest a novel indication of this traditional anti-inflammatory, phytoestrogenic and an-
tiallergic herb.
1. Introduction
Search for inhibitors of cholinesterases has been driven by their
pivotal role as a drug category that helps to slow down the debilitating
symptoms of neurodegenerative conditions, such as Alzheimer's disease
(AD). The cognitive impairment, developing towards severe dementia
can be temporarily managed by one of the few available
Acetylcholinesterase (AChE) inhibitors based on natural structures -
galanthamine and physostigmine. However, many other natural com-
pounds exert such action in vitro and in vivo but clinical evidence is
missing and their activity is usually rather moderate (Perry and Howes,
2011). Natural compounds usually differ in their selectivity to one of
the two forms, i.e AChE and butyrylcholinesterase (BChE), while the
typically preferred is rather AChE targeting. BChE, which is also
considered as promising target for drug discovery since it enzymatic
activity upsurges in the late stages of AD. In fact, it has been reported
that BChE inhibitors can also act in a similar way to those of AChE
inhibitors and slow down cognitive decline (Li et al., 2008).
Among a huge number of natural products that have been shown to
be inhibitors of in vitro activity of cholinesterases (Orhan et al., 2017,
2018), several classes of polyphenols are usually considered promising
(Pinho et al., 2013; Politeo et al., 2018). On the other hand, poly-
phenols showing such activity could also contribute to the dementia
prevention via their well-established antiinflammatory properties
(Sawikr et al., 2017). Thereof, stilbenoids, such as resveratrol, and
isoflavonoids, such as genistein are mentioned as markedly active and
as potential lead structures. However, among these two structural
classes, there are many more compounds that have not been studied.
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This drew our attention to the traditional medicinal plant that contains
both isoflavonoids and stilbenoids, among others.
Iris domestica (L.) Goldblatt & Mabb. (syn. Belamcanda chinensis L.)
DC. (Iridaceae) occurs naturally in South and East Asia. Despite the fact
that former monotypic genus Belamcanda has been included in the ex-
tended genus Iris, this classification has been questioned (Wilson, 2011;
Mavrodiev et al., 2014) and the final systematic position of this plant is
possible to be changed. To avoid the nomenclature ambiguity, we use
the commonly acknowledged pharmacognostic name of the drug Be-
lamcandae chinesis rhizoma instead of full binomial name (I. domestica).
Rhizomes are a pharmacopoeial raw material of East and South-East
Asian traditional phytotherapies under the pharmacognostic name
Belamcandae chinensis rhizoma, also known under the TCM name she-
gan. Pharmacological properties that have been confirmed by now,
include: antiinflammatory, antidiabetic, antiosteoporotic, estrogenic,
anti-allergic, anti-asthmatic, cytotoxic, and antimicrobial (Woźniak and
Matkowski, 2015; Szandruk et al., 2018). Apart from the Chinese,
Korean and a couple of other Asian Pharmacopoeias, also the European
Pharmacopoeia has been monographing the raw material of this plant
for several years, which proves its increasing popularity and usefulness
around the world. The main class of compounds responsible for this
broad spectrum of activity are polyphenols, among them isoflavones,
xanthones, stilbenes, and phenolic acids. Several cytotoxic iridal tri-
terpenes are also contributing to the overall phytochemical profile of
the plant (Woźniak and Matkowski, 2015). In the literature, various
methods of isolation and identification of main constituents from this
raw material can be found. On the other hand, there is still some degree
of inconsistency and ambiguity in the composition assessment. Despite
previous reports showing no anti-AChE activity of methanol extract
from she-gan (Kaufmann, 2016), we hypothesize that individual poly-
phenols due to their structural characteristics may demonstrate such
activity, also against BChE. Tectorigenin has been shown to have anti-
neuroinflammatory activity (Lim et al., 2018), and related Iris species
were active against cholinesterases (Conforti et al., 2009). The aim of
this work was to develop and optimize the method of isolation and
identification of polyphenolic compounds from Belamcandae chinensis
rhizoma for further bioactivity testing towards in vitro inhibition of two
cholinesterases - BChE and AChE. The most active compounds were also
assessed for their affinity to these enzymes by the molecular docking
study.
2. Results and discussion
2.1. Identification of compounds 1-10
All isolated compounds from Iris domestica extract (a representative
HPLC profile shown in Fig. 1) were identified based on MS/MS and
NMR spectra and have been characterized as given below. Their
structures and the annotation of NMR shift data are presented in Fig. 2.
The identification was based on the spectra analysis and available lit-
erature (Monthakantirat et al., 2005; Gómez-Zaleta et al., 2006; Lee
et al., 2011; Jun et al., 2012; Tisserant et al., 2016)
From this species, we obtained:
Compound 1 Irisflorentin white needle fluff (c= 0.13, MeOH:H2O
(1:1, v/v)). UV λmax (nm):220,265,323, HR-Q-TOF-MS (pos.) m/z
387.1082 [M+H]+, (calc.for C20H19O8 + =387.1074), diagnostic
fragment ions in positive at m/z m/z 372.0831 [M+H-15]+, 357.0600
[M+H-30]+, lost one and two −CH3 group respectively, 326.0782 lost
another two methyl groups. Lack of a clear and unambiguous signal in
negative mode.
Compound 2 5,7,4′-trihydroxy-6-methoxyisoflavone, Tectorigenin,
white amorphous powder (c= 0.13, MeOH:H2O (1:1, v/v)). UV λmax
(nm):220,265, HR-Q-TOF-MS (pos.) m/z 301.0704 [M+H]+, (calc.for
C16H13O6 + =301.0707), diagnostic fragment ions in positive at m/z
m/z 286.0466 [M+H-15]+, 268.0361 [M+H-18]+, lost methyl and
hydroxyl groups, HR-Q-TOF-MS (neg.) 299.0555[M−H]−,
621.0995[2M−H+Na]−, 284.0320[M−H-15]−, 256.0370[M−H-
28]−.
Compound 3 5,7,4′-Trihydroxy-6,3′–dimethoxyisoflavone, Iristecto-
rigenin B, white amorphous powder (c=0.13, MeOH:H2O (1:1, v/v)).
UV λmax (nm):210,265, HR-Q-TOF-MS (pos.) m/z 331.0809[M+H]+,
(calc.for C17H15O7 +=331.0812), diagnostic fragment ions in positive at
m/z m/z 316.0574 [M+H-15]+, 301.0342 [M+H-30]+ lost two methyl
groups, 2,730,391[M+H-28]+, HRQ-TOF-MS (neg.) 329.0658[M−H]−,
314.0426[M−H-15]−299.0193[M−H-30]−, 271.0243[M−H-30-28]−,
255.0296[M−H-15-28]−
Compound 4, 5,7,3′-trihydroxy-6,4′,5′-trimethoxyisoflavone, Irigenin,
white amorphous powder (c=0.13, MeOH:H2O (1:1, v/v)). UV λmax
(nm):215,265, HR-Q-TOF-MS (pos.) m/z 361.0917 [M+H]+, (calc.for
C18H17O8 + =361.0918), diagnostic fragment ions in positive at m/z m/z
345.0602 [M+H-15]+, 331.0444 [M+H-30]+, 303.0494[M+H-60]+.
285.0390[M+H-60-18]+, lost one,two and three −CH3 group and H2O
respectively, HR-Q-TOF-MS (neg.) 359.0765[M−H]−, 344.0529[M−H-
15]−, 329.0296[M−H-30]−, 314.0062[M−H-45]−.
Compound 5 5,7,3′,4′-tetrahydroxy-6-methoxyisoflavone, Irilin D
white needle fluff (c= 0.13, MeOH:H2O (1:1, v/v)). UV λmax
(nm):220,265, HR-Q-TOF-MS (pos.) m/z 315.0852 [M+H]+, (calc.for
C17H15O6 + =315.0863), diagnostic fragment ions in positive at m/z
m/z 300.0625 [M+H-15]+, 285.0388 [M+H-30]+, lost one and two
−CH3 group respectively, 299.0914 [M+H-18]+. Lack of a clear and
unambiguous signal in negative mode.
Compound 6 5,3′-Dihydroxy-6,4′,5′-trimethoxyisoflavone-7-O-glu-
coside, Iridin white amorphous powder (c= 0.13, MeOH:H2O (1:1, v/
v)). UV λmax (nm):215,265, HR-Q-TOF-MS (pos.) m/z 523.1442 [M
+H]+, (calc.for C24H27O13 + =523.1446), diagnostic fragment ions in
positive at m/z m/z 1045.2808 [2M+H]+, 361.0917 [M+H-162]+,
lost glucose moiety, 346.0680[M+H-15]+. 331.0449[M+H-30]+, lost
one and two −CH3 group, 301.0705 [M+H-60]+,286.0469. HRQ-




Tectoridin, white amorphous powder (c = 0.13, MeOH:H2O (1:1, v/
v)). UV λmax (nm):220,265, HR-Q-TOF-MS (pos.) m/z 463.1241 [M
+H]+, (calc.for C22H23O11 + =463.1235), diagnostic fragment ions
in positive at m/z m/z 485.1058 [M+H+Na]+, 301.0708 [M+H-
162]+ lost glucosyl, HR-Q-TOF-MS (neg.) 461.1086[M−H]−,
299.0556[M−H-162]−, 283.0248[M−H-162-15]−.
Compound 8 5,7,4′-trihydroxy-6,3′-methoxyisoflavone, Iristectorin B,
white amorphous powder (c=0.13, MeOH:H2O (1:1, v/v)). UV λmax
(nm):210,265, HR-Q-TOF-MS (pos.) m/z 493.1348[M+H]+, (calc.for
C23H25O12 + =493.1341), diagnostic fragment ions in positive at m/z m/z
331.0815 [M+H-162]+, 316.0580 [M+H-162-15]+, lost glucosyl and
methyl groups, 301.0343 [M+H-162-30]+, 273.0394, HRQ-TOF-MS
(neg.) 491.1188[M−H]−, 329.0670[M−H-162]−, 313.0358[M−H-18]−,
Fig. 1. A representative HPLC-MS BPC (Base Peak Chromatogram) of the pri-
mary extract from dried Belamcandae chinensis rhizoma (extracting solvent 80%
MeOH). Identification of particular compounds based on High Resolution Mass
Spectrometry, supported with electronic database.
S. Ślusarczyk, et al. Phytochemistry Letters 30 (2019) 261–272
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Fig. 2. Structures and 1H-NMR (blue) and 13C-NMR (green) signals of the compounds (1-11) isolated from Belamcandae chinensis rhizome (Based on 1H and 13C‐NMR
data and direct comparison of spectral data from the literature).
S. Ślusarczyk, et al. Phytochemistry Letters 30 (2019) 261–272
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256.0370[M−H-28]−.
Compound 9 3,3′,4′,5-tetrahydroxystilbene, piceatannol, brownish
amorphous powder (c= 0.13, MeOH:H2O (1:1, v/v)). UV λmax
(nm):220,305, HR-Q-TOF-MS (pos.) m/z 245.0805[M+H]+, (calc.for
C14H13O4 + =245.0808), diagnostic fragment ions in positive at m/z
[M+H-15]+, [M+H-30]+, HRQ-TOF-MS (neg.) 243.0659[M−H]−,
Fig. 2. (continued)
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201.0548[M−H-15]−159.0441 [M−H-30]−,
Compound 10 3,4′,5-trihydroxystilbene, resveratrol, brownish
amorphous powder (c= 0.13, MeOH:H2O (1:1, v/v)). UV λmax
(nm):220,305, HR-Q-TOF-MS (pos.) m/z 229.0861[M+H]+, (calc.for
C14H13O3 + =229.0859), diagnostic fragment ions in positive at m/z
165.0702 [M+H-64]+, 181.0650[M+H-48]+,153.0699,107.0492,
Fig. 2. (continued)
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Fig. 2. (continued)
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Fig. 2. (continued)
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HR-Q-TOF-MS (neg.) 227.0711[M−H]−, 185.0608[M−H-42]−,
143.0504 [M−H-42-42]−, 159.0817, 119.0505
2.2. Inhibition of cholinesterase isoforms
None of the tested compounds had significant (above 50% inhibi-
tion at 100 μg/mL) activity against AChE. The standard drug selective
for AChE, the alkaloid galanthamine had IC50 value in the lower mi-
cromolar range (2.02 μM), whereas for the polyhydroxylated stilbene -
piceatannol - the only compound for which we were able to calculate
this value, IC50 was over 100 times higher (218.93 μM). Quite opposite,
piceatannol was highly and dose-dependently active against BChE (over
90% inhibition with IC50 at 18 μg/mL (74 μM), that is stronger than
galanthamine (IC50= 98.16 μM). The second stilbenoid - resveratrol,
well-known for its broad spectrum of bioactivities, was only moderately
active against BChE and completely inactive against AChE. Other re-
sveratrol analogues can also exhibit AChE inhibitory activity. For ex-
ample several oligomeric highly hydroxylated compounds isolated from
Hopea chinensis with IC50 values lower (ca. 5–11 μM) than in our study,
but the experimental details were different and could account for the
discrepancy (Yan et al., 2012). Also, anti-BChE activity was not con-
sidered in the cited paper. On the other hand, Csuk et al (2013) re-
ported selective anti-BChE properties of several semisynthetic resvera-
trol derivatives, with a fluorinated derivative being both the strongest
and the most selective. It suggests that modifications of structure can
further improve the enzyme-inhibitory properties. Also, natural stil-
benes from Ficus sp. (Sermboonpaisarn and Sawasdee, 2012, Badgujar
et al., 2014), showed selectivity to BChE, but resveratrol and gnetol (a
positional piceatannol isomer) were the most potent and their IC50
lower than in our study. However, the experimental differences could
result in the different absolute values. Another positional isomer of
piceatannol - oxyresveratrol administered in an improved-
bioavailability drug delivery system, demonstrated significant neuro-
protective in vivo in a β-amyloid-based murine model of neurodegen-
eration (Sangsen et al., 2018). The superior activity of piceatannol over
resveratrol in our study suggests that it can be even more promising
compound for further studies.
All isoflavonoids were generally weaker than both isolated stil-
benes, disregarding the enzyme isoform. However, the most methoxy-
lated isoflavone aglycone - irisflorentin had clear selectivity towards
AChE (36% inhibition compared to 9% of BChE activity). This com-
pound is also a pharmacopoeial quality marker but the research on its
pharmacological properties lags behind the more studied tectorigenin
and irigenin (Woźniak and Matkowski, 2015). Due to its relatively low
polarity (XLogP3 is 2.9 - compared to tectorigenin's 2.6 - source Pub-
Chem) its pharmacokinetic and pharmacodynamic properties are likely
to differ from other isoflavonoids. Therefore, this structure might be
considered for further studies to elucidate the mechanisms of its se-
lectivity.
Other isoflavonoid aglycones were moderately but specifically ac-
tive against BChE only (20–40% inhibition at 100 μg/mL).
Isoflavonoids have been previously reported as a class that could be
considered as moderate cholinesterase inhibitors. For example, pomi-
ferin was inhibiting AChE at IC50 of 96 μM but did not act against BChE
(Orhan et al., 2009). However, Iridaceae-type isoflavonoids were rather
weakly inhibiting both cholinesterases in the study by Conforti et al.
(2009) using Iris pumila as source of the isolated compounds.
Also, like in stilbenoids, semisynthetic derivatives were designed as
dual-target cholinesterase inhibitors and a decoration of the iso-
flavonoid skeleton with piperidine was shown to be most promising
(Feng et al., 2017). It would be thus recommended to try similar ap-
proach using Iridaceae-isoflavones as a scaffold for such amendment.
Some evidence exists for in vivo action of isoflavonoids in the im-
provement of brain function in dementia. For example, a mixture of
Fig. 2. (continued)
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soybean isoflavones improved cognitive function in mice model of se-
nescent dementia, with concurrently observed decrease in AChE ac-
tivity in brain cortex. It clearly suggests that cholinesterase inhibition
can be one also a mechanism of action in vivo (Yang et al.,2011)
Methoxylated isoflavonoids have also an additional advantage over
non-methoxylated counterparts in having higher bioavailability (Walle,
2009; Chen et al., 2018) Unfortunately, piceatannol exibited rather
poor bioavailability, albeit not lower than other stilbenoids (Kershaw
and Kim, 2017).
The activity of all glycosides (both isoflavonoids and a xanthonoid
mangiferin) was either negligible or none at all. This is in agreement
with the well established general rule that most of glycosides have
weaker activity than the respective aglycons. However, in vivo studies
are necessary to account for the potential biotransformation of the
glycosides that would facilitate aglycone release resulting in higher
activity than observed in vitro. Mangiferin, a strong antioxidant and
antiinflammatory polyphenol has been frequently mentioned as a po-
tential preventive and complementary remedy in neurodegenerative
disorders (Matkowski et al., 2013). However, in our study it had no
activity against any of the two isoforms. Hence, other mechanisms
should be explored to elucidate its contribution to the postulated neu-
roprotective potential of Belamcandae chinensis rhizoma.
The low activity of glycosides, which predominate in the crude drug
and in some solvent extracts may explain the lack of Belamcandae
chinesis rhizoma extract in a comprehensive screening published by
Kaufmann et al. (2016) where 80 TCM herbs were compared against
AChE and only a couple of isoquinoline alkaloid-containing drugs were
shown to be active. However, we cannot exclude a composition di-
versity between herbs of different origin to play a role and Iris domes-
tica, a source of this herb has been repeatedly shown to be quite vari-
able (Woźniak and Matkowski, 2015).
Other species of Iris were also studied in similar experiments with
various results. For example I. schachtii, in which the main constituents
were kaempferol and catechin (Mocan et al., 2018) had negligible ac-
tivity against both cholinesterases. Conversely, I. germanica total fla-
vonoid aglycones (hydrolyzed ethyl acetate fraction) exhibited high
activity against AChE and BChE [(Ullah et al., 2016). However, in no
previous studies, any of the isolated here isoflavonoids or stilbenoids
were suggested as anti-cholinesterase active principle of Iris sp.
Taking the marked in vitro AChE and BChE inhibitory data of the
studied compounds into consideration (Table 1), irilin B, piceatannol
and resveratrol were subjected to molecular docking experiments in
order to understand, at the molecular level, the rationale under their
inhibitory activity. Having that information in hand is important since
it can help to discover new molecules in the same context. After ana-
lysis of docking results, structural analysis of docking results for se-
lected compounds from Table 1 for which IC50 was calculated, is dis-
played in Figs. 3 and 4. On these figures one can appreciate a
representation of the active site of the enzyme with the different
compounds docked and hydrogen bonds highlighted. When the detailed
representation of docking poses was investigated, we could observe the
directionality of the network of hydrogens bond established. Main hy-
drogen bonds are formed with residues from catalytic triad (yellow
color) and peripheral anionic site (green color). Therefore, studied
compounds block the access to key residues involved in the normal
functioning of the enzyme such as parts of the catalytic triad and per-
ipheral anionic sites. These reasons can explain the inhibitory activity
of the mentioned compounds.
Although the in vitro screening gives only approximate picture into
the therapeutic potential of the bioactive compounds, the lack of a
perfect animal model and the still disputed etiopathology of many
neurodegeneration - based dementias - including AD (Makin, 2018), the
in vitro and in silico results can provide some input to the rational drug
design as well as to more evidence-based implementation of herbal
drugs into the management of these globally increasing maladies, at
least before a specific targeted drug will have been discovered. The
postulated contribution of inflammatory response to progression of
neurodegeneration renders natural polyphenols interesting candidate
structures to be involved in search for antidementive therapeutics.
In summary, we conclude that several polyphenols from
Belamcandae chinensis rhizoma have been enough active in the in vitro
and in silico screening to warrant future studies aimed at their anti-
cholinesterase properties and potential further development as com-
plementary therapeutics in cognitive impairment of various back-
grounds in which inhibition of BuChE isoform would be beneficial.
Piceatannol and irilin B, although minor constituents in the phyto-
chemical profile, demonstrate the high selectivity combined with high
(piceatannol) or moderate (irilin B) inhibition strength. The mechan-
isms of the inhibition need to be verified experimentally, though. This is
a novel area of indication for this traditional antiinflammatory medic-
inal plant.
Table 1
Inhibition of Acetylcholinesterase (AChE) and Butyrylcholinesterase (BChE) by isoflavonoids and stilbenoids isolated from Belamcandae chinensis rhizoma as well as
reference drug - galanthamine. Inhibition % given at 100 μg/mL (± S.D. n= 6) compound concentration and IC50 in μg/mL and μM (in brackets). Statistically









(1) Irisflorentin 36.25 ± 1.22 – 9.34 ± 2.21a –
(2) Tectorigenin – – 18.08 ± 2.93b –
(3) Iristectorigenin A – – 37.07 ± 0.47 –
(4) Irigenin – – 20.12 ± 2.47b –
(5) Irilin B 3.67 ± 1.44 – 49.72 ± 2.83 109.53 ± 6.02/
(348.82 ± 19.17)
(6) Iridin – – 4.29 ± 2.04 –
(7) Tectoridin – – – –
(8) Iristectorin A – – 9.44 ± 0.09a
(9) Piceatannol 67.07 ± 1.52 53.42 ± 2.22/
(218.93 ± 9.10)
91.10 ± 1.26 18.20 ± 0.89/
(74.55 ± 3.65)
(10) Resveratrol 14.43 ± 1.46 – 56.30 ± 2.33 78.07 ± 4.24/
(342.41 ± 18.60)
(11) Mangiferin – – 8.99 ± 2.26a –
Galanthamine 97.17 ± 2.89 0.58 ± 0.02/
(2.02 ± 0.07)
86.77 ± 2.86 28.16 ± 1.51/
(98.12 ± 5.26)
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3. Materials and methods
3.1. Chemicals
All solvents: methanol, acetonitrile n-hexan used for this work were
of analytical grade and purchased from Merck (Darmstad, Germany),
deuterated solvents : water-d2, methanol-d4, 3-(Trimethylsilyl)-1-pro-
panesulfonic acid sodium salt (TSP) from Armar AG (Döttingen
Switzerland), Ultrapure water was obtained from (Milli-Q® Simplicity
185, Millipore Corp., Billerica MA) system. Formic acid (FA), MS-grade
was purchased from Sigma-Aldrich (St. Louis, USA). The chromato-
graphic stationary phases were purchased: Cosmosil 140C18-PREP from
Nacalai Tesque Inc. (Kyoto, Japan), Sephadex LH-20and Silica gel 60
(60–200 mesh) from Sigma-Aldrich, (Steinheim, Germany). Mangiferin
analytical standard was from ChromaDex (Irvine, CA, USA).
3.2. Plant material
The underground parts of cultivated Iris domestica (third year of
cultivation) were harvested from the certified collection (under the
approval of Ministry of Environment, Republic of Poland, Decision No.
DOPogiz-4210-26-6024-/05/kl) of the Botanical Garden of Medicinal
Plants in Wrocław, Poland (17°04′27′'E, 51°07′03′'N, 117m asl) in the
fall of 2017. The voucher specimen have been preserved in the her-
barium of the Botanical Garden under the accession no. Iridaceae-
Belamcandachinensis-2017-1″. The rhizomes were washed under tap
water to remove soil and debris, cut into approximately 1 cm pieces and
dried in the herbal dryer at 30 °C. Then, the dried material was ground
in the herbal mill for further processing.
3.3. Instrumentation and chromatographic conditions
3.3.1. Liquid chromatography-mass spectrometry and high-resolution mass
spectrometry
The primary aqueous methanol extract of Belamcandae chinensis
rhizoma was profiled by LC–MS using a Dionex UltiMate 3000RS
(Thermo Scientific, Darmstadt, Germany) system with a charged
aerosol detector for preliminary peak detection, interfaced with a high-
resolution quadrupole time-of-flight mass spectrometer (HR/Q-TOF/
MS, Impact II, Bruker Daltonik GmbH, Bremen, Germany). Separation
was achieved on an Acquity UPLC BEH C18 column (100×2.1mm,
1.7 μm, Waters, Manchester, UK) maintained at 30 °C. The mobile phase
consisted of: A (0.1% formic acid in Milli-Q water, v/v) and B (0.1%
formic acid in acetonitrile, v/v). The gradient elution at a flow rate of
0.4 ml/min was: 2% B from 0 to 1min with a short 0.3 min calibration
segment, and the concentration of B was then increased to 60% from 1
to 20min. The column was eluted with this concentration of solvent B
for 4min and was then re-equilibrated for 0.3 min. The samples were
kept at 15 °C in the autosampler. The injection volume was 5.0 μl.
Operating parameters of the ESI ion source in positive and negative
modes were as follows: capillary voltage 3 kV (negative) or 4.5 kV
(positive), drying gas flow 6 L/min, temperature 200 °C, nebulizer
pressure 0.7 bar, collision radio frequency 700.0 V, transfer time
100.0 μs, and pre pulse storage 7.0 μs. Ultrapure nitrogen was used as
drying and nebulizer gas, and argon was used as collision gas. Collision
energy was set automatically from 15 to 75 eV depending on the m/z of
fragmented ion. Acquired data were calibrated internally with sodium
formate introduced to the ion source at the beginning of each separa-
tion via a 20 μL loop. Processing of spectra was performed with Bruker
DataAnalysis 4.3 software. (Bruker Daltonik GmbH, Bremen, Germany).
All analyses were performed in triplicate and repeated twice.
3.3.2. NMR spectroscopy
NMR data (compound 1–10) were acquired at room temperature on
a Bruker Avance III™ 500MHz spectrometer (Bruker, BioSpin,
Rheinstetten, Germany) equipped with 5mm 1H{109Ag–31 P} broad-
band inverse (BBI) probe operating at 500.13MHz for 1H, and
125.77MHz for 13C experiments. NMR data for compound 11 (mangi-
ferin) were acquired at room temperature on a Bruker Avance 300MHz
spectrometer. Topspin 2.0 software was used for data processing.
3.3.3. Preparative chromatography
Semi-preparative HPLC was performed on a chromatographic
system equipped with a Gilson 321 pump, a Gilson GX-271 liquid
handler with a 2mL sample loop, a Gilson Prep ELS™ II detector, and
either a semi-preparative reversed phase columns Atlantis Prep T3
250mm×10mm i.d., 5 μm (Waters, Milford, MA). All fractions were
lyophilized using Gamma 2–16 LSC freeze dryer (Martin Christ
Gefriertrocknungsanlagen GmbH, Germany).
Fig. 3. Interactions of piceatannol (purple skeleton) that interact
with both AChE (A) and BChE (B), in transparent grey cartoon
fashion. Residues are colored according to their binding area as
yellow (catalytic triad), and green (peripheral anionic site).
Hydrogen bonds established between compounds and depicted
residues are shown with deep yellow dashed lines.
Fig. 4. Interactions of isolated compounds from extracts (purple
skeleton) that only interact with BChE, in transparent grey cartoon
fashion. Shown compounds are irilin B (A) and resveratrol (B).
Residues are colored according to their binding area as yellow
(catalytic triad), and green (peripheral anionic site). Hydrogen
bonds established between compounds and depicted residues are
shown with deep yellow dashed lines.
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3.4. Procedure of compounds isolation
500 g of powdered rhizomes were extracted three times with 1.5 L
ethyl acetate in ultrasonic bath at 40 °C for 40min each repetition.
Combined filtered extracts were concentrated under reduced pressure,
dissolved in 80% aq. MeOH solution (v/v) and defatted in the separ-
ating funnel with n-hexane. Subsequently the obtained extract was
lyophilized to obtain 19.8 g.
Afterwards, the extract (4 g x 5) was applied onto 95 cm×3.2 cm i.d.
glass column (Millipore Corp., Bedford, MA) packed with Sephadex LH-20
(40–120 μm) and eluted with methanol (acidified with 0.1% formic acid)
at a flow rate of 5mL min−1. As a result, 6 fractions were obtained
according to the ELS™ II detector and checked by UPLC-PDA-MS. Fraction
I (FI) 6.8 g consisting of nonpolar fatty acids was discarded.
Fractions FII through FV enriched in isoflavones was subjected to
semipreparative HPLC, on Atlantis Prep T3 at 25 °C, using isocratic
elution with MeCN:H2O:FA in various proportions (see below) at 4mL
min−1.
FII (1.76 g) – MeCN:H2O:FA (5:5:0.1, v/v), gave irisflorentin (1)
(12.4 mg).
Fraction FIII (2.94 g) eluted with MeCN:H2O:FA (4:6:0.1, v/v),
yielded tectorigenin (2) 60mg, iristectorigenin (3) 26mg, and irigenin
(4) 220mg.
Fraction FIV (0.59 g) was separated with MeCN:H2O:FA (3:7:0.1, v/
v) to obtain: irilin B (5) 5.2mg, iridin (6) 45mg.
FV (0.59 g) was separated with MeCN:H2O:FA (2:8:0.1, v/v) and
tectoridin(7) 6.1 mg, iristectorin (8) 3.1mg were obtained.
FVI (0.15 g) was separated with MeCN:H2O:FA (1:9:0.1, v/v) to obtain
both stilbenes - picetannol (9) 70.6mg, and resveratrol (10) 6mg.
Isolation of mangiferin (11) was performed using the same proce-
dure as published previously (Matkowski et al., 2009; Nowak et al.,
2018). The dried primary extract was suspended in 10% MeOH, and
subjected to sequential liquid-liquid extraction with diethyl ether and
butanol (in a 300mL separatory funnel, aqueous:organic fractions in
1:1 ratio, fractionation repeated 6 times). The butanol fraction was
further purified using SPE with C-18 silica gel (Fluka, Switzerland)
eluted sequentially with water, 40% MeOH, and pure MeOH. The
fraction obtained with 40% MeOH contained mangiferin. Mangiferin
was purified using reversed-phase Flash Chromatography in an isocratic
system eluted with 25% ACN in 1% acetic acid. Mangiferin was eluted
within the first four of 12 fractions and recrystallized three times from
dioxane:water mixture (1:1). The yield of pure mangiferin was 396mg
from 150 g of crude extract.The identity and purity of the obtained
compounds were confirmed by liquid chromatography-mass spectro-
metry (LC-HRMS) and NMR spectroscopy (1H, 13C). Purity of the iso-
lated compound was at least 95%, and none of the detected impurities
exceeded 1% of the peak area.
3.5. Microtiter assays for AChE and BChE enzyme inhibition
AChE and BChE inhibitory activity of the extracts was determined
by modified spectrophotometric method of Ellman et al. (1961). Elec-
tric eel acetylcholinesterase (Type-VI-S, EC 3.1.1.7, Sigma) and horse
serum butyrylcholinesterase (EC 3.1.1.8, Sigma) were used as the en-
zyme sources, while acetylthiocholine iodide and butyrylthiocholine
chloride (Sigma, St. Louis, MO, USA) were employed as substrates of
the reaction. 5,5´-Dithio-bis(2-nitrobenzoic)acid (DTNB, Sigma, St.
Louis, MO, USA) was used for the measurement of the cholinesterase
activity. All the other reagents and conditions were the same as de-
scribed in our previous publication10. In brief, 140 μL of 0.1 mM sodium
phosphate buffer (pH 8.0), 20 μL of 0.2M DTNB, 20 μL of sample so-
lutions (in a dilution series of 1–100 μg/mL) and 20 μL of 0.2M acet-
ylcholinesterase/butyrylcholinesterase solution were added by multi-
channel automatic pipette (Gilson Pipetman, France) in a 96-well
microplate and incubated for 15min at 25 °C. The reaction was then
initiated with the addition of 10 μL of 0.2M acetylthiocholine iodide/
butyrylthiocholine chloride. The hydrolysis of acetylthiocholine iodide/
butyrylthiocholine chloride was monitored by the formation of the
yellow 5-thio-2-nitrobenzoate anion as a result of the reaction of DTNB
with thiocholines, catalyzed by enzymes at a wavelength of 412 nm
utilizing a 96-well microplate reader (VersaMax, Molecular Devices,
USA). Galanthamine, the reference anticholinesterase alkaloid-type of
drug isolated from the bulbs of snowdrop (Galanthus sp.), was pur-
chased from Sigma (St. Louis, MO, USA).
3.6. Data processing for enzyme inhibition assays
The measurements and calculations were evaluated by using Softmax
PRO 4.3.2.LS software. Percentage of inhibition of AChE/BChE was de-
termined by comparison of rates of reaction of test samples relative to
blank sample (ethanol in phosphate buffer pH=8). IC50 was calculated
from the dose-response curve as a concentration at which half of the
maximum extrapolated inhibition occurred. Extent of the enzymatic re-
action was calculated based on the following equation: E = (C–T)/
C×100, where E is the activity of the enzyme. E value expresses the effect
of the test sample or the positive control on acetylcholinesterase and bu-
tyrylcholinesterase enzyme activity articulated as the percentage of the
remaining activity in the presence of test sample or positive control. C
value is the absorbance of the control solvent (blank) in the presence of
enzyme, where T is the absorbance of the tested sample (plant extract or
positive control in the solvent) in the presence of enzyme.
3.7. Statistical analysis of data
Data obtained from in vitro enzyme inhibition experiments were
expressed as means (± S.D.) from at least three independent experi-
ments performed in triplicate. Statistical differences between the re-
ference and the sample groups were evaluated by ANOVA (one way).
Dunnett’s multiple comparison tests was used as post hoc tests. p <
0.05 was considered to be significant.
3.8. Molecular modeling
The initial geometries of the studied compounds were built up with
GaussView by using the standard parameters, which were next fully
optimized at the B3LYP/6–31 G(d) level (Becke, 1993), within the
density functional theory (DFT) framework. The stability of all localized
structures were confirmed by performing additional vibrational calcu-
lations, e.g., all minima in the potential energy surface present real
frequencies only. The DFT study was eventually completed by com-
puting all partial atomic charges as described in the Merz-Singh-
Kollman ESP protocol (Singh and Kollman, 1984; Besler et al., 1990).
All DFT calculations were performed with the Gaussian 16 suite of
program. (Gaussian 16).
The molecular structures for the enzymes AChE and BChE were
extracted from the crystal structures of Protein Data Bank (PDB) files
with codes 1EVE and 1P0I. Their molecular files were prepared with
Autodock Tools (Morris et al., 2009) for docking by removing water
molecules, adding hydrogen atoms and Gasteiger charges, merging non-
polar hydrogens and assigning AD4 atom types. Molecular docking
calculations were carried out in the active site of both enzymes using
default parameters in AutoDock Vina (Trott and Olson, 2009). Top pose
of each compound was retained for further analysis. Graphical re-
presentations of the docking results were prepared using PyMOL (Mo-
lecular Graphics System, version 1.6, Schrödinger, LLC).
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2.7 Structure-based discovery of clinically approved drugs
as Zika virus NS2B-NS3 protease inhibitors that potently
inhibit Zika virus infection in vitro and in vivo
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predicted that novobiocin bound to ZIKV NS2B-NS3-protease with high stability. Dexamethasone-
immunosuppressed mice with disseminated ZIKV infection and novobiocin treatment had significantly
(P < 0.05) higher survival rate (100% vs 0%), lower mean blood and tissue viral loads, and less severe
histopathological changes than untreated controls. This structure-based drug discovery platform should
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© 2017 Elsevier B.V. All rights reserved.
* Corresponding author. State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine,
The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Pokfulam, Hong Kong Special Administrative Region.
** Corresponding author. State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine,
The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Pokfulam, Hong Kong Special Administrative Region.
*** Corresponding author. Bioinformatics and High Performance Computing Research Group (BIO-HPC), Computer Engineering Department, Universidad Catolica San
Antonio de Murcia (UCAM), Spain.
**** Corresponding author. Bioinformatics and High Performance Computing Research Group (BIO-HPC), Computer Engineering Department, Universidad Catolica San
Antonio de Murcia (UCAM), Spain.
E-mail addresses: jfwchan@hku.hk (J.F.-W. Chan), hperez@ucam.edu (H. Perez-Sanchez), jpceron@ucam.edu (J.P. Ceron-Carrasco), kyyuen@hku.hk (K.-Y. Yuen).
1 These authors contributed equally to the study as co-first authors.
2 These authors contributed equally to the study as co-corresponding authors.
Contents lists available at ScienceDirect
Antiviral Research
journal homepage: www.elsevier .com/locate/ant iv iral
http://dx.doi.org/10.1016/j.antiviral.2017.07.007
0166-3542/© 2017 Elsevier B.V. All rights reserved.
Antiviral Research 145 (2017) 33e43
68 Articles that are part of the doctoral thesis
1. Introduction
Zika virus is an emerging human-pathogenic flavivirus that has
caused an unprecedented large-scale epidemic of congenital
microcephaly and malformations in the Americas (Chan et al.,
2017a; Zhu et al., 2016). Initially thought to be a completely self-
limiting illness in infected adults, an increasing number of serious
complications were recently reported among adult patients as the
epidemic expanded in the Americas and other regions (Duffy et al.,
2009; Musso and Gubler, 2016). These included severe neurological
complications, such as Guillain-Barre syndrome, menigoencepha-
litis, and myelitis, thrombocytopenia and disseminated intravas-
cular coagulation with hemorrhagic complications, hepatic
dysfunction, acute respiratory distress syndrome, shock, multi-
organ dysfunction syndrome, and death (Arzuza-Ortega et al.,
2016; Azevedo et al., 2016; Cao-Lormeau et al., 2016; Carteaux
et al., 2016; Chraibi et al., 2016; Mecharles et al., 2016; Sarmiento-
Ospina et al., 2016; Soares et al., 2016). Alarmingly, human cases of
hematospermia and mouse models of orchitis with possible long-
term effects on male fertility were also described (Chan et al.,
2016c; Foy et al., 2011; Govero et al., 2016; Ma et al., 2016; Musso
et al., 2015). Currently, treatment options for ZIKV infection in
pregnant patients and severe ZIKV-associated complications
remain limited.
To identify immediately available anti-ZIKV treatment options, a
number of drug repurposing programmes have been conducted by
screening drug libraries using cell culture-based antiviral assays
(Barrows et al., 2016; Retallack et al., 2016; Xu et al., 2016). How-
ever, most of these clinically approved drugs found to have in vitro
anti-ZIKV activity are anti-cancer or immunomodulating agents
which are immunosuppressive or contraindicated in pregnancy
(FDA pregnancy category D). Moreover, such screening approach
does not elucidate the anti-ZIKV mechanisms of these drugs which
are important for further development of safer and more effective
drug analogues than the lead drug compound. An alternative
approach to discover other potential anti-ZIKV treatment options is
by repurposing clinically approved drugs which inhibit the key
enzymes of ZIKV, including protease, helicase, and/or polymerase.
In this study, we performed an in silico structure-based virtual
screening of a large chemical library consisting >8000 drug com-
pounds to identify potential ZIKV NS2B-NS3 protease inhibitors.
Among the validated ZIKV NS2B-NS3 protease inhibitors, novobi-
ocin and lopinavir-ritonavir were verified to inhibit virus replica-
tion in vitro. Importantly, treatment with novobiocin significantly
improved the clinical outcome of mice with disseminated ZIKV
infection. These results illustrated the capability of our systematic
in silico, in vitro, and in vivo approach to expand the treatment
options for ZIKV infection. Our findings provided a new avenue for
the development of novel anti-ZIKV agents.
2. Materials and methods
2.1. In silico structure-based virtual screening of chemical library
and molecular docking
All compounds deposited in the DrugBank v5.0.1 were set up for
docking simulations by using AmberTools (AMBER 2017; University
of California, San Francisco) (Case et al., 2017). The crystal structure
of ZIKV NS2B-NS3 protease (Protein Data Bank (PDB) code 5LC0)
was used to build up the protein model system (Lei et al., 2016).
Other details of virtual screening calculations are specified in the
Supplementary Methods.
2.2. Molecular dynamics simulations
Molecular dynamics simulations were conducted to predict the
stability of the novobiocin-ZIKV NS2B-NS3 complex. Protocols are
fully outlined in the Supplementary Methods.
2.3. Virus strain and titration
A clinical isolate of ZIKV (Puerto Rico strain PRVABC59) obtained
from a patient in the recent South American epidemic was kindly
provided by Brandy Russell and Barbara Johnson, Centers for Dis-
ease Control and Prevention, USA. The virus was cultured and
titrated as we previously described with slight modifications (Chan
et al., 2016b; Zhou et al., 2014) (Supplementary methods).
2.4. Cell lines and drug compounds
Vero and Huh-7 cell lines were obtained from American Type
Culture Collection and JCRB cell bank of Okayama University, Japan,
respectively, as we previously described (Chan et al., 2013a, 2016b).
Aprotinin (Sigma-Aldrich, Missouri, USA), desmopressin acetate
(Ferring Pharmaceuticals, Saint Prex, Switzerland), lopinavir-
ritonavir (Abbott Laboratories, Illinois, USA), montelukast (Merck
& Co., Inc., New Jersey, USA), novobiocin sodium (Sigma-Aldrich
Chemie GmbH, Steinheim, Germany), octreotide acetate (Novartis,
Basel, Switzerland), rifampicin (Gruppo Lepetit Srl, Milan, Italy),
sirolimus (Pfizer, New York city, USA), tacrolimus (Astellas Pharma,
Tokyo, Japan) were used for the in vitro and/or in vivo studies.
2.5. Cell viability assay and CPE inhibition assay
The 50% effective cytotoxic concentration (CC50) of the selected
drugs in Vero and Huh-7 cells were determined by thiazolyl blue
tetrazolium bromide (MTT) assay as we previously described with
modifications (Chan et al., 2017a; Yuan et al., 2016). To confirm the
antiviral activity of novobiocin, the MTT-based CPE inhibition assay
was also performed as previously described with slight modifica-
tions (Chan et al., 2017a). The half maximal inhibitory concentra-
tion (IC50) and CC50 were calculated using Sigma plot (SPSS) in an
Excel add-in ED50V10. Other details are described in the Supple-
mentary Methods.
2.6. Viral load reduction and plaque reduction assays
Viral load reduction assay and plaque reduction assay was per-
formed for the evaluation of antiviral activity. Experimental pro-
tocols are specified in supplementary methods as previously
described with modifications (Chan et al., 2013b, 2016b, 2017a,
2017b). Both assays were performed in triplicate and repeated
twice for confirmation.
2.7. Time-of-drug-addition assay
Time-of-drug-addition assay was performed for novobiocin to
determine which phase(s) of virus cycle the drug interfered with
(Chan et al., 2017a; Kato et al., 2016). Details are described in the
Supplementary Methods.
2.8. Fluorescence-based protease inhibition assay
The recombinant ZIKV NS2B-NS3 protease was produced as
previously described with some modifications (Lei et al., 2016).
Experimental conditions are described in supplementary methods.
To detect ZIKV NS2B-NS3 protease activity, a fluorescence-based
enzymatic assay was conducted in 96-well black micro-plates
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(Greiner Bio-One, Kremsmünster, Germany). A 7-amino-4-
methylcoumarine substrate, Bz-Nle-Lys-Lys-Arg-AMC, was used
(Lei et al., 2016). To detect if each drug inhibited ZIKV NS2B-NS3
protease activity, 5 nM ZIKV NS2B-NS3 protease and 10 mM sub-
strate was fixed in the assay. The assay protocol was optimized
according our recent report (Chan et al., 2017a). Other details are
outlined in the Supplementary Methods.
2.9. Mouse model and in vivo evaluation of novobiocin treatment
The in vivo treatment effect of novobiocin was evaluated in our
recently established animal model for ZIKV infection using
dexamethasone-immunosuppressed mice with disseminated ZIKV
infection (Chan et al., 2016c). Approval was obtained from the
Committee on the Use of Live Animals in Teaching and Research of
The University of Hong Kong. Experimental design and other details
are described in Table S1 and Supplementary Methods,
respectively.
2.10. Statistical analyses
All statistical analyses were performed with GraphPad Prism
software (GraphPad Software, Inc). Kaplan-Meier survival curves
were analyzed by the log-rank test. Student's t-test was used to
determine significant differences in weight losses and virus titers
among individual treatment groups as previously reported (Chan
et al., 2016c). P-values <0.05 were considered statistically
significant.
3. Results
3.1. Identification of primary hit compounds in in silico structure-
based virtual screening
To identify potential inhibitors of ZIKV NS2B-NS3 protease, a
total of 8227 entries from the DrugBank database were screened
using Lead Finder software (Stroganov et al., 2008), in which the
ZIKV NS2B-NS3 protease crystal structure was utilized as inputs to
the program (Lei et al., 2016) (Fig. 1). The top 100 primary hit
compounds were ranked by their predicted binding affinities to the
ZIKV NS2B-NS3 protease (Table S2).
3.2. Validation of ZIKV NS2B-NS3 protease inhibition by primary hit
compounds belonging to different drug classes
To verify whether the primary hit compounds inhibited ZIKV
NS2B-NS3 protease activity, we selected 8 clinically approved drugs
that belonged to different drug classes (i.e. desmopressin acetate,
lopinavir-ritonavir, montelukast, novobiocin, octreotide acetate,
rifampicin, sirolimus, and tacrolimus) for further evaluation.
Lopinavir-ritonavir instead of ritonavir was used for further eval-
uation because lopinavir-ritonavir is the commercially available
preparation that is more commonly used clinically. Other drug
compounds were not selected because most of them were not
clinically approved drugs, did not have well-known pharmacoki-
netic and pharmacodynamic properties, and/or belonged to the
same drug classes as these 8 drugs. We performed a fluorescence-
based protease inhibition assay that recorded fluorescence signals
in the presence or absence of the drugs. To detect the enzymatic
activity of the purified ZIKV NS2B-NS3 protein, we first used four
concentrations of the protease substrate (0.1 mM, 1 mM, 10 mM, and
100 mM) for comparison and observed a dose-dependent increase
of fluorescence intensity upon protein addition to the substrate
(Fig. 2A). Cleavage of the peptide substrate released fluorescence
signals, which reached a plateau when 50 nM protein was added.
Compared to the baseline control, as much as 25-fold increase in
fluorescence intensity was detected with input of 10 mM and
100 mM substrate. These results suggested that the purified ZIKV
NS2B-NS3 protein maintained protease activity. To detect the
inhibitory effect of the drugs on ZIKV NS2B-NS3 protease activity,
Fig. 1. Screening pipeline. In silico virtual screening of a chemical library with 8277
drug compounds was performed. Among the top 100 primary hit compounds with the
highest predicted binding affinities with ZIKV NS2B-NS3 protease, 8 clinically
approved drugs belonging to different drug classes were selected for validation of anti-
ZIKV NS2B-NS3 protease activity. Other drug compounds were not selected because
most of them were not clinically approved drugs, did not have well-known pharma-
cokinetic and pharmacodynamic properties, and/or belonged to the same drug classes
as these 8 drugs (see also Table S2). Among them, 5 (62.5%) were demonstrated to have
anti-ZIKV NS2B-NS3 protease activity in a fluorescence-based enzymatic assay. Three
of these 5 drugs which have high potentials for clinical use in pregnancy and/or pa-
tients with severe ZIKV-associated complications were then selected for further
evaluation. The anti-ZIKV activity of these 3 drugs (novobiocin, lopinavir-ritonavir, and
rifampicin) were then evaluated by viral load reduction, cytopathic effect inhibition,
and/or plaque reduction assays. Novobiocin and lopinavir-ritonavir demonstrated anti-
ZIKV activity in viral load reduction assay. Based on its higher selectivity index than
lopinavir-ritonavir, novobiocin was then selected for further evaluation in a mouse
model.
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we measured fluorescence signals in the presence of a range of
different concentrations of the drugs, using aprotinin as a positive
control (Phoo et al., 2016). As shown in Fig. 2B, aprotinin inhibited
ZIKV NS2B-NS3 protease activity in a dose-dependent manner,
with an apparent IC50 of 13.6 ± 1.1 KIU/ml. This result validated the
specificity of our protease inhibition assay. At the fixed concen-
tration of 10 mM substrate and 5 nM ZIKV NS2B-NS3 protease, we
observed a dose-dependent reduction in protease activity with
increasing concentrations of 5 of the 8 (62.5%) drugs, including
novobiocin (Fig. 2C), desmopressin acetate, octreotide acetate,
lopinavir-ritonavir, and rifampicin (Figs. S1AeH). Our results
confirmed that these drugs inhibited ZIKV NS2B-NS3 protease ac-
tivity and that the in silico virtual screening was useful in predicting
potential ZIKV NS2B-NS3 protease inhibitors.
3.3. Validation of the in vitro anti-ZIKV activity of selected ZIKV
NS2B-NS3 protease inhibitors
Among the validated ZIKV NS2B-NS3 protease inhibitors, we
further selected 3 clinically approved drugs with good side effect
profiles that could potentially be used in pregnant patients and/or
patients with severe ZIKV-associated complications (novobiocin,
lopinavir-ritonavir, and rifampicin) for in vitro anti-ZIKV activity
testing. Cytotoxicity and antiviral potency of the drugs were eval-
uated in two different cell lines (Vero and Huh-7 cells) that could
robustly support ZIKV replication (Chan et al., 2016b). The 50%
effective cytotoxic concentrations (CC50) of novobiocin, lopinavir-
ritonavir, and rifampicin in Vero cells were 850.50 mg/ml
(1388.02 mM), 30.00 mg/ml, and 400.00 mg/ml (486.00 mM),
respectively, while in Huh-7 cells, 1103.18 mg/ml (1800.39 mM),
32.12 mg/ml, and 400.00 mg/ml (486.00 mM), respectively. In the
viral load reduction assay, dose-dependent reduction in virus titer
was observed in novobiocin-treated (half maximal inhibitory con-
centration (IC50) ¼ 26.12 ± 0.33 mg/ml or 42.63 mM in Vero cells and
38.14 ± 4.53 mg/ml or 62.24 mM in Huh-7 cells) and lopinavir-
ritonavir-treated (IC50 ¼ 4.78 ± 0.41 mg/ml in Vero cells and
3.31 ± 0.36 mg/ml in Huh-7 cells) (Figs. 3A, B, S2A, and S2B), but not
rifampicin-treated culture supernatants (data not shown). The
mean virus titer was significantly reduced (P < 0.05) at 25.00 mg/
ml (40.80 mM) of novobiocin and at 50.00 mg/ml of lopinavir-
ritonavir. The apparent lack of potent antiviral activity of
lopinavir-ritonavir against ZIKV in our previous study was likely
related to the lower drug concentrations used (Chan et al., 2017a).
Given the higher selectivity index (CC50/IC50) of novobiocin
(28.92e32.56) than lopinavir-ritonavir (6.28e9.70), we further
validated the anti-ZIKV activity of novobiocin in cytopathic effect
(CPE) inhibition and plaque reduction assays. In the CPE inhibition
assay, novobiocin protected Vero cells from developing ZIKV-
induced CPE (IC50 ¼ 53.26 ± 2.48 mg/ml or 86.92 mM). In the pla-
que reduction assay, novobiocin achieved 100% plaque reduction at
concentrations 50.00 mg/ml (81.60 mM) (IC50 ¼ 15.21 ± 0.14 mg/ml
or 24.82 mM) (Fig. 3C).
3.4. Novobiocin was predicted to interact with the key enzymatic
sites of ZIKV NS2B-NS3 protease
To better characterize the structural interactions between
novobiocin and ZIKV NS2B-NS3 protease, molecular docking was
performed to predict the binding site of novobiocinwithin the ZIKV
NS2B-NS3 protein (Fig. 4AeC). As shown in Fig. 4B, three hydrogen
bonds were formed between the ligand and the protein through
residues MET51* (*denotes ZIKV NS2B residues), SER81*, and
LYS54, and broad areas of hydrophobic stabilization were formed
between the compound and residues HIS51 and VAL155 (Fig. 4B
and C). Interestingly, two of these predicted interacting residues
(SER81* and HIS51) were also identified as contacting residues
between the boronate inhibitor cn-716 and the ZIKV NS2B-NS3
protease in another report (Lei et al., 2016). These results sug-
gested that novobiocin, like the protease inhibitor cn-716, might
also impair the ZIKV NS2B-NS3 catalytic efficiency. To explore the
mode of protease inhibition, enzyme kinetic experiments were
performed in the presence or absence of the drug. As showed in
Fig. 4D, novobiocin appeared as a competitive ZIKV NS2B-NS3
protease inhibitor (global R2 ¼ 0.99). Molecular dynamics simula-
tions provided additional insights into the stability of the
Fig. 2. Novobiocin inhibited protease activity of ZIKV NS2B-NS3. (A) ZIKV NS2B-NS3
protein dose-dependent of fluorescence intensity are shown, indicating the cleavage
of the fluorescent substrate (Bz-Nle-Lys-Lys-Arg-AMC) by the protein. Four concen-
trations of the substrate (100 mM,10 mM,1 mM, and 0.1 mM) were tested for the purpose
of assay optimization. A pET32a (þ)-blank protein (Fig. S5), incubated with 100 mM
substrate, was included as a mock-purified enzyme control. Results are shown as the
number of fold changes of fluorescence intensity after ZIKV NS2N-NS3 protein was
added as compared to baseline level. Kinetic parameters were analyzed and plotted
using Michaelis-Menten equation with GraphPad Prism version 6 (GraphPad Software,
San Diego California USA). (B) and (C) Increasing concentrations of aprotinin (positive
control) and novobiocin blocked the protease cleavage activity as measured by the
decrease in fluorescence intensity values. The concentrations of substrate and ZIKV
NS2B-NS3 protease were fixed as 10 mM and 5 nM, respectively. The experiments were
carried out in triplicate and repeated twice for confirmation. Data are presented as
mean values ± standard error of the mean (error bars). IC50, half maximal inhibitory
concentration (concentration of the drug at which there was 50% reduction in protease
activity).
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novobiocin-ZIKV NS2B-NS3 complex and showed that the
geometrical fluctuations associated with the drug-protein binding
were quickly stabilized (Figs. S3A and S3B). Overall, these findings
suggested that the binding of novobiocin to its binding pocket at
ZIKV NS2B-NS3 was highly stable and that the drug potentially
inhibited ZIKV NS2B-NS3 protease activity by diminishing its cat-
alytic efficiency.
3.5. Novobiocin inhibited the post-entry events of ZIKV replication
cycle
To investigate the phase of ZIKV replication cycle interrupted by
novobiocin, we performed a time-of-drug-addition assay by
exposing ZIKV-infected cells to novobiocin at different timepoints
during the virus replication cycle, followed by measurement of
virus titers at 18 h post-inoculation (hpi). Vero cells were infected
by 2 multiplicity of infection (MOI) of ZIKV, when novobiocin was
added during the virus replication stage (0,3,6,9, or 12hpi), viral
loads were significantly reduced (P < 0.05) within 12 h (Fig. S4). No
significant inhibitory activity was observed when novobiocin was
added at the virus adsorption stage (0-1hpi) or at the release stage
(14hpi). ZIKV attachment was also not affected when the Vero cells
were pretreated by novobiocin (1 to 0hpi). As the duration of a
single ZIKV life cycle has been previously determined to be around
12e14 h, in which the onset of intracellular viral RNA production
occurs at ~10-12hpi, and progeny virions are assembled and
released after 12hpi (Zmurko et al., 2016; Chan et al., 2017a), our
time-of-drug-addition results indicated that novobiocin interfered
with post-entry events during the ZIKV replication cycle within
stages after virus internalization and prior to budding, which was
Fig. 3. Evaluation of the in vitro anti-ZIKV activity of novobiocin. (A) ZIKV viral load reduction quantified by quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
in Vero cells at 48 h after ZIKV inoculation (0.05 MOI) with novobiocin. (B) ZIKV viral load reduction quantified by qRT-PCR in Huh-7 cells at 48 h after ZIKV inoculation (0.05 MOI)
with novobiocin. (C) Half maximal inhibitory concentration (IC50) of novobiocin as determined by plaque reduction assay. All experiments were performed in triplicates and
repeated twice for confirmation. * denotes P < 0.05 and *** denotes P < 0.0001 (compared to the DMSO control group by Student's t-test). Data are presented as mean
values ± standard error of the mean (error bars).
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compatible with its hypothesized role as a ZIKV NS2B-NS3 protease
inhibitor.
3.6. Treatment with novobiocin improved clinical outcome of
dexamethasone-immunosuppressed mice with disseminated ZIKV
infection
Extending from the in silico and in vitro findings, we further
evaluated the in vivo therapeutic effects of novobiocin in our
recently established animal model of dexamethasone-
immunosuppressed mice with disseminated ZIKV infection (Chan
et al., 2016c). We treated the dexamethasone-immunosuppressed
mice with subcutaneous novobiocin 100 mg/kg q12h from 1 to 13
day-post-infection (dpi) as they tolerated this dosage well without
developing clinical symptoms and had weight loss of <5% (Fig. 5A).
Higher dosages (150 mg/kg q12h or 200mg/kg q12h) of novobiocin
led to the development of lethargy, poor feeding, and body weight
loss of >10% among the mice after 6e8 days of treatment and were
therefore not used in our in vivo treatment study. Consistent with
our previous findings, the control mice with dexamethasone-
immunosuppression and ZIKV inoculation developed 10% body
weight loss with high clinical scores soon after dexamethasone
withdrawal (10dpi), which warranted euthanasia of all the mice at
12dpi (Fig. 5AeC). Immunohistochemical (5dpi) and hematoxylin
and eosin (H&E) (12dpi) staining of themajor organ tissues of these
mice showed abundant ZIKV NS1 antigen expression (Fig. 6A, D and
G) and marked inflammatory infiltrates (Fig. 7A, D and G), respec-
tively. In contrast, all the novobiocin-treated, dexamethasone-
immunosuppressed mice with ZIKV inoculation survived and
developed 8% weight loss with minimal clinical symptoms after
dexamethasone withdrawal which gradually recovered at 13-14dpi
(survival, 100% novobiocin-treated mice vs 0% untreated control
mice, P < 0.05). Corroborating with the clinical parameters, ZIKV
NS1 antigen expression was rarely detected by immunohisto-
chemical staining in the organs (5dpi) (Fig. 6B, E and H) and min-
imal inflammatory infiltrates were seen in H&E-stained tissues
(12dpi) (Fig. 7B, E and H) of these novobiocin-treated mice. The
absence of ZIKV NS1 antigen expression in immunohistochemical
staining (Fig. 6C, F and I) and inflammatory infiltrates in H&E
staining (Fig. 7C, F and I) in the organ tissues of the mock-infected
control mice with dexamethasone immunosuppression and novo-
biocin treatment indicated that these changes were not due to
drug-induced effects. The mean viral loads of the blood and most
major organ tissues of the novobiocin-treated mice were signifi-
cantly lower than those of the untreated control mice (with 2-log
reduction) at both 5dpi and 14dpi (Fig. 8A and B).
4. Discussion
Our recent report on the identification of bromocriptine as an
anti-ZIKV inhibitor validated ZIKV NS2B-NS3 protease as a drug-
gable target for the development of Zika therapeutics (Chan et al.,
2017a). In this study, we adopted an in silico structure-based
approach to rapidly screen a large chemical library and success-
fully identified numerous other clinically approved drugs with
inhibitory activity on the ZIKV NS2B-NS3 protease. We further
Fig. 4. Molecular model of novobiocin docked with ZIKV NS2B-NS3. (A) Chemical structure of novobiocin. (B) Ribbon-and-stick representation showing the predicted interacting
amino acid residues between novobiocin and ZIKV NS2B-NS3 using the crystal structure of ZIKV NS2B-NS3 protease (PDB ID:5LC0). Novobiocin is represented by sticks where the
carbon skeleton is displayed with light grey color, oxygen atoms in red color, nitrogen atoms in blue color, and polar hydrogen atoms in white color. ZIKV NS2B-NS3 is represented
by ribbons, with blue ribbons for monomer A and purple ribbons for monomer B. Established hydrogen bonds between the ligand and the protein are depicted with deep blue
dashed lines with bond length shown in Å. Main interacting residues are represented by lines and labeled. Interacting residues from NS2B are marked by *. (C) Two-dimensional
representation of the protein-ligand interactions between novobiocin and ZIKV NS2B-NS3. Hydrogen bonds and hydrophobic contact areas are represented by black dashed lines
and green lines, respectively. The main interacting residues are labeled. The dashed lines represent bonds between hydrogen and acceptor atoms that are involved. The 3D and 2D
figures were generated in PyMol (The PyMOL Molecular Graphics Syst, Version 1.8 Schr€odinger, LLC) and PoseView (Stierand and Rarey, 2010), respectively. (D) Novobiocin exhibited
a competitive mode of protease inhibition. In the assay, concentration of ZIKV NS2B-NS3 protease was fixed as 5 nM, while different concentrations of substrate (100, 50, 25, 12.5,
6.25, 3.125 and 0 mM) were added to plot the enzyme kinetic curves. Four concentrations of the drug (1000, 250, 62.5 and 0 mg/ml) were tested individually against the different
concentrations of substrate. The experiments were repeated twice for confirmation. The data were analyzed for mode of inhibition by GraphPad Prism 6 in the module of enzyme
kinetics. R2 > 0.95 was considered as statistically significant. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article.)
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validated the anti-ZIKV activity of novobiocin in multiple in vitro
antiviral assays and in an immunodeficient mouse model. Novo-
biocin, also known as albamycin or cathomycin, is an amino-
coumarin antibiotic that exerts its antibacterial effects (mainly
against Staphylococcus sp.) by targeting the GyrB subunit of bac-
terial DNA gyrase to competitively inhibit the adenosine triphos-
phatase reaction catalyzed by GyrB (Kirby et al., 1956; Flatman
et al., 2006). The inhibitory activity of novobiocin on the replica-
tion of various DNA viruses, including herpesviruses (herpes sim-
plex virus, cytomegalovirus, Epstein-Barr virus, Kaposi sarcoma-
associated herpes virus, and vaccinia virus), simian virus 40, and
duck hepatitis B virus, have been previously described (Civitico
et al., 1990; Droge et al., 1985; Furlini et al., 1983; Gonzalez-
Molleda et al., 2012; Pessina et al., 1992; Sekiguchi and Shuman,
1997; Wu et al., 2014). The proposed antiviral mechanism of
novobiocin against these DNA viruses is via blockade of host top-
oisomerases to inhibit viral replication and assembly (Sekiguchi
and Shuman, 1997; Wu et al., 2014). Our findings described a
novel mechanism by which novobiocin inhibited the replication of
an RNA virus belonging to Flaviviridae.
Molecular docking and molecular dynamics simulations indi-
cated that the binding between novobiocin and ZIKV NS2B-NS3
was highly stable. We employed the deposited structure with
PDB code 5LC0, which is the ZIKV protease dimer, in our in silico
analysis. The dimerization is mediated by a set of polar contacts
from both NS2B cofactor and NS3 and may be further driven by the
membrane association of the polyprotein in the in vivomembrane-
rich environment where the effective local concentration of the
replicative enzyme is very high (Lei et al., 2016; Phoo et al., 2016).
The HIS51 residue predicted to be interacting with novobiocin is a
conserved catalysis residue of ZIKV N2SB-NS3 protease activity
(Phoo et al., 2016). These results suggested that novobiocin may
provide cross-protection against different ZIKV subtypes/strains.
The functional fluorescence-based protease inhibition assay
confirmed that novobiocin inhibited ZIKV NS2B-NS3 protease ac-
tivity. The ZIKV NS2B-NS3 protease is an attractive antiviral target
because it plays a pivotal role in processing the viral polyprotein to
generate structural and non-structural viral proteins during viral
replication (Lei et al., 2016).
The treatment efficacy of novobiocin for ZIKV infection was also
evaluated in our recently established mouse model (Chan et al.,
2016c). In contrast to the untreated control mice which devel-
oped disseminated ZIKV infection with abundant ZIKV NS1 antigen
expression in organ tissues collected at 5dpi and clinical deterio-
ration with multiorgan inflammation soon after dexamethasone
withdrawal at 10dpi warranting euthanasia at 12dpi, novobiocin-
Fig. 5. Comparison of the clinical findings of the dexamethasone-immunosuppressed and ZIKV-infected BALB/c mice with and without novobiocin treatment. (A) Body weights, (B)
clinical scores, and (C) survival times and rates. Body weights of the mice were monitored for 14 days (survival mice) or until euthanasia. The mice were treated with novobiocin
100 mg/kg every 12 h subcutaneously at 1dpi to 13dpi inclusively (see also Table S1). n ¼ 8 for each group. Results were combined from two independent experiments. Clinical
scores: normal ¼ 0; ruffled fur ¼ 2; lethargy, pinched, hunched, wasp waisted ¼ 3; labored breathing, rapid breathing, inactive, neurological ¼ 5; and immobile ¼ 10. Abbreviations:
DEXA, dexamethasone; NOVO, novobiocin; ZIKV, Zika virus.
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treated mice had minimal ZIKV NS1 antigen expression in their
organ tissues collected at 5dpi and little inflammatory infiltrate
upon dexamethasonewithdrawal at 12dpi. Therewere significantly
reduced mean viral loads in the blood and the major organ tissues,
including the testis and kidney which are important in the trans-
mission of ZIKV, during both early (5dpi) and late (14dpi) stages of
infection. Although novobiocin's penetration into the central ner-
vous system through non-inflamed meninges may be limited, the
early control of viremia and penetration of the drug through
possibly inflamed meninges likely contributed to the improved
clinical outcome of the novobiocin-treated mice.
Novobiocin was withdrawn from sale in the United States in
2011 because it was no longer considered an effective antibacterial
agent, as numerous other newer anti-staphylococcal antibiotics
became available. Nevertheless, treatment with novobiocin is
generally well tolerated clinically and may be considered in preg-
nant women if the potential benefits outweigh the side effects (FDA
pregnancy category C) (Kirby et al., 1956). A few other clinically
approved drugs that are non-immunosuppressive and belong to
FDA pregnancy categories B or C have also recently been reported to
have in vitro anti-ZIKV effects. These included azithromycin, chlo-
roquine, daptomycin, ivermectin, mefloquine, niclosamide, and
sofosbuvir (Barrows et al., 2016; Bullard-Feibelman et al., 2016;
Delvecchio et al., 2016; Retallack et al., 2016; Xu et al., 2016).
However, except for sofosbuvir, none of these has been proven to be
effective in animal models (Bullard-Feibelman et al., 2016).
Importantly, most of these drugs have IC50 values that are not
achievable by routine oral therapeutic dosages. The Cmax:IC50 ratio
achievable with routine therapeutic dosage of oral novobiocin
(1.17e4.11) is markedly higher than those of oral mefloquine (0.58),
oral ivermectin (0.30), oral azithromycin (0.26), and oral chloro-
quine (0.12) (Barrows et al., 2016; Drusano et al., 1986; Retallack
et al., 2016; Xu et al., 2016). Oral and parenteral niclosamide are
insoluble (Zhang et al., 2015). Daptomycin is only available for
intravenous administration. Sofusovir is expensive (1000 USD/
tablet). Moreover, the mechanisms of anti-ZIKV activity of most of
these drugs have not been elucidated. The limitations of these
drugs make our findings especially important for further
Fig. 6. Representative immunohistochemistry findings in different groups of mice in this study. Representative immunohistochemistry findings at 5 days post-ZIKV inoculation in
the brain (top row: A, B, C), testis (middle row: D, E, F), and kidney (bottom row: G, H, I) (original magnification 400) of dexamethasone-immunosuppressed BALB/c mice with
ZIKV inoculation but without novobiocin treatement (left column: A, D, G), dexamethasone-immunosuppressed BALB/c mice with ZIKV inoculation and novobiocin treatment
(middle column: B, E, H), and dexamethasone-immunosuppressed BALB/c mice with mock infection and novobiocin treatment (right column: C, F, I). Arrows indicate cells with ZIKV
NS1 protein expression stained in brown by 3,3'-diaminobenzidine (DAB) in the organ tissue sections. (For interpretation of the references to colour in this figure legend, the reader
is referred to the web version of this article.)
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development of novobiocin into a clinically useful anti-ZIKV
treatment option. Nevertheless, these drugs may still be useful
for treating different groups of ZIKV-infected patients when used
under special circumstances (e.g.: Cmax:IC50 ratio of a 500 mg
intravenous dose of azithromycin against ZIKV can be as high as
2.31). Further evaluation of their in vivo effects, alone or in com-
bination, in animal models and clinical trials should be considered.
The successful identification of numerous ZIKV NS2B-NS3 pro-
tease inhibitors among primary hit compounds and validation of
novobiocin as a potent anti-ZIKV drug has demonstrated the
capability of our combined in silico, in vitro, and in vivo platform to
discover enzyme inhibitors of ZIKV among immediately available
clinically approved drugs. The same approach should be considered
for screening other large chemical libraries for potential ZIKV
helicase or polymerase inhibitors to expand the treatment options
for ZIKV infection.
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Abstract: Medicinal plants containing complex mixtures of several compounds with various potential
beneficial biological effects are attractive treatment interventions for a complex multi-faceted disease
like diabetes. In this study, compounds identified from African medicinal plants were evaluated for
their potential anti-diabetic activity. A total of 867 compounds identified from over 300 medicinal
plants were screened in silico with the DIA-DB web server (http://bio-hpc.eu/software/dia-db/) against
17 known anti-diabetic drug targets. Four hundred and thirty compounds were identified as
potential inhibitors, with 184 plants being identified as the sources of these compounds. The plants
Argemone ochroleuca, Clivia miniata, Crinum bulbispermum, Danais fragans, Dioscorea dregeana, Dodonaea
angustifolia, Eucomis autumnalis, Gnidia kraussiana, Melianthus comosus, Mondia whitei, Pelargonium
sidoides, Typha capensis, Vinca minor, Voacanga africana, and Xysmalobium undulatum were identified
as new sources rich in compounds with a potential anti-diabetic activity. The major targets
identified for the natural compounds were aldose reductase, hydroxysteroid 11-beta dehydrogenase
1, dipeptidyl peptidase 4, and peroxisome proliferator-activated receptor delta. More than
30% of the compounds had five or more potential targets. A hierarchical clustering analysis
coupled with a maximum common substructure analysis revealed the importance of the flavonoid
backbone for predicting potential activity against aldose reductase and hydroxysteroid 11-beta
dehydrogenase 1. Filtering with physiochemical and the absorption, distribution, metabolism,
excretion and toxicity (ADMET) descriptors identified 28 compounds with favorable ADMET
properties. The six compounds—crotofoline A, erythraline, henningsiine, nauclefidine, vinburnine,
and voaphylline—were identified as novel potential multi-targeted anti-diabetic compounds, with
favorable ADMET properties for further drug development.
Keywords: diabetes; anti-diabetic; DIA-DB; medicinal plants; in silico; virtual screening
1. Introduction
According to the World Health Organization, in 2016, diabetes was the seventh leading cause of
death, with an estimated 1.6 million people having died from the disease [1]. Diabetes is a chronic
disease arising from impaired insulin secretion and insulin resistance, leading to its defining feature
of hyperglycemia [2]. It is a multi-organ disease affecting the pancreas, liver, muscles, kidney, and
central nervous system, and several complications such as hypertension, stroke, blindness, and kidney
Molecules 2019, 24, 2002; doi:10.3390/molecules24102002 www.mdpi.com/journal/molecules
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disease are associated with diabetes [2,3]. The main type of treatment for diabetes and controlling the
associated hyperglycemia is in the form of insulin that primarily focuses on lowering and maintaining
blood glucose levels [2]. However, in more recent years, as diabetes is a multifaceted disease, there
has been an increase in the development of specific enzyme-targeted drugs, and specific inhibitors
for targets like alpha-glucosidase, dipeptidyl peptidase-4 (DPP4), glucagon-like peptide-1 (GLP-1)
receptor, and sodium-glucose co-transporter-2 (SGLT2) have been approved [3]. Unfortunately, some
of these approved drugs have been met with some adverse effects [3]. As a better understanding of the
pathogenesis and complexity in treating the disease arises, so too does the need for the development of
more effective and safer drugs to treat the disease.
Throughout history, plants have played an important role in medicinal drug discovery as rich
sources of unique and novel compounds for drug development. In several cultures, there is widespread
traditional use of decoctions prepared from medicinal plants in the treatment of diabetes [4–8]. The use
of decoctions prepared from medicinal plants in the treatment of a complex multi-faceted disease like
diabetes is attractive, as they often contain more than one compound with various beneficial biological
effects, thus potentially creating an effective and affordable multi-targeted treatment strategy [9,10].
In some cases, extensive scientific evaluations have been conducted on some of these traditional
medicinal plants to validate their use in the treatment of diabetes, however, for the majority, there is
a lack of scientific knowledge.
In silico virtual screening methodologies are ideal for initial exploratory evaluations of the potential
anti-diabetic activity of traditional medicinal plants. As plants are complex mixtures of several different
compounds, with in silico virtual screening methods, hundreds of compounds can be screened against
multiple diabetes targets rapidly and cost effectively. This strategy has been employed to identify
anti-cancer, anti-stroke, and anti-Alzheimer’s compounds from traditional Chinese medicines, as well
as their potential mechanisms of action [11–13]. In this study, we have implemented similar in silico
methodologies to identify novel African medicinal plants as rich sources of compounds with potential
anti-diabetic activity.
2. Results and Discussion
2.1. Inverse Virtual Screening and Identification of Compounds with Potential Anti-Diabetic Activity
In this study, the anti-diabetic potential of natural compounds from African medicinal plants
was explored with the DIA-DB web server (http://bio-hpc.eu/software/dia-db/) [14]. A total of
867 compounds were screened in silico against 17 diabetes targets. The ligands found crystallized with
each protein target were also screened to decide a cutoff docking score, so as to distinguish between
potential active and inactive compounds. The docking scores of the crystallized ligands ranged from
−11.3 to −5.7 kcal/mol, and in some cases, the test compounds had better docking scores than the
docking scores for the crystallized ligands (Table 1). A docking cutoff score of −9 kcal/mol was set, as it
was deemed a reasonable average docking score that covered the top 10%–20% of the test compounds
for each protein target [11–13].
Of the 867 test compounds, a total of 430 were predicted as potentially active compounds, and the
majority of these compounds were not limited to a single protein target only, with 30% of the predicted
active compounds having five or more protein targets (Figure 1 and Table S2). Hydroxysteroid 11-beta
dehydrogenase 1 (HSD11B1), peroxisome proliferator-activated receptor delta (PPARD), and DPP4
had the most predicted active compounds, with 208, 190, and 149, respectively, while protein targets
peroxisome proliferator-activated receptor alpha (PPARA), insulin receptor (INSR), and intestinal
maltase-glucoamylase (MGAM) had the least, with 6, 18, and 18, respectively (Figure S1). The difference
in the number of predicted active compounds likely reflects the differences in the nature of the binding
pockets of the target proteins, with some having large binding cavities that can accommodate different
types and sizes of scaffolds.
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Table 1. The docking scores obtained for the ligands crystallised with protein targets versus the lowest energy obtained for a test compound.










DPP4 Degrades and inactivates glucagon-like peptide-1 thatstimulates insulin secretion from the pancreas [15] 4A5S −10.5 −11.8 Cryptospirolepine
FFAR1 Binding of free fatty acids to the receptor results inincreased glucose-stimulated insulin secretion [16] 4PHU −9.8 −11.6 Procyanidin C1
HSD11B1
Coverts inactive glucocorticoid precursors to active
glucocorticoids; glucocorticoids counteract the effects
of insulin [17]
4K1L −8.3 −12.8 Cryptomisrine
INSR Regulates glucose uptake, as well as glycogen, lipid,and protein synthesis [15] 3EKN −8.7 −10.9 Typharin
PTPN9 Dephosphorylates the insulin receptor, therebyreducing insulin sensitivity [18] 4GE6 −7.7 −10.2 Cryptospirolepine




Catalyses the reduction of glucose to sorbitol in the
polyol pathway, and plays a role in diabetic
complications [20]
3G5E −11.3 −11.9 Pterygospermin
AMY2A Hydrolyses alpha-1,4-glycosidic bonds to starch duringdigestion of starch to glucose [21] 4GQR −7.9 −11.5 Clivimine
GCK Phosphorylates glucose to glucose-6-phosphate forglycolysis or glycogen synthesis [18] 3IMX −10.6 −13 Cryptomisrine
MGAM Hydrolyzes 1,4-alpha bonds, the last step in thedigestion of starch to glucose [21] 3L4Y −5.7 −10 Cryptospirolepine
PDK2
Responsible for inactivating the pyruvate
dehydrogenase complex that is involved during
glucose oxidation [22]
4MPC −7.8 −11.5 Clivimine
PYGL Catalyses the first step of glycogenolysis by thephosphorolysis of glycogen to glucose-1-phosphate [23] 3DDS −9.6 −10.8 Cryptomisrine
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Table 1. Cont.











Regulates the expression of the genes involved in bile
acid synthesis, cholesterol synthesis, and
steroidogenesis [24]
4DOR −6.5 −12.2 Clivimine
PPARA
Regulates the expression of the genes involved in lipid
metabolism, in particular, the oxidation of fatty acids,
as well as lipoprotein assembly and lipid transport [25]
3FEI −8.3 −11.4 Biscryptolepine
PPARD Regulates the expression of the genes involved in fattyacid catabolism [25] 3PEQ −11.3 −14.3 Cryptomisrine
PPARG
Regulates the expression of the genes involved in
adipogenesis and lipid metabolism, particularly fatty
acid transport, lipid droplet formation, triacyglycerol
metabolism, and lipolysis of triglycerides [25]
2FVJ −10 −11.9 Cryptoquindoline
RXRA Heterodimerizes with PPARs, thereby initiating genetranscription [25] 1FM9 −10.6 −10.9 Crinasiatine
Aldose reductase (AKR1B1); dipeptidyl peptidase-4 (DPP4); free fatty acid receptor 1 (FFAR1); glucokinase (GCK); hydroxysteroid 11-beta dehydrogenase 1 (HSD11B1); insulin
receptor (INSR); intestinal maltase-glucoamylase (MGAM); liver glycogen phosphorylase (PYGL); liver receptor homolog-1 (NR5A2); pancreatic alpha-amylase (AMY2A); peroxisome
proliferator-activated receptor alpha (PPARA); peroxisome proliferator-activated receptor delta (PPARD); peroxisome proliferator-activated receptor gamma (PPARG); protein tyrosine
phosphatase non-receptor type 9 (PTPN9); pyruvate dehydrogenase kinase isoform 2 (PDK2); retinoid X receptor alpha (RXRA); retinol binding protein 4 (RBP4).
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Figure 1. The network of compounds identified by virtual screening with the DIA-DB web server
and their predicted targets. All of the predicted active compounds are represented by a number that
corresponds to those given to the compounds in Table S2. The size of the target node depicts the
number of predicted compounds, while the size of the compound node depicts the number of predicted
targets. For the individual compound–target networks, please refer to Figure S1.
The significance of the potential for multi-targeted compounds becomes apparent when one looks
at the complexity of the diabetes disease pathogenesis. Diabetes is not the result of the dysregulation
of a single target and/or pathway, but rather the dysregulation of multiple processes such as glucose
and lipid metabolism, as well as insulin signaling in several organ systems, such as the pancreas, liver,
muscles, and adipose tissue, leading to the hallmark of hyperglycemia [2,26] (Figure 2). Compounds
capable of regulating one or more of the protein targets associated with these dysregulated processes
across the different organ systems may be more effective in managing the disease than a “single target
single drug” approach [27–29]. Not surprising, several manuscripts can be found in the literature on
the potential use of combination drug therapy for the treatment of diabetes, including the combination
of drugs with medicinal plants or herbs [9,10,30].
A total of 184 plants were identified as sources for the predicted active compounds (Table 2 and
Table S3). Some plants were found to contain several predicted active compounds, while with others
only one compound was identified. A limitation to this study was that one could not look at plants
specifically enriched for anti-diabetic compounds, as not all of the compounds for all of the plants were
listed in the books, and in several cases, only one major compound was listed for a plant. Following
extensive literature searches for previous literature on the anti-diabetic potential of the plants and the
compounds, it was found that of the 430 predicted active compounds, 125 had previous literature on
their anti-diabetic potential, leaving a total of 305 newly identified potential anti-diabetic compounds.
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Figure 2. A simplified overview of some of the organ systems and their dysregulation involved in
diabetes pathogenesis (adapted from Moller, 2001 [26]; Defronzo et al., 2014 [2]). Potential targets
identified in each organ system relate to some of the virtual screening targets of the DIA-DB web server.
Dipeptidyl peptidase-4 (DPP4); free fatty acid receptor 1 (FFAR1); glucokinase (GCK); hydroxysteroid
11-beta dehydrogenase 1 (HSD11B1); insulin receptor (INSR); liver glycogen phosphorylase (PYGL); liver
receptor homolog-1 (NR5A2); pancreatic alpha-amylase (AMY2A); peroxisome proliferator-activated
receptor alpha (PPARA); peroxisome proliferator-activated receptor delta (PPARD); peroxisome
proliferator-activated receptor gamma (PPARG); protein tyrosine phosphatase (PTP); pyruvate
dehydrogenase kinase isoform 2 (PDK2); retinoid X receptor alpha (RXRA).
From the plants, 82 plants were found with previous literature (namely traditional and experimental
evidence) (Table S3); 12 plants were identified with traditional use for diabetes (Table S3), but no
experimental evidence to date; and 90 plants were identified as new potential sources of anti-diabetic
compounds (Table 2). Of particular interest was that the majority of these 90 plants were sourced from
Poisonous Plants of South Africa [31], indicating the potential for toxicity of the compounds.
More than 60% of the plants with previous experimental literature on their anti-diabetic activity
were found to contain one or more compound/s that were also found to have previous literature
on their anti-diabetic potential. This suggests that these compounds are likely responsible for the
observed experimental activity of the medicinal plant. This is true in the case of several plants, such as
Aspalathus linearis and compounds aspalathin, isoorientin, orientin, and quercetin [32–34]; Cryptolepis
sanguinolenta and compound cryptolepine [35]; Garcinia kola and compounds garcinia biflavonoid
1 and 2 and kolaflavanone [36,37]; Glycyrrhiza glabra and compound glycyrrhizin [38]; Hoodia
gordonii and compound P57 [39]; Ligustrum lucidum and compound oleanolic acid [40]; Moringa
oleifera and compounds kaempferol and quercetin [41]; Olea europaea and compounds oleuropein and
oleanolic acid [42]; Punica granatum and compounds punicalin and punicalagin [43]; Ruta graveolens
and compound rutin [44]; Styphnolobium japonicum and compound sophoricoside [45]; Syzygium
cordatum and compound oleanolic acid [46]; Vernonia amygdalina and compounds 1,5-dicaffeoylquinic
acid, chlorogenic acid and luteolin-7-rutinoside [47]; and Withania somnifera and compound withaferin
A [48]. The identification of both plants and compounds with previous literature on their potential
anti-diabetic activity provides some validation for the methodology used in this study.
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Table 2. Plants with no previous anti-diabetic evidence, identified by virtual screening and their
predicted bioactive compounds.
Plant Name Family Compounds
Acokanthera oppositifolia Apocynaceae Acolongifloroside K31, acovenoside A32, ouabain304
Adenium multiflorum Apocynaceae Obebioside294
Agapanthus africanus Amaryllidaceae Agapanthagenin36
Amaryllis belladonna Amaryllidaceae Acetylcaranine30, caranine*97, lycorine277
Anagallis arvensis Primulaceae Arvenin I60, arvenin II61
Asclepias fruticosa Apocynaceae Afroside35, 19-deoxyuscharin20, gomphoside195
Aster bakeranus Asteraceae ent-16-Kauren-18-oic-acid
162,
ent-16-Kauren-19-oic-acid163, friedelin*174
Balanites maughamii Zygophyllaceae Cryptogenin127, diosgenin*153
Bersama lucens Melianthaceae Melianthugenin282
Boophane disticha Amaryllidaceae 3-Acetylnerbowdine16, buphanisin93
Bowiea volubilis Asparagaceae Bovogenin A89, bovoside A90
Brabejum stellatifolium Proteaceae Amygdalin*51
Cestrum laevigatum Solanaceae Parquin310
Chrysanthemum cinerariifolium Asteraceae Pyrethrin I330
Clivia miniata Amaryllidaceae Cliviamartine
112, cliviasine113, clividine114,
clivimine115, clivonine116, hippeastrine217, lycorine277





Crinum macowanii Amaryllidaceae Crinamine122, lycorine277, pratorimine319
Crotalaria spartioides Fabaceae Retrorsine343
Croton gratissimus Euphorbiaceae Crotofolin A125, crotonin126
Cucumis africanus Cucurbitaceae Cucurbitacin B133
Cyclamen persicum Primulaceae Cyclamin137





Datura stramonium Solanaceae Hyoscyamine220
Delphinium grandiflorum Ranunculaceae Nudicauline293
Digitalis purpurea Plantaginaceae Digitoxin150
Dioscorea dregeana Dioscoreaceae Deltonin
145, deltoside146, dioscin*152, diosgenin*153,
hircinol*218
Dodonaea angustifolia Sapindaceae Beta-sitosterol*70, hautriwaic acid205, stigmasterol*375
Drimia robusta Hycinthaceae 12-Beta-hydroxyscillirosidin4, proscillardin A324
Eriocephalus africanus Asteraceae Ivangustine246
Erythrina caffra Fabaceae Erythraline169
Erythrina lysistemon Fabaceae Erythraline169
Erythrophleum lasianthum Fabaceae Erythrophleine170
Eschscholzia californica Papaveraceae Dihydrosanguinarine*151
Eucomis autumnalis Asparagaceae Autumnariniol
65, autumnariol66,
3,9-dihydroeucomnalin19, eucosterol171
Euphorbia ingens Euphorbiaceae Ingenol231
Ficus salicifolia Moraceae Aviprin69
Geigeria ornativa Asteraceae Vermeerin407
Geranium incanum Geraniaceae Geraniin*189
Gnidia kraussiana Thymelaeaceae Gnidicin
192, gnidilatin193, gniditrin194,
12-hydroxydaphnetoxin5
Griffonia simplicifolia Fabaceae Indole-3-acetyl aspartic acid230
Homeria pallida Iridaceae 1,2-Epoxyscillirosidin1
Hyaenanche globosa Picrodendraceae Urushiol III402
Hypericum aethiopicum Hypericaceae Hypericin222
Ipomoea purpurea Convolvulaceae Ergine167
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Table 2. Cont.
Plant Name Family Compounds
Kalanchoe lanceolata Crassulaceae Lanceotoxin A258, hellebrigenin210
Lippia rehmannii Verbenaceae Icterogenin229, lantadene A259
Lotononis laxa Fabaceae Integerrimine234, senecionine359
Melianthus comosus Francoaceae 3-Epioleanolic acid*
17, hellebrigenin-3-acetate211,
melianthugenin282, oleanolic acid*299
Melilotus alba Fabaceae Dicoumarol148
Moraea polystachya Iridaceae 16-Beta-formyloxybovogenin A7
Mundulea sericea Fabaceae Deguelin142, rotenone347, tephrosin384
Ocotea bullata Lauraceae Ocubullenone295
Peddiea africana Thymelaeaceae Peddiea factor A1311
Pelargonium sidoides Geraniaceae Catechin*
100, gallocatechin*181, quercetin*331,
sitosterol-3-glucoside*364
Phytolacca dodecandra Phytolaccaceae Lemmatoxin262, oleanoglycotoxin298
Plumbago auriculata Plumbaginaceae Plumbagin*318
Polygala fruticosa Polygalaceae Frutinone A175, presenegenin321
Ptaeroxylon obliquum Rutaceae Umtatin22
Quercus robur Fagaceae Catalagin*99, digallic acid149
Rapanea melanophloeos Primulaceae 3-Oxo-20,24-dammaradien-26-ol18, sakurasosaponin353
Rhododendron indicum Ericaceae Grayanotoxin I197
Rhus undulata Anacardiaceae Apigenin dimethylether56
Sanseviera hyacinthoides Asparagaceae Ruscogenin-(25S)-form350
Sarcostemma viminale Apocynaceae Sarcovimiside B356
Scabiosa columbaria Caprifoliaceae Chlorogenic acid*106
Scadoxus puniceus Amaryllidaceae Haemanthamine206, haemanthidine207
Schotia brachypetala Fabaceae 3,3,4,5,5-Pentahydroxystilbene*14
Scilla natalensis Asparagaceae Proscillardin A324
Senecio retrorsus Asteraceae Retrorsine343
Senecio serratuloides Asteraceae Platyphylline317, senecionine359
Smodingium argutum Anacardiaceae 3,8,11-Heptadecadienylcatechol15
Solanum pseudocapsicum Solanaceae Solanocapsine367
Spirostachys africana Euphorbiaceae Stachenol372, stachenone373
Strophanthus speciosus Apocynaceae Christyoside107
Synadenium grantii Euphorbiaceae 4-Deoxy-13-O-phenylacetyl-12-O-tigloylphorbol21
Synaptolepis kirkii Thymelaeaceae Synaptolepis factor K1381, synaptolepis factor K7382
Tetradenia riparia Lamiaceae Ibozol228, 8-(14)-15-isopimaradiene-7,18-diol26
Thesium minkwitzianum Santalaceae Thesinine389
Thesium hystrix Santalaceae Quercetin*331
Thevetia peruviana Apocynaceae Thevetin A390, thevetin B391
Tylecodon wallichii Crassulaceae Cotyledoside121
Typha capensis Typhaceae Catechin*
100, typhaphtalide398, typharin399,
thyphasterol400
Urginea maritima Asparagaceae Scillaren A357, scillarenin358
Urginea sanguinea Asparagaceae Scillaren A357
Valeriana capensis Valerianaceae Valerenic acid405
Vinca minor Apocynaceae Eburnamonine*160, vincamine*417
Xerophyta retinervis Velloziaceae Amentoflavone*49
Zanthoxylum capense Rutaceae Sanguinarine*354
The numbers 1–430 serves as the identification of each compound in Figure 1. * All of the compounds identified
with some previous literature on their potential anti-diabetic activity.
Of interest were the plants found containing compounds with previous literature on the
compound’s potential anti-diabetic activity, but to date, the medicinal plant itself has not been
evaluated for its potential antidiabetic activity. These plants were Argemone ochroleuca with compounds
berberine [49], protopine [50] and sanguinarine [51]; Dioscorea dregeana with compounds dioscin [52,53],
diosgenin [18,54] and hiricinol [55]; Dodonaea angustifolia with compounds beta-sitosterol [56] and
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stigmasterol [57,58]; Melianthus comosus with compounds 3-epioleanolic acid [59] and oleanolic
acid [60]; Pelargonium sidoides with compounds catechin [61], gallocatechin [62,63], quercetin [64] and
sitosterol-3-glucoside [65,66]; and Vinca minor with compounds eburnamonine and vincamine [67].
These plants represent a good initial point for exploratory in vitro anti-diabetic studies. These plants
with their bioactive compounds and predicted targets are depicted in Figure 3.
Other plants of interest were those that had no previous literature, but contained several
compounds (also with no previous literature) that were identified in this study as having
a potential anti-diabetic activity. These plants were Mondia whitei and compounds 5-chloropropacin,
7-hydroxy-4,6-dimethoxypropacin and propacin; Voacanga Africana and its compounds ibogaine,
ibogamine, iboxygaine, vinburnine, voacamine, voacangine, voacorine, voaphylline and vobtusine; and
Xysmalobium undulatum and compounds allouzarin, alloxysmalorin, uzarigenin, uzarin (Figure 3).
Of note, these three plants have been used traditionally to treat diabetes, but lack the accompanying
scientific evidence [68–70]. The identification of the compounds found in these plants with a potential
anti-diabetic activity provide some rationale for the traditional use of these plants in the treatment
of diabetes. The plants Clivia miniata, Crinum bulbispermum, Danais fragans, Eucomis autumnalis,
Gnidia kraussiana, and Typha capensis were also of interest, as these plants were found to contain
four or more compounds that had been previously identified as having potential anti-diabetic activity
(Figure 3).
2.2. Identification of Potentially Important Scaffolds for Enzyme Activity
A hierarchical clustering analysis of the compounds identified in each protein target group
was performed using Tanimoto similarities to identify whether any compounds showed some
similar molecular features [11–13] (Figure S2). From these clustering results, the maximum common
substructure (MCS) analysis was performed in an attempt to identify any potential scaffolds important
for predicting the potential activity within the largest cluster group identified (Table 3). No clustering
of compounds was found for six of the protein target-compound groups, namely INSR, liver receptor
homolog-1 (NR5A2), pyruvate dehydrogenase kinase isoform 2 (PDK2), PPARA, protein tyrosine
phosphatase non-receptor type 9 (PTPN9), liver glycogen phosphorylase (PYGL), and retinoid X
receptor alpha (RXRA). This is not surprising, as these protein target–compound groups were relatively
small groups, with the number of predicted active compounds below 50—the two exceptions being
the free fatty acid receptor 1 (FFAR1) and the MGAM protein-compound groups, which had only 37
and 18 predicted active compounds, respectively. Within the FFAR1 and MGAM groups, two clusters
of similar compounds were evident that encompassed the majority of the compounds within the
groups, namely 26 of 37 for FFAR1 and 12 of 18 for MGAM. Interestingly though, the MCS analysis
produced only relatively small scaffold structures for the similar compounds within these groups,
namely, a phenol group for FFAR1 and a methoxyphenol for MGAM. The importance of the benzene
ring with a substituent group was also evident in the protein–compound groups of glucokinase (GCK),
PPARD, peroxisome proliferator-activated receptor gamma (PPARG), and retinol binding protein 4
(RBP4).
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Figure 3. Fifteen plants identified as new sources rich in compounds with potential anti-diabetic activity for exploratory in vitro anti-diabetic studies. Compounds
represented by their assigned numerical identity (Table S2); compounds represented by pink ellipses are compounds with previous literature on their anti-diabetic
potential; compounds represented by yellow ellipses are novel compounds. Dashed edges represent the edges connecting the plant with its predicted bioactive
compounds; solid edges represent the edges connecting the compounds with their predicted protein targets.
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Table 3. Summary of hierarchical clustering and maximum common substructure found in the largest cluster for each protein target group.







90 Articles that are part of the doctoral thesis
Molecules 2019, 24, 2002 12 of 30
Table 3. Cont.







HELENA DEN HAAN 91
Molecules 2019, 24, 2002 13 of 30
Table 3. Cont.









92 Articles that are part of the doctoral thesis
Molecules 2019, 24, 2002 14 of 30
The hierarchical clustering analysis of the HSD11B1 group revealed a total of 37 different clusters
(Figure S2), with the largest cluster containing 40 similar compounds, and based on an MCS analysis,
an important scaffold for HSD11B1 activity would be a flavonoid type of backbone. Interestingly, three
compounds found in this group, namely apigenin, quercetin, and genistein, were recently shown to
inhibit HSD11B1 [71]. Similarly, in the aldose reductase (AKR1B1) group, the centroid of the largest
cluster found was calycosin, an isoflavone, and the MCS was a benzopyranol scaffold that can be
found in the backbone of flavonoids. As with HSD11B1, there is literature on the inhibitory activity
of AKR1B1 by flavonoids and their glycosides [72,73]. For the DPP4 and pancreatic alpha-amylase
(AMY2A) groups, a more hydrophobic core scaffold with a hydrophilic head/tail was observed as the
MCS for these two protein targets. The compounds found in the largest cluster of these groups had
predominately triterpenoid or steroidal backbones with/without a glycosidic group attached, such as
shown in the two centroid compounds maslinic acid and balanitin-6. The compounds corosolic acid,
betulinic acid, glycyrrhizin, and sitosterol-3-glucoside with this type of backbone found in the AMY2A
group, have been shown in previous literature to inhibit the enzyme [52,66,74].
2.3. Molecular Similarity Evaluation of Predicted Active Compounds and Known/Experimental Anti-Diabetic
Drugs
A Tanimoto similarity analysis was performed to determine whether any similar molecular features
occurred between the natural compounds and known/experimental anti-diabetic drugs [11–13]. As seen
in Figure 4, only a small portion (approximately 10%) of the predicted active compounds showed some
similarity with the known anti-diabetic drugs. Thus, for the most part, natural compounds from African
medicinal plants present rather novel and unique scaffolds for anti-diabetic drug design. The majority
of these compounds showed similar molecular features to fasiglifam (TAK-875), an experimental
FFAR1 agonist [2].
Figure 4. Molecular similarity analysis of predicted active compounds and some known/experimental
anti-diabetic drugs. The similarity was performed on the extended connectivity fingerprint 4 (ECFP4)
molecular fingerprints of compounds with a Tanimoto similarity cut-off score of 0.7.
Three of these compounds, namely, biochanin A (86), fujikinetin (176), and hesperitin (213), were
also found by the DIA-DB web server as potential FFAR1 agonists; thus, these similarity studies with
known drugs may further support their potential activity. Of interest was that seven of the predicted
active compounds, namely, 8-hydroxypinoresinol (27), aspalathin (64), epicatehin (164), gallocatechin
(181), hypoxoside (224), leucocyanidin (263), and pinoresinol (315), showed some structural similarity
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with the gliflozins bexagliflozin, dapagliflozin, empagliflozin, and sotagliflozin. The gliflozins are
SGLT2 inhibitors [3]. Although SGLT2 was not included in the DIA-DB target screening panel, the
similarity of these compounds with the known drugs may present SGLT2 as a novel anti-diabetic
target for these seven compounds, and, of note, aspalathin has been found to be an inhibitor of
SGLT2 [75]. Similarly, compounds carapanaubine (98), gelsemicine (187), and rauvoxinin (338), as well
as hyoscyamine (220), showed some molecular similarity with repaglinide and nateglinide, respectively.
Repaglinide and nateglinide are ATP-dependent potassium (K+) channel binders that stimulate the
release of insulin from the pancreatic β-cells [76].
2.4. Prediction of Oral Bioavailability and Favourable Abosrption, Distribution, Metabolism, Excretion and
Toxicity (ADMET) Properties of the Predicted Active Compounds
The oral bioavailability, as well as some ADMET parameters, were evaluated for each of the
compounds. These are not only important parameters to evaluate for further drug development [11–13],
but considering that in some areas where easy access to anti-diabetic medication is not always
a possibility, an important way for patients to receive some form of anti-diabetic treatment would
be through the use of a decoction from a medicinal plant having anti-diabetic properties. Therefore,
factors such as the aqueous solubility and oral bioavailability of the bioactive compounds would be of
great importance. Also, as several of the compounds investigated in this study were found in Poisonous
Plants of South Africa [31], it is important to study the potential toxicity of these compounds.
The ADMET parameters for the predicted active compounds were compared to a group of 48
approved and experimental anti-diabetic drugs [2,3]. Also, a comparison of the ADMET parameters for
the predicted active compounds with no previous literature (novel compounds) was compared to that
of the predicted active compounds that had some previous literature on their potential anti-diabetic
activity (known compounds). These known compounds would serve as another “positive control”.
A summary of the Lipinski’s rule of five is depicted in Figure 5. As can be seen from Figure 5,
a major violation of Lipinski’s rule of five was the molecular weight of the compounds, with 30% of
the predicted active compounds violating this rule, namely, that the molecular weight must not exceed
500 g/mol (Figure 5a) [77]. This was also the major violation for the anti-diabetic drug control group.
The number of hydrogen bond donors and acceptors for the majority of predicted active compounds
was within the limitations (Figure 5b,c). No compound was found to violate all four rules, and 16% had
three violations—only acarbose in the anti-diabetic drug control group had three violations. Nearly
50% of the predicted active compounds violated one or more of Lipinski’s rule of five, versus only 25%
of the anti-diabetic drug control group. This is not surprising, as often such target-specific anti-diabetic
drugs are designed taking these factors into consideration. It was also observed that the compounds
predicted as having poor oral absorption were also predicted to have poor Caco-2 cell permeability
and vice versa (Figure 5d).
A complete summary of all of the ADMET parameters evaluated for the compounds can be found
in Table 4. The two major toxicity failures and points of concern for the predicted active compounds were
immunotoxicity and blockage of the hERG K+ channels, with 75% of the compounds being predicted
as potential immunotoxins, and 45% predicted as potential inhibitors of the hERG K+ channels.
Interestingly, these two toxicity parameters were also the two major failures for the anti-diabetic drug
control group. The model for the prediction of immunotoxicity is built on a training set of T- and
B-cell growth inhibition data from the National Cancer Institute [78]. In some cases, it is likely that the
predicted immunotoxicity may rather be a function of the compound concentration than a specific
effect, and also, the model cannot distinguish immunosuppressive effects from immunomodulatory or
immunostimulant effects. The predictive model for the human ether-a-go-go-related gene potassium
(hERG K+) channel blockage is often used to predict the potential cardiac toxicity of the compounds [79].
It was expected that some of the compounds would be predicted as potential cardiac toxins, as some
of the predicted active compounds are known cardiac glycosides, such as digitoxin, tyledoside C,
bovoside, oleandrin, proscillaridin A, scillaren A, uzarin, and gomphoside [31,80].
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Figure 5. Prediction of druglikeness and bioavailability of hit compounds (novel and known) versus diabetic drugs (a) molecular weight versus AlogP, Lipinski’s rule
of five, namely: compounds need to have a molecular weight of 500 g/mol or less and AlopP must be below 5; (b) frequency of hydrogen bond acceptors, Lipinski’s
rule of five—not more than 10 hydrogen bond acceptors; (c) frequency of hydrogen bond donors, Lipinski’s rule of five—not more than 5 hydrogen bond donors;
(d) QikProp prediction of percent human oral absorption versus Caco-2 cell permeability, percentage oral bioavailability below 25% is poor and above 80% is high,
predicted cell permeability for non-active transport below 25 nm/s is poor, while above 500 nm/s is very good.
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Table 4. Summary of the Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET)
parameters predicted in silico for predicted active compounds versus diabetes drugs.
ADMET Property Unknown Compounds Known Compounds Diabetes Drugs
Lipinski violations (1–4) 136/305 (45%) 75/125 (60%) 12/48 (25%)
Veber violations (1–2) 89/305 (29%) 42/125 (36%) 9/48 (19%)
Aqueous solubility QPlogS 34/305 (11%) 33/125 (26%) 6/48 (13%)
Caco-2 cell permeability (<25 nm/s) 66/305 (22%) 40/125 (32%) 3/48 (6%)
Binding to human serum albumin 37/305 (12%) 23/125 (18%) 6/48 (13%)
Human oral absorption (<25%) 55/305 (18%) 32/125 (26%) 3/48 (6%)
Rat oral LD50 (1–50 mg/kg) 53/305 (17%) 4/125 (3%) 1/48 (2%)
Hepatotoxicity 4/305 (1%) 4/125 (3%) 8/48 (17%)
Carcinogenicity 70/305 (23%) 31/125 (25%) 6/48 (13%)
Immunotoxicity 233/305 (76%) 89/125 (71%) 16/48 (33%)
Mutagenicity 49/305 (16%) 17/125 (14%) 1/48 (2%)
Cytotoxicity 58/305 (19%) 11/125 (9%) 1/48 (2%)
Blockage of hERG K+ channels 132/305 (43%) 58/125 (46%) 20/48 (42%)
* Recommended values: QPlogS: predicted aqueous solubility should be between −6.5 and 0.5 mol dm−3; Caco-2
cell permeability: <25 nm/s poor and >500 nm/s great; Binding to human serum albumin: QPlogKhsa should be
between −1.5 and 1.5; Human oral absorption: <25% poor and >80% great; Rat oral LD50: <50mg/kg is fatal if
swallowed; Blockage of hERG K+ channels: concern if predicted QPlogHERG is <−5.
After taking all of the ADMET parameters into account, only 28 of the predicted active compounds
were found to have favorable ADMET properties, and these are shown in Table 5. These compounds
present novel scaffolds with potential anti-diabetic activity and favorable ADMET properties for further
drug design and development. Of these 28 compounds, eight have shown anti-diabetic properties in
previous studies, and these were 2-hydroxygenistein [81], apigenin [82], catechin [61], cyanidin [83],
eburnamonine [67], epicatechin [84], eriodictyol [85], and lapachol [86].
Ten of the compounds, namely, apigenin, catechin, crotofoline A, cyanidin, eburnamonine,
erythraline, henningsiine, nauclefidine, vinburnine, and voaphylline were predicted as potential
inhibitors of three or more anti-diabetic targets. AKR1B1, HSD11B1 PPARD, and RBP4 were the major
targets identified for the 28 compounds. Also, of particular note, was that the plant Voacanga africana
was found to contain three of these compounds with favorable ADMET properties, namely vinburnine,
voaphylline, and withasomnine, and two of these compounds, vinburnine and voaphylline, were
identified as potential multi-targeted compounds. These observations provide some evidence for the
traditional use of Voacanga africana in the treatment of diabetes and further in vitro and in vivo studies
are now needed to validate its use for diabetes.
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Table 5. Predicted active compounds with favorable ADMET properties.
Compound Structure Predicted Targets (DockingScore in kcal/mol) Potential Anti-Diabetic Effect Plant
2-Hydroxygenistein AKR1B1 (−9.1) Regulation of glucosemetabolism Cajanus cajan
Apigenin AKR1B1 (−9.1), HSD11B1 (−9.0),RBP4 (−9.9), and RXRA (−9.1)
Regulation of insulin secretion,
glucose metabolism, and lipid
metabolism
Cajanus cajan
Autumnarinol RBP4 (−9.0) Regulation of insulin secretion Eucomis autumnalis
Catechin AKR1B1 (−9.0), HSD11B1 (−9.5),and RBP4 (−9.3)





sidoides, and Typha capensis
Crotofoline A AMY2A (−9.2), HSD11B1 (−9.9),and PPARD (−9.3)
Regulation of insulin secretion,
glucose metabolism, and lipid
metabolism
Croton gratissimus
Cyanidin AKR1B1 (−9.1), HSD11B1 (−9.5),and RBP4 (−9.2)
Regulation of insulin secretion
and glucose metabolism Rhoicissus tridentate
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Table 5. Cont.
Compound Structure Predicted Targets (DockingScore in kcal/mol) Potential Anti-Diabetic Effect Plant
Desacetylformonoakuammiline HSD11B1 (−9.1), PPARD (−9.0) Regulation of insulin secretionand lipid metabolism Rauvolfia vomitoria
Eburnamonine AKR1B1 (-9.4), HSD11B1 (−9.2),PPARD (−9.3), and RBP4 (−9.4)
Regulation of insulin secretion,
glucose metabolism, and lipid
metabolism
Vinca minor
Ent-16-kauran-19-oic acid HSD11B1 (−9.4) and PPARD(−9.4)
Regulation of insulin secretion
and lipid metabolism Aster bakeranus




Ergine HSD11B1 (−9.5) and RBP4(−9.4) Regulation of insulin secretion Ipomoea purpurea
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Table 5. Cont.
Compound Structure Predicted Targets (DockingScore in kcal/mol) Potential Anti-Diabetic Effect Plant
Eriodictyol HSD11B1 (−9.2) and RBP4(−9.5) Regulation of insulin secretion Cyclopia intermedia
Erythraline AKR1B1 (−9.0), GCK (−9.8),and RBP4 (−9.0)




Furanoeudesma-1,3-diene RBP4 (−9.0) Regulation of insulin secretion Commiphora myrrha
Hautriwaic acid AKR1B1 (−9.3) Regulation of glucosemetabolism Dodonaea angustifolia
Henningsiine
AMY2A (−9.1), HSD11B1 (−9.6),
PPARD (−10.0), and PPARG
(−9.0)
Regulation of insulin secretion,
glucose metabolism, and lipid
metabolism
Strychnos henningsii
Ibozol GCK (−9.7) Regulation of glucosemetabolism Tetradenia riparia
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Table 5. Cont.
Compound Structure Predicted Targets (DockingScore in kcal/mol) Potential Anti-Diabetic Effect Plant
Integerrimine HSD11B1 (−9.1) and PPARD(−9.3)
Regulation of insulin secretion
and lipid metabolism Lotononis laxa
Lapachol AKR1B1 (−9.2) Regulation of glucosemetabolism Kigelia africana
Nauclefidine AKR1B1 (−10.1), HSD11B1(−9.0), and RBP4 (−10.0)
Regulation of insulin secretion
and glucose metabolism Nauclea latifolia
N-methylflindersine AKR1B1 (−9.2) and RBP4 (−9.5) Regulation of insulin secretionand glucose metabolism Toddalia asiatica
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Table 5. Cont.
Compound Structure Predicted Targets (DockingScore in kcal/mol) Potential Anti-Diabetic Effect Plant
Platyphylline HSD11B1 (−9.4) and PPARD(−9.3)
Regulation of insulin secretion
and lipid metabolism Senecio serratuloides
Rhinocerotinoic acid HSD11B1 (−9.2) and RBP4(−9.9) Regulation of insulin secretion Elytropappus rhinocerotis
Senecionine HSD11B1 (−10.3) and PPARD(−9.4)
Regulation of insulin secretion
and lipid metabolism Senecio serratuloides
Valerenic acid AKR1B1 (−9.0) Regulation of glucosemetabolism Valeriana capensis
Vinburnine
AKR1B1 (−9.6), HSD11B1 (−9.1),
PPARD (−9.3), PPARG (−9.4),
RBP4 (−10.7), and RXRA (−9.3)
Regulation of insulin secretion,
glucose metabolism and lipid
metabolism
Voacanga africana
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Table 5. Cont.
Compound Structure Predicted Targets (DockingScore in kcal/mol) Potential Anti-Diabetic Effect Plant
Voaphylline
AMY2A (−9.0), DPP4 (−9.6),
GCK (−9.1), HSD11B1 (−9.3),
PPARD (−9.1), PPARG (−9.8),
and RBP4 (−9.2)
Regulation of insulin secretion,
glucose metabolism, and lipid
metabolism
Voacanga africana
Withasomnine FFAR1 (−9.1) Regulation of insulin secretion Voacanga africana
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3. Materials and Methods
3.1. Preparation of Compound Structures and Inverse Virtual Screening of Potential Anti-Diabetic Activity
The natural compounds were sourced from three books that catalogue the different medicinal
plants found in Africa, as well as their medicinal uses and chemical constituents. These three books
were African Herbal Pharmacopoeia [87], Medicinal Plants of South Africa [80], and Poisonous Plants of
South Africa [31]. Where a graphical representation of the compound was given in the books, the
two-dimensional structure of the compounds was created with Advanced Chemistry Development
(ACD)/ChemSketch freeware version 12.02, 2010 [88], and then converted to its representative simplified
molecular-input line-entry system (SMILES) notation. Where only the name of the compound was
given, the two-dimensional structure and SMILES notation was obtained from PubChem [89]. The
SMILES notations for the compounds analyzed in this study can be found in Table S1.
The SMILES notation of each compound was subsequently submitted to the DIA-DB web server
that employs inverse virtual screening of compounds with Autodock Vina against a given set of
17 protein targets associated with diabetes [14]. These targets were AKR1B1, DPP4, FFAR1, GCK,
HSD11B1, INSR, MGAM, PYGL, NR5A2, AMY2A, PPARA, PPARD, PPARG, PTPN9, PDK2, RXRA,
and RBP4.
A cutoff docking score of −9 kcal/mol was set to distinguish between potential active and
inactive compounds. The predicted compound–target network was generated by Cytoscape version
3.4.0 [90], and the NetworkAnalyzer Application version 2.7 [91] was used to evaluate some of the
basic network features.
3.2. Clustering and Maximum Common Substructure Analysis of Predicted Active Compounds
A hierarchical clustering analysis was performed for each compound–target group using
Schrödinger Canvas Suite version 3.2.013 [92]. The molecular fingerprint was calculated from
the two-dimensional structure of the compounds in the form of extended connectivity fingerprint 4
(ECFP4). From these fingerprints, a hierarchical clustering analysis was performed using the metric
of the Tanimoto similarity and the average cluster linkage method, which clusters according to the
average distance between all of the inter-cluster pairs. An MCS analysis was then performed on the
largest cluster identified within each compound–target group using the criteria of atomic number,
aromaticity, and bond order.
3.3. Similarity Studies with Known/Experimental Anti-Diabetic Drugs
The known/experimental anti-diabetic drugs were sourced from Defronzo et al., 2014 [2], and
Gougari et al., 2017 [3], and their SMILES representations were obtained from PubChem. The molecular
similarity network was generated with Cytoscape and the ChemViz2 Application version 1.1.0 [93].
The molecular similarity was performed using the metric of the Tanimoto similarity on the calculated
ECFP4 molecular fingerprints of the compounds. A Tanimoto score of 0.7 or greater indicated
molecular similarity.
3.4. Studies on Oral Bioavailability and ADMET Properties of the Predicted Active Compounds
The physiochemical descriptors of molecular weight, AlogP, hydrogen bond acceptors, hydrogen
bond donors, number of rotatable bonds, and polar surface area were calculated from the
two-dimensional structures of the compounds using the Schrödinger Canvas Suite [92]. For the
calculation of the QikProp descriptors, three-dimensional structures of the compounds were generated
and optimized with LigPrep from Schrödinger Maestro version 11.2.013 [94]. The QikProp descriptors
of aqueous solubility (QPlogS), Caco-2 cell permeability, binding to human serum albumin, percent
human oral absorption, and blockage of the hERG K+ channels, were subsequently calculated from the
three-dimensional structures with the Schrödinger Canvas Suite. The ProTox-II web server was used
to predict the potential toxicity of the compounds from their SMILES notation representations [95].
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The rat oral lethal dose 50 (LD50), hepatotoxicity, carcinogenicity, cytotoxicity, mutagenicity, and
immunotoxicity were evaluated with the ProTox-II web server.
4. Conclusions
African medicinal plants were identified as rich sources of compounds with potential anti-diabetic
activity through the use of inverse virtual screening with the DIA-DB web server (Figure 6). The
observation that some of the compounds identified with the DIA-DB web server had some previous
literature on their potential anti-diabetic activity provided validation for the use of the DIA-DB web
server for the identification of compounds with potential anti-diabetic activity. Also, the identification
of compounds with previous literature on their potential anti-diabetic activity provided some clues
as to the bioactive constituents of medicinal plants with known anti-diabetic activity, as well as the
rationale for the traditional use of some medicinal plants.
Figure 6. A brief summary of the methodology and results obtained for the in silico exploration of
African medical plants for potential anti-diabetic compounds.
Several plants were identified as new sources rich in compounds with potential anti-diabetic
activity, and included Argemone ochroleuca, Clivia miniata, Crinum bulbispermum, Danais fragans,
Dioscorea dregeana, Dodonaea angustifolia, Eucomis autumnalis, Gnidia kraussiana, Melianthus
comosus, Mondia whitei, Pelargonium sidoides, Typha capensis, Vinca minor, Voacanga Africana,
and Xysmalobium undulatum. These plants represent a good initial point for exploratory in vitro
anti-diabetic studies. As for the compounds, a total of 28 compounds were identified as having
favorable ADMET properties, and importantly, several of these were identified as novel potential
multi-targeted anti-diabetic compounds, such as crotofoline A, erythraline, henningsiine, nauclefidine,
vinburnine, and voaphylline. These compounds present as novel scaffolds for further drug design and
development. There is now the need for further in vitro and in vivo studies to confirm the potential
bioactivity of these compounds identified by the DIA-DB web server.
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/24/10/2002/
s1: Table S1—SMILES notations of all compounds evaluated in the study. Table S2—Assigned numerical
identity of predicted active compounds, their plant sources and predicted targets. Figure S1—Individual
predicted active compound–protein target networks. Table S3—Plants having scientific anti-diabetic evidence
and evidence of traditional use only identified by virtual screening and their predicted bioactive compounds.
Figure S2—Dendrograms of hierarchical clustering analysis.
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Chapter 3
Industrial part of the thesis
3.1 Introduction
The Industrial PhD Programme is a strategy from the Catholic University of Murcia
(UCAM) to promote applied research within several companies. The technology
transfer from the university to the industrial sector seeks, through innovation, to
provide a competitive advantage and promote the internationalization of our in-
dustry. Within the project, one of the main goals is to understand the needs of com-
panies and what technology and knowledge can be provided from the university
environment.
Eurofins Villapharma (https://www.eurofinsdiscoveryservices.com/cms/
cms-content/services/chemistry) is a company focused on the design and syn-
thesis of high value chemical compounds, with an original chemical structure, and
potential to become new medicines in the future. This company has forged partner-
ships with several research entities and groups, allowing them to further diversify
the collection of molecules it offers to its customers within the biopharmaceutical
industry.
The drug discovery process has become very complex over the last few decades.
Strategies in the industry have been changing to adapt to today’s requirements,
which demand greater efficiency in the developing process, both in terms of costs
and time, and the discovery of innovative drugs. Following the guidelines of
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the current market, Eurofins Villapharma tries to position itself as a company
that plays a key role in its sector by expanding its technology. In this context,
Eurofins Villapharma’s collaboration with the research group Bioinformatics and
High Performance Computing Group (BIO-HPC) arose. BIO-HPC research group
is located at UCAM (http://bio-hpc.eu). Its main research area of interest is
the exploitation of high-performance computing resources for the development
and application of different chemoinformatics programs mainly oriented to drug
discovery.
The industrial projects in which participated are mentioned below. Given that
all these works have been carried out in collaboration with third parties and that
the intellectual property of the results obtained has not yet been properly protected,
and consequently with the confidentiality agreement that binds me to the company,
I cannot reveal the results of these works.
3.2 Discovery and optimization of bioactive compounds in
the context of Cancer
The industrial part of this PhD has been developed mainly within two projects in
which Eurofins Villapharma is a collaborating partner, FRIDASTEM (funded by the
H2020 programme in the Eurostars call) and STEMHIT (funded by MINECO in the
Retos-Colaboration industrial call), both aimed at the discovery of new chemical
compounds for inhibiting the development of cancer stem cells.
Phosphorylation is one of the most often occurring post-transcriptional modi-
fications in proteins (Khoury et al., 2011). This process is regulated by specific en-
zymes known as kinases (they add phosphate) and phosphatases (they remove it).
518 kinases have been described in the human proteome (Manning et al., 2002),
which regulate critical vital functions in cells. These include those involved in mo-
bility, proliferation and metabolism as well as survival, cell cycle control points
(DNA damage control), antitumour immunity evasion and angiogenesis (Gross
et al., 2015). Given the processes that regulate, frequently, an aberrant expression of
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these enzymes is involved in the development of various diseases, including cancer.
This revelation was confirmed by the text Cancer Gene Census in a report in 2004
where it revealed that the protein domain most commonly encoded by oncogenes
is the quinoma (Futreal et al., 2004). Subsequent studies conducted by The Cancer
Genome Atlas (TCGA) and the International Cancer Genome Consortium. (ICGC)
showed that most protein kinases have mutation frequencies from low (less than
10%) to intermediate and others, to a lesser extent, frequencies greater than 10% in
one or more types of cancer (Fleuren et al., 2016).
Considering the above-mentioned data, kinases have become a very attractive
therapeutic target for the treatment of different types of cancer, being the discovery
of small kinase-inhibiting compounds the goal for which more effort and resources
are being invested both among research groups and by the pharmaceutical industry
(Wu et al., 2015). However, finding these compounds is not a trivial affair, as evi-
denced by the fact that the first FDA-approved drug that acted as a kinase inhibitor
(kinase STI-571, belonging to the Abl group of protein-tyrosine kinases) dates from
2001 (Müller et al., 2015) more than 20 years after the first oncogene of protein ki-
nases(Cohen, 2002) was identified. However since then, 37 kinase inhibitors have
been approved worldwide and more than 250 candidate drug compounds are at
some stage of clinical trials (Klaeger et al., 2017).
In kinases the ATP binding site is found forming a cavity in an area arranged be-
tween the two catalytic lobes of the enzyme. This cavity has structural and morpho-
logical characteristics that make it druggable. This region of the enzyme is highly
conserved throughout the kinome, which makes the task of finding selective in-
hibitors for a specific type of kinase especially complicated. Therefore, a funda-
mental objective of these projects was to optimize the compounds for which initial
inhibition was obtained, considering as a hit those compounds with a LE (Ligand
efficiency) lower than 0.3, in order to obtain new molecular entities with greater in-
hibition potential. For this purpose, different cheminformatic techniques were used,
such as QSAR modeling (Gramatica, 2007; Pérez-Garrido et al., 2009) or the simula-
tion of molecular coupling (Imbernón et al., 2017; Sánchez-Linares et al., 2012) and
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molecular dynamics (Shivakumar et al., 2010; Tapia-Abellán et al., 2019).
The virtual screening techniques employed have played a fundamental role in
the discovery of new molecules potentially active in the different contexts men-
tioned above. The simulation of the molecular docking used for the discovery of
kinase-inhibiting molecules had a success rate of more than 60%. We have also ob-
served that this technique is very dependent on the quality of the protein model
being used.
3.3 Discovery of bioactive compounds enhancers of the cys-
tic fibrosis transmembrane regulating protein (CFTR)
Cystic fibrosis transmembrane regulating protein (CFTR) acts as a chlorine channel.
Certain mutations in the gene encoding for the protein cause the expression of the
transporter, as well as its activity, to be impaired in epithelial cells of respiratory
organs. More than 2000 different mutations are known, being the PHE508 residue
deletion the most common of all (W Loo et al., 2002), occurring in approximately
70% of patients. The consequence of these mutations is that the transcribed protein
cannot acquire the correct quaternary structure and either degrades before reaching
the membrane of the epithelial cells or manifests itself in the epithelials but is
only partly functional (Lukacs and Verkman, 2011). Therefore, the objective of this
project is to find bioactive compounds that act as pharmacological chaperones and
allow the normal folding of the protein recovering its transport activity and normal
distribution in the cell membranes more effectively than the two drugs currently
approved for the treatment of the disease.
Within the framework of this industrial PhD we have collaborated to search for
compounds that could be used in the treatment of cystic fibrosis. In this context, a
virtual screening of different libraries of commercial compounds (including those
of Eurofins Villapharma) was carried out. A total of twenty-eight three-dimensional
pharmacophoric models were created based on the physical-chemical properties of
the compounds, both activators and modulators of the activity of the CFTR, located
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in the patents available in the databases to which the company has access.
The screening of approximately one million of compounds was carried out in
three stages:
• In a first stage the compounds were clustered according to their structural
similarity and filtered based on their molecular structure finally selecting
approximately 500000 compounds of diverse structure and chemical nature.
• In the second stage the compounds were filtered considering certain mini-
mum criteria that drugs must comply such as eliminating PAINS (Pan-Assay
Interference), compounds with a molecular weight lower than 160 Da and
higher than 650 Da and compounds with long aliphatic chains or contain-
ing more than 5 aromatic rings. This stage is performed on two-dimensional
models of the compounds to accelerate the process using a textworkbench in
KNIME (Berthold et al., 2009).
• In a third stage, up to 100 conformations of each of the molecules of the
remaining chemical library were generated and the pharmacoforic models
created before were used to filter the database.
When the three-dimensional structure of the therapeutic target is not available,
virtual screening techniques based on ligands are a very good alternative. Of
the different techniques available, pharmacoforic modeling is a very attractive
method due to the reduced computational requirements and it has shown very
promising results in the specific case of the discovery of drugs that enhance the
CFTR transporter. Of the 611 compounds selected, 5 hits were obtained whose





This doctoral thesis presented as a compilation of publications, has its starting-
point in the drug discovery assisted by computer and the common denominator
are the different computational techniques used for the search and optimization of
bioactive compounds against different therapeutic targets: kinases proteins, CFTR
transporter, cholinesterases, α-galactosidase, Zika virus protease NS2B-NS3 and
various proteins involved in diabetes.
In this chapter we synthesize the conclusions derived from the results that have
been gradually obtained and that we can gather from all the thesis development
and that perfectly can become premises to continue the research line.
4.1 Conclusions
The most relevant contributions derived from the different articles that make up
this doctoral thesis are described below:
4.1.1 Discovery of a novel pharmacological chaperone for the treatment
of Fabry disease
• Virtual screening based on the three-dimensional shape of chemical com-
pounds is a fast strategy that can reduce the molecular spectrum in large col-
lections of molecules when looking for bioactive compounds that must fit to-
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gether with a specific topology where compounds of a higher volume than the
pocket where these compounds must interact cannot be accommodated.
• The simulation of the molecular docking carried out with the same pool of
compounds in two different regions of the protein, the active site and an
allosteric site, made it possible to identify compounds for which the method
predicted a maximum affinity energy difference between the active site and
the allosteric site. That is, compounds for which the computational method
estimated an affinity at least twice lower at the active site than at the allosteric
site comprising the enzyme residues A37, R38, T39, P40, T41, M42, E87, Y88,
none of which overlap with the enzyme’s active site.
• The experimental techniques carried out by our collaborators of the Univer-
sity of Naples demonstrated that the compound selected by this computa-
tional technique, 2,6-ditiopurine (DTP), is able not only to stabilize the en-
zyme α-galactosidase, but also it is able to promote, both individually and
in synergy with other chaperones, the maturation of the α-galactosidase, as
well as the mutant variety (A230T) that does not respond to treatment with 1-
deoxygalacto-nojirimycin (DGJ), the only pharmacological chaperone on the
market. In addition, DTP does not inhibit enzyme activity at concentrations
of 6 mM at which DGJ does inhibit it completely.
• Experimental trials on variants of the enzyme α-galactosidase with mutations
that alter the conformation of the allosteric binding site proposed for DTP by
the use of textitin silico methods show that the compound loses the ability
to promote maturation and rescue enzyme activity. This implies that there is
strong evidence to support the predictive model used.
4.1.2 Description of the mode of action of cholinesterase-inhibiting
bioactive compounds
• By simulating the molecular docking the binding mode between the com-
pound N-acetyl-tryptophan and acetylcholinesterase at its active site was
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modelled. According to this simulation the compound is bound by hydro-
gen bonds to the residues GLU199 and TYR121 which would prevent acetyl-
choline access to the catalytic triad. The preducted three-dimensional confor-
mation of the compound N-acetyl-tryptophan also overlaps with the crystal-
lographic conformation of donepezil, from which it can be deduced that the
mechanism of action of N-Acetyl-tryptophan must be similar to that of this
drug.
• The first study in silico on the inhibitory effect of different kinds of tanshi-
nones and rosmarinic acid on cholinesterase enzymes is shown in the sci-
entific production that makes up this thesis. This study, by simulating the
molecular docking, reveals how these compounds bind in the pocket of the
catalytic site of the enzyme where hydrophobic and pi-pi stacking interac-
tions with the enzyme acetylcholinesterase are most predicted and hydrogen
bonds with residues of the catalytic triad in the case of butyrylcholinesterase.
Additionally, a QSAR model was created to evaluate the selectivity of the com-
pounds for the different cholinesterases according to their chemical structure.
Thus, it was determined that the compounds with more aliphatic substituents
had a greater affinity for butyrylcholinesterase, while those with more aro-
matic radicales had more selectivity for acetylcholinesterase than for butyrol-
cholinesterase.
• The simulation of the molecular docking of the compounds hyperforin and
hyuganin C shows the potential interactions of both compounds at the active
site of butyrylcholinesterase. In the case of hyuganin C a strong web of hydro-
gen bonds formed with the catalytic triad residues GLY115, GLY116, GLY117,
SER198 and LEU286 and hydrophobic interactions with the residues TRP82
(peripheral anionic site), PHE329 (anionic site) and PHE398 were predicted.
According to the same model, the stabilization of hyperforin in the active site
is mainly due to hydrophobic interactions established with residues of the pe-
ripheral anionic site (TRP82, THR120, TRP231, VAL288, TYR332) and other
120 Conclusions
residues (PHE398, TRP430, TYR440) and to the hydrogen bonds that would
be formed with SER79 and HIS438 residues of the catalytic triad. These inter-
actions would explain how they inhibit butyrylcholinesterase by occupying
the active site and by preventing access to its substrates up to the catalytic
triad.
4.1.3 Repositioning of an antibiotic as a NS2B-NS3 protease inhibitor for
the treatment of Zika virus infection.
• By modelling the molecular docking, the molecular pool of the Drugbank
database (Law et al., 2013) were ranked according to the predicted energy
affinity value of each compound for the protease NS2B-NS3 at the active site
of a boronate inhibitor using as the structural model for the simulation the
crystal 5LC0 (Lei et al., 2016). 8 compounds out of the 100 best molecules were
selected for characterization in vitro as these drugs were already approved for
therapeutical use and therefore had already passed clinical safety trials. 5 of
the 8 selected drugs showed ability to inhibit viral protease in fluorescence-
based inhibition assays conducted by our collaborators at the University of
Hong Kong. In other words, more than 60% of the compounds tested that
were selected by virtual screening techniques were active.
• A molecular dynamics simulation using the structural model of the protease
bound to novobiocin, taking as a starting point the spatial conformation of
the drug obtained by means of docking, made it possible to analyse in more
detail the possible interactions between novobiocin and the protein that are
responsible for the drug’s inhibition potential. This simulation suggested
that the bond between the drug and the catalytic site of the enzyme was
highly stable. Our model predicted interactions by hydrogen bonds between
novobiocin and residues MET51, SER81 and LYS54, as well as hydrophobic
stabilization areas with residues HIS51 and VAL155. It should be noted that
residues HIS51 and SER81 of protease also interact with boronate inhibitor as
can be read in the work of Lei et al. (2016) and therefore perhaps these residues
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play a key role in the catalytic activity of the enzyme. The HIS51 residue is also
highly conserved in NS3B-NS2 proteases of different ZIKA virus strains, so
novobiocin could be active against infection by different Zika virus subtypes.
• The efficacy of novobiocin treatment against Zika virus infection was evalu-
ated using animal models (mice). It was found that viral load in organ tissues
such as kidneys or testicles in novobiocin-treated mice was significantly lower
than in untreated mice and the survival rate reached 100% in mice that were
administered the drug versus 0% in untreated mice.
4.1.4 Development of a virtual screening platform for the identification
of new anti-diabetic compounds
results
• The DIA-DB web server in which the doctoral candidate has participated
in its development (see section 5.1.4) has been used to carry out a reverse
virtual screening which aims to identify the potential therapeutic target of
several natural compounds in the field of diabetes. Of the 867 natural com-
pounds identified, through bibliographic references, in approximately 200
African plant species, potential anti-diabetic activity was predicted for a to-
tal of 430 compounds. For the vast majority of these compounds more than
one possible therapeutic target was predicted, with proteins with larger ac-
tive sites (Hydroxisteroid 11-beta dehydrogenase 1 (HSD11B1), peroxisome-
proliferator-activated delta receptor, and dipeptidyl peptidasa 4) being those
for which higher affinity energies are predicted (above the threshold estab-
lished in the study to consider a bioactive compound). More than 60% of
the plants containing the compounds for which affinity for proteins involved
in diabetes was predicted had already been linked by other scientists with
anti-diabetic activity, which implies a validation of the relative efficacy of the
predictive method used.
• The hierarchical classification of each group of compounds with affinity to
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a protein obtained by means of the Tanimoto similarity index (Bajusz et al.,
2015) made it possible to identify some molecular scaffolds common to several
of the compounds identified as bioactive in the context of diabetes, such as the
flavonoids inhibitors of HSD11B1.
• This same Tanimoto index was used to identify the degree of similarity of
the compounds for which bioactivity was predicted with approved drugs
and other experimentally evaluated bioactive molecules, observing that only
10% of the molecules modeled have a chemical structure similar to these
compounds. This evaluation determines that most of the chemical com-
pounds evaluated have original molecular scaffolds with respect to anti-
diabetic drugs.
• Bioactive compounds that are candidates for drugs must comply with certain
Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) pa-
rameters, in addition to the ability to be soluble in water since most of these
compounds are usually administered orally as plant extracts. Of the com-
pounds evaluated, the computational method used for predicting ADMET
properties predicts that only 28 compounds are favorable, of which 8 com-
pounds have already been evaluated experimentally and 20 are presented as
novel chemical structures with potential antidiabetic activity for four thera-
peutic targets.
4.2 Outlook
• The DTP pharmacological chaperone discovered in this research work is effec-
tive at high concentrations. Although the compound can accumulate in body
cells at millimolar concentrations (Powell et al., 2010) without causing dam-
age to the cells (Boulware et al., 2012; Qing et al., 1995) there is a risk of DTP
interacting with other proteins in the cells, causing undesirable side effects. In
addition, the compound has been shown to be ineffective in stabilizing some
of the α-galactosidase mutations that negatively impact its catalytic activity.
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Therefore, it is necessary to carry out optimization techniques modifying the
chemical structure of the compound to achieve greater specificity and affinity
for the enzyme at the allosteric site.
• Through a QSAR study, hyuganin C was determined to be a potentially
hepatotoxic compound. It would therefore be important to conduct studies
in vitro of its biological activity, to assess its possible adverse effects, which
would be helpful in the process of developing new drugs.
• Novobiocin is an antimicrobial agent that was withdrawn from sale because
bacteria developed resistance to the drug being less effective compared to
other available drugs. Despite excellent laboratory results, the compound
has difficulty crossing the blood-brain barrier when the meninges are not in-
flamed. In addition, although it is not a contraindicated drug for pregnant
women, it falls within the category C of the Food and Drug Administration
(FDA), which means that its administration has not been shown to be com-
pletely safe for the fetus. Considering that one of the most serious sequelae of
the disease is neurological damage in neonates, these two limitations could be
an impediment for the use of the drug, so it would be advisable to optimize
the compound by in silico techniques taking into account these two limiting
factors.
• To check the computational method carried out in the section 2.8 of this
thesis it is necessary to conduct the relevant experimental trials to corroborate
whether the in silico characterized molecules actually exhibit the predicted
anti-diabetic activity. If the experimental characterization is successful, the
same computational method could be applied to other natural compounds






5.1 Collaborations and other publications
The ultimate goal of an industrial doctoral thesis is to establish cooperative ties
between the university and the company so as to ensure a steady flow of knowl-
edge, innovation and production between the two entities. During the course of
the research work, which outcome is the thesis presented, collaborations have been
established both with other companies (as detailed in the Chapter 3) and with other
research groups. Below are the scientific publications and research projects in which
the PhD student has been involved as a result of these collaborations that have not
been included as results of the thesis:
5.1.1 Publications in journals indexed in ISI
1. Budryn, G., Zaczyńska, D., Pałecz, B., Rachwał-Rosiak, D., Belica, S., den
Haan, H., Peña-Garcı́a, J., and Pérez-Sánchez, H. (2016). Interactions of free
and encapsulated hydroxycinnamic acids from green coffee with egg ovalbu-
min, whey and soy protein hydrolysates. LWT - Food Science and Technology,
65:823–831
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2. Cerón-Carrasco, J. P., den Haan, H., Peña-Garcı́a, J., Contreras-Garcı́a, J., and
Pérez-Sánchez, H. (2016). Exploiting the cyclodextrins ability for antioxidants
encapsulation: A computational approach to carnosol and carnosic acid em-
bedding. Computational and Theoretical Chemistry, 1077:65–73
3. Pérez-Sánchez, H., Rezaei, V., Mezhuyev, V., Man, D., Peña-Garcı́a, J., den
Haan, H., and Gesing, S. (2016). Developing science gateways for drug
discovery in a grid environment. SpringerPlus, 5(1):1300
4. Yar, M., Shahzadi, L., Farooq, A., Jalil Imran, S., Cerón-Carrasco, J. P., den
Haan, H., Kumar, S., Peña-Garcı́a, J., Pérez-Sánchez, H., Grycova, A., Dvorak,
Z., and Vrzal, R. (2017). In vitro modulatory effects of functionalized pyrim-
idines and piperidine derivatives on Aryl hydrocarbon receptor (AhR) and
glucocorticoid receptor (GR) activities. Bioorganic Chemistry, 71:285–293
5. Rauf, A., Farooq, U., Khan, A., Hadda, T. B., Naz, S., Ibrar, A., Jehan, N., Cerón-
Carrasco, J. P., Haan, H. d., Peña-Garcı́a, J., Pérez-Sánchez, H., Khan, H., Ra-
madan, M. F., Abu-Izneid, T., Bawazeer, S., Rauf, A., Farooq, U., Khan, A.,
Hadda, T. B., Naz, S., Ibrar, A., Jehan, N., Cerón-Carrasco, J. P., Haan, H. d.,
Peña-Garcı́a, J., Pérez-Sánchez, H., Khan, H., Ramadan, M. F., Abu-Izneid,
T., and Bawazeer, S. (2017). Sedative and muscle relaxant activities of diter-
penoids from Phlomidoschema parviflorum. Revista Brasileira de Farmacog-
nosia, 27(5):636–640
6. Jerbi, J., Springborg, M., den Haan, H., and Cerón-Carrasco, J. P. (2017). S-
adenosyl-l-methionine analogs as enhanced methyl donors: Towards novel
epigenetic regulators. Chemical Physics Letters, 690:74 – 81
7. Khan, H., Zafar, M., Den-Haan, H., Perez-Sanchez, H., and Kamal, M. A.
(2018). In-silico Studies of Isolated Phytoalkaloid Against Lipoxygenase:
Study Based on Possible Correlation. Combinatorial Chemistry & High Through-
put Screening, 21(3):215–221
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5.1.2 Editorials
1. den-Haan, H., Fassihi, A., Bueno-Crespo, A., Soto, J., Vegara-Meseguer, J.,
Montoro, S. and Pérez-Sánchez, H. (2015). Application of Modern Drug
Discovery Techniques in the Context of Diabetes Mellitus and Atherosclerosis.
Drug Designing: Open Access, 04(01)
5.1.3 Preprints
1. den Haan, H., José Hernández Morante, J., and Pérez-Sánchez, H. (2016).
Computational evidence of a compound with nicotinic α4β2-ach receptor
partial agonist properties as possible coadjuvant for the treatment of obesity.
The preprint server for biology (bioRxiv)
5.1.4 Congresses
1. Fahimeh Ghasemi, Alireza Mehri, Jorge Peña-Garcı́a, Helena den-Haan, Al-
fonso Pérez-Garrido, Afshin Fassihi, and Horacio Pérez-Sánchez (2015). Im-
proving activity prediction of Adenosine A2b receptor antag- onists by ma-
chine learning methods. In International Work-Conference on Bioinformatics and
Biomedical Engineering, pages 635–644, IWBBIO
2. Sánchez-Pérez, A., Muñoz, A., Peña-Garcı́a, J., den Haan, H., Bekas, N., Katsik-
oudi, A., Tzakos, A. G., and Sánchez, H. P. (2015). DIA-DB: A Web-Accessible
Database for the Prediction of Diabetes Drugs. In Bioinformatics and Biomedical
Engineering - Third International Conference, IWBBIO 2015, Granada, Spain, April
15-17, 2015. Proceedings, Part II, pages 655–663
3. Peña-Garcı́a, J., den Haan, H., Caballero, A., Imbernón, B., Cerón-Carrasco,
J. P., Vicente-Contreras, A., and Pérez-Sánchez, H. (2016). GrantFinder, a web
based tool for the search of research grant calls. In 4th International Work-
Conference on Bioinformatics and Biomedical Engineering, pages 326–333, IWBBIO
4. Jorge Peña-Garcı́a, Alfonso Pérez-Garrido, Andrés Muñoz, Helena den-Haan,
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Baldomero Imbernón, José Pedro Cerón-Carrasco, Antonio Banegas-Luna,
Jesús Soto, and Darius Mrozek (2016). ZincFetcher: a tool for easy compound
filtering from ZINC database. In 4th International Work-Conference on Bioinfor-
matics and Biomedical Engineering, pages 343–351, IWBBIO
5. Ricardo Rodrı́guez-Schmidt, Jorge Peña-Garcı́a, Alfonso Pérez-Garrido, He-
lena den-Haan, Andrés Bueno-Crespo, José Pedro Cerón-Carrasco, Jesús Soto,
Anil Thapa, and Jon Atli-Benediktsson (2016). A hybrid machine learning and
molecular modeling methodology for the prediction of novel blood anticolag-
ulants. pages 334–342, IWBBIO
6. Pérez-Sánchez, H., Peña-Garcı́a, J., den Haan, H., Rodrı́guez-Schmidt, R.,
Cerón-Carrasco, J. P., Raposo, A. N., Bouarkat, M., Sabeur, S. A., and Dı́az-
Baños, F. G. (2016). HYDROWEB, an Online Tool for the Calculation of Hy-
drodynamic Properties of Macromolecules. In Ortuño, F. and Rojas, I., editors,
Bioinformatics and Biomedical Engineering, Lecture Notes in Computer Science,
pages 82–90, IWBBIO. Springer International Publishing
5.1.5 Patents
1. Yuan, S. Chan, J. Y. K. d.-H. H. P.-G. J. C.-C. J. and Pérez-Sánchez, H. (PC-
T/CN2017/088420, US 62491007 (2017). Patent pending). Zika virus protease
inhibitors and methods of use thereof
5.2 Data on quality of publications
The articles that compose this PhD thesis have been published in journals indexed
in the Journal Citation Reports, a platform used to assess the relative importance of
each journal within its thematic area based on a series of standard indicators that
measure the quality of each journal. The following subsections show a series of
indicators associated with each journal in which the work has been published. In
summary, two articles belong to the first quartile of at least one of their categories,
two to the second quartile, one to the third quartile and two to the fourth quartile.
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5.2.1 Identification of an allosteric binding site on human lysosomal
alpha-galactosidase opens the way to new pharmacological chap-
erones for Fabry disease - PLOS ONE
In this section we present the data related to the journal where the first article that
forms part of this thesis Identification of an allosteric binding site on human lysosomal
alpha-galactosidase opens the way to new pharmacological chaperones for Fabry disease has
been published. In the figures 5.1, 5.2 and 5.3 we present the quality indicators and
the impact factor of the journal PLOS ONE.
Figure 5.1: Title and data of the journal publishing the article Identification of an
allosteric binding site on human lysosomal alpha-galactosidase opens the way to new
pharmacological chaperones for Fabry disease.
Figure 5.2: Key indicators of the past five years of the magazine PLOS ONE.
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Figure 5.3: Impact factor of the past five years of the magazine PLOS ONE.
5.2.2 Selective in vitro and in silico butyrylcholinesterase inhibitory ac-
tivity of diterpenes and rosmarinic acid isolated from Perovskia
atriplicifolia Benth. and Salvia glutinosa L. - Phytochemistry
In this section we present the data related to the journal where the first article that
forms part of this thesis Selective in vitro and in silico butyrylcholinesterase inhibitory
activity of diterpenes and rosmarinic acid isolated from Perovskia atriplicifolia Benth. and
Salvia glutinosa L.. In the figures 5.4, 5.5 y 5.6 we present the quality indicators and
the impact factor of the journal Phytochemistry.
Figure 5.4: Title and data of the journal publishing the article Selective in vitro and
in silico butyrylcholinesterase inhibitory activity of diterpenes and rosmarinic acid isolated
from Perovskia atriplicifolia Benth. and Salvia glutinosa L..
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Figure 5.5: Key indicators of the past five years of the magazine Phytochemistry.
Figure 5.6: Impact factor of the past five years of the magazine Phytochemistry.
5.2.3 Acetylcholinesterase inhibitory assessment of isolated constituents
from Salsola grandis Freitag, Vural & Adıgüzel and molecular mod-
eling studies on N-acetyltryptophan - Phytochemistry Letters
In this section we present the data related to the journal where the first article
that forms part of this thesis Acetylcholinesterase inhibitory assessment of isolated con-
stituents from Salsola grandis Freitag, Vural & Adıgüzel and molecular modeling studies
on N-acetyltryptophan. In the figures 5.7, 5.8 y 5.9 we present the quality indicators
and the impact factor of the journal Phytochemistry Letters.
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Figure 5.7: Title and data of the journal publishing the article Acetylcholinesterase in-
hibitory assessment of isolated constituents from Salsola grandis Freitag, Vural & Adıgüzel
and molecular modeling studies on N-acetyltryptophan.
Figure 5.8: Key indicators of the past five years of the magazine Phytochemistry
Letters.
Figure 5.9: Impact factor of the past five years of the magazine Phytochemistry Letters.
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5.2.4 Profiling Auspicious Butyrylcholinesterase Inhibitory Activity of
Two Herbal Molecules: Hyperforin and Hyuganin C - Chemistry &
Biodiversity
In this section we present the data related to the journal where the first article that
forms part of this thesis Profiling Auspicious Butyrylcholinesterase Inhibitory Activity
of Two Herbal Molecules: Hyperforin and Hyuganin C. In the figures 5.10, 5.11 y 5.12
we present the quality indicators and the impact factor of the journal Chemistry &
Biodiversity.
Figure 5.10: Tı́tulo y datos de la revista donde se ha publicado el artı́culo Profiling
Auspicious Butyrylcholinesterase Inhibitory Activity of Two Herbal Molecules: Hyperforin
and Hyuganin C.
Figure 5.11: Key indicators of the past five years of the magazine Chemistry &
Biodiversity.
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Figure 5.12: Impact factor of the past five years of the magazine Chemistry &
Biodiversity.
5.2.5 Selective in vitro and in silico cholinesterase inhibitory activity
of isoflavones and stilbenes from Belamcandae chinensis rhizoma
- Phytochemistry letters
In this section we present the data related to the journal where the first article that
forms part of this thesis Selective in vitro and in silico cholinesterase inhibitory activity
of isoflavones and stilbenes from Belamcandae chinensis rhizoma. In the figures 5.13,
5.14 y 5.15 we present the quality indicators and the impact factor of the journal
Phytochemistry letters.
Figure 5.13: Title and data of the journal publishing the article Selective in vitro and
in silico cholinesterase inhibitory activity of isoflavones and stilbenes from Belamcandae
chinensis rhizoma.
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Figure 5.14: Key indicators of the past five years of the magazine Phytochemistry
letters.
Figure 5.15: Impact factor of the past five years of the magazine Phytochemistry
letters.
5.2.6 Structure-based discovery of clinically approved drugs as Zika
virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus
infection in vitro and in vivo - Antiviral Research
In this section we present the data related to the journal where the first article that
forms part of this thesis Structure-based discovery of clinically approved drugs as Zika
virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection in vitro and
in vivo. In the figures 5.16, 5.17 y 5.18 we present the quality indicators and the
impact factor of the journal Antiviral Research.
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Figure 5.16: Title and data of the journal publishing the article Structure-based
discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that
potently inhibit Zika virus infection in vitro and in vivo.
Figure 5.17: Key indicators of the past five years of the magazine Antiviral Research.
Figure 5.18: Impact factor of the past five years of the magazine Antiviral Research.
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5.2.7 Exploring African Medicinal Plants for Potential Anti-Diabetic
Compounds with the DIA-DB Inverse Virtual Screening Web
Server - Molecules (MDPI)
In this section we present the data related to the journal where the first article that
forms part of this thesis Exploring African Medicinal Plants for Potential Anti-Diabetic
Compounds with the DIA-DB Inverse Virtual Screening Web Server. In the figures 5.19,
5.20 y 5.21 we present the quality indicators and the impact factor of the journal
Molecules (MDPI).
Figure 5.19: Title and data of the journal publishing the article Exploring African
Medicinal Plants for Potential Anti-Diabetic Compounds with the DIA-DB Inverse Virtual
Screening Web Server.
Figure 5.20: Key indicators of the past five years of the magazine Molecules (MDPI).
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Figure 5.21: Impact factor of the past five years of the magazine Molecules (MDPI).
Bibliography
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Jorge Peña-Garcı́a, Alfonso Pérez-Garrido, Andrés Muñoz, Helena den-Haan, Bal-
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Pérez-Sánchez, H., Rezaei, V., Mezhuyev, V., Man, D., Peña-Garcı́a, J., den Haan, H.,
and Gesing, S. (2016). Developing science gateways for drug discovery in a grid
environment. SpringerPlus, 5(1):1300.
Peña-Garcı́a, J., den Haan, H., Caballero, A., Imbernón, B., Cerón-Carrasco, J. P.,
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F., Cerón-Carrasco, J., den Haan, H., Peña-Garcı́a, J., Pérez-Sánchez, H., Do-
146 BIBLIOGRAPHY
maradzki, K., and Orhan, I. (2017). Selective in vitro and in silico butyryl-
cholinesterase inhibitory activity of diterpenes and rosmarinic acid isolated from
Perovskia atriplicifolia Benth. and Salvia glutinosa L. Phytochemistry, 133:33–44.
Shivakumar, D., Williams, J., Wu, Y., Damm, W., Shelley, J., and Sherman, W. (2010).
Prediction of Absolute Solvation Free Energies using Molecular Dynamics Free
Energy Perturbation and the OPLS Force Field. Journal of Chemical Theory and
Computation, 6(5):1509–1519.
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